

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12390135
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Hayter; Gary Alan et al.

Method and apparatus for providing data processing and control in a medical communication system

Abstract

Methods and apparatus for providing data processing and control for use in a medical communication system are provided.

Inventors: Hayter; Gary Alan (Oakland, CA), McGarraugh; Geoffrey V. (Bodega Bay, CA), Doniger; Kenneth J. (Menlo Park, CA)

Applicant: ABBOTT DIABETES CARE INC. (Alameda, CA)

Family ID: 1000008763922

Assignee: ABBOTT DIABETES CARE INC. (Alameda, CA)

Appl. No.: 17/392209

Filed: August 02, 2021

Prior Publication Data

Document Identifier	Publication Date
US 20210361196 A1	Nov. 25, 2021

Related U.S. Application Data

continuation parent-doc US 15681345 20170819 US 11076785 child-doc US 17392209
continuation parent-doc US 14741457 20150617 US 9737249 20170822 child-doc US 15681345
continuation parent-doc US 14106000 20131213 US 9060719 20150623 child-doc US 14741457
continuation parent-doc US 13599847 20120830 US 8612163 20131217 child-doc US 14106000
continuation parent-doc US 12152636 20080514 US 8260558 20120904 child-doc US 13599847
us-provisional-application US 60917889 20070514

Publication Classification

Int. Cl.: **A61B5/1486** (20060101); **A61B5/00** (20060101); **A61B5/145** (20060101); **A61B5/1473** (20060101); **G16H40/63** (20180101); G16H15/00 (20180101)

U.S. Cl.:

CPC **A61B5/1486** (20130101); **A61B5/0008** (20130101); **A61B5/002** (20130101); **A61B5/0022** (20130101); **A61B5/1451** (20130101); **A61B5/14532** (20130101); **A61B5/14546** (20130101); **A61B5/1473** (20130101); **A61B5/4845** (20130101); **A61B5/7275** (20130101); **G16H40/63** (20180101); A61B2560/0223 (20130101); A61B2560/0242 (20130101); A61B2560/0276 (20130101); G16H15/00 (20180101)

Field of Classification Search

CPC: A61B (5/1486); A61B (5/0008); A61B (5/002); A61B (5/0022); A61B (5/145); A61B (5/14532); A61B (5/14546); A61B (5/1473); A61B (5/7275); A61B (2560/0223); A61B (2560/0276); A61B (5/7221)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
3581062	12/1970	Aston	N/A	N/A
3926760	12/1974	Allen et al.	N/A	N/A
3949388	12/1975	Fuller	N/A	N/A
3960497	12/1975	Acord et al.	N/A	N/A
4033330	12/1976	Willis et al.	N/A	N/A
4036749	12/1976	Anderson	N/A	N/A
4055175	12/1976	Clemens et al.	N/A	N/A
4129128	12/1977	McFarlane	N/A	N/A
4245634	12/1980	Albisser et al.	N/A	N/A
4327725	12/1981	Cortese et al.	N/A	N/A
4344438	12/1981	Schultz	N/A	N/A
4349728	12/1981	Phillips et al.	N/A	N/A
4373527	12/1982	Fischell	N/A	N/A
4392849	12/1982	Petre et al.	N/A	N/A
4425920	12/1983	Bourland et al.	N/A	N/A
4431004	12/1983	Bessman et al.	N/A	N/A
4441968	12/1983	Emmer et al.	N/A	N/A
4464170	12/1983	Clemens et al.	N/A	N/A
4478976	12/1983	Goertz et al.	N/A	N/A
4494950	12/1984	Fischell	N/A	N/A
4509531	12/1984	Ward	N/A	N/A
4527240	12/1984	Kvitash	N/A	N/A
4538616	12/1984	Rogoff	N/A	N/A
4619793	12/1985	Lee	N/A	N/A
4671288	12/1986	Gough	N/A	N/A
4703756	12/1986	Gough et al.	N/A	N/A

4731726	12/1987	Allen, III	N/A	N/A
4749985	12/1987	Corsberg	N/A	N/A
4757022	12/1987	Shults et al.	N/A	N/A
4777953	12/1987	Ash et al.	N/A	N/A
4779618	12/1987	Mund et al.	N/A	N/A
4847785	12/1988	Stephens	N/A	N/A
4854322	12/1988	Ash et al.	N/A	N/A
4871351	12/1988	Feingold	N/A	N/A
4890620	12/1989	Gough	N/A	N/A
4925268	12/1989	Iyer et al.	N/A	N/A
4953552	12/1989	DeMarzo	N/A	N/A
4986271	12/1990	Wilkins	N/A	N/A
4995402	12/1990	Smith et al.	N/A	N/A
5000180	12/1990	Kuypers et al.	N/A	N/A
5002054	12/1990	Ash et al.	N/A	N/A
5019974	12/1990	Beckers	N/A	N/A
5050612	12/1990	Matsumura	N/A	N/A
5051688	12/1990	Murase et al.	N/A	N/A
5055171	12/1990	Peck	N/A	N/A
5068536	12/1990	Rosenthal	N/A	N/A
5082550	12/1991	Rishpon et al.	N/A	N/A
5106365	12/1991	Hernandez	N/A	N/A
5122925	12/1991	Inpyn	N/A	N/A
5135004	12/1991	Adams et al.	N/A	N/A
5165407	12/1991	Wilson et al.	N/A	N/A
5202261	12/1992	Musho et al.	N/A	N/A
5204264	12/1992	Kaminer et al.	N/A	N/A
5210778	12/1992	Massart	N/A	N/A
5228449	12/1992	Christ et al.	N/A	N/A
5231988	12/1992	Wernicke et al.	N/A	N/A
5243696	12/1992	Carr et al.	N/A	N/A
5246867	12/1992	Lakowicz et al.	N/A	N/A
5251126	12/1992	Kahn et al.	N/A	N/A
5262035	12/1992	Gregg et al.	N/A	N/A
5262305	12/1992	Heller et al.	N/A	N/A
5264104	12/1992	Gregg et al.	N/A	N/A
5264105	12/1992	Gregg et al.	N/A	N/A
5279294	12/1993	Anderson et al.	N/A	N/A
5285792	12/1993	Sjoquist et al.	N/A	N/A
5293877	12/1993	O'Hara et al.	N/A	N/A
5299571	12/1993	Mastrototaro	N/A	N/A
5320725	12/1993	Gregg et al.	N/A	N/A
5322063	12/1993	Allen et al.	N/A	N/A
5330634	12/1993	Wong et al.	N/A	N/A
5340722	12/1993	Wolfbeis et al.	N/A	N/A
5342789	12/1993	Chick et al.	N/A	N/A
5356786	12/1993	Heller et al.	N/A	N/A
5360404	12/1993	Novacek et al.	N/A	N/A
5372427	12/1993	Padovani et al.	N/A	N/A
5379238	12/1994	Stark	N/A	N/A

5384547	12/1994	Lynk et al.	N/A	N/A
5390671	12/1994	Lord et al.	N/A	N/A
5391250	12/1994	Cheney, II et al.	N/A	N/A
5408999	12/1994	Singh et al.	N/A	N/A
5410326	12/1994	Goldstein	N/A	N/A
5411647	12/1994	Johnson et al.	N/A	N/A
5425868	12/1994	Pedersen	N/A	N/A
5429602	12/1994	Hauser	N/A	N/A
5431160	12/1994	Wilkins	N/A	N/A
5431921	12/1994	Thombre	N/A	N/A
5438983	12/1994	Falcone	N/A	N/A
5462645	12/1994	Albery et al.	N/A	N/A
5472317	12/1994	Field et al.	N/A	N/A
5489414	12/1995	Schreiber et al.	N/A	N/A
5497772	12/1995	Schulman et al.	N/A	N/A
5505828	12/1995	Wong et al.	N/A	N/A
5507288	12/1995	Bocker et al.	N/A	N/A
5509410	12/1995	Hill et al.	N/A	N/A
5514718	12/1995	Lewis et al.	N/A	N/A
5531878	12/1995	Vadgama et al.	N/A	N/A
5532686	12/1995	Urbas et al.	N/A	N/A
5552997	12/1995	Massart	N/A	N/A
5555190	12/1995	Derby et al.	N/A	N/A
5564434	12/1995	Halperin et al.	N/A	N/A
5568400	12/1995	Stark et al.	N/A	N/A
5568806	12/1995	Cheney, II et al.	N/A	N/A
5569186	12/1995	Lord et al.	N/A	N/A
5582184	12/1995	Erickson et al.	N/A	N/A
5586553	12/1995	Halili et al.	N/A	N/A
5593852	12/1996	Heller et al.	N/A	N/A
5601435	12/1996	Quy	N/A	N/A
5609575	12/1996	Larson et al.	N/A	N/A
5628310	12/1996	Rao et al.	N/A	N/A
5634468	12/1996	Platt et al.	N/A	N/A
5653239	12/1996	Pompei et al.	N/A	N/A
5660163	12/1996	Schulman et al.	N/A	N/A
5665222	12/1996	Heller et al.	N/A	N/A
5707502	12/1997	McCaffrey et al.	N/A	N/A
5711001	12/1997	Bussan et al.	N/A	N/A
5711861	12/1997	Ward et al.	N/A	N/A
5724030	12/1997	Urbas et al.	N/A	N/A
5726646	12/1997	Bane et al.	N/A	N/A
5733259	12/1997	Valcke et al.	N/A	N/A
5735285	12/1997	Albert et al.	N/A	N/A
5748103	12/1997	Flach et al.	N/A	N/A
5749907	12/1997	Mann	N/A	N/A
5772586	12/1997	Heinonen et al.	N/A	N/A
5791344	12/1997	Schulman et al.	N/A	N/A
5804047	12/1997	Karube et al.	N/A	N/A
5833603	12/1997	Kovacs et al.	N/A	N/A

5842189	12/1997	Keeler et al.	N/A	N/A
5891049	12/1998	Cyrus et al.	N/A	N/A
5899855	12/1998	Brown	N/A	N/A
5914026	12/1998	Blubaugh, Jr. et al.	N/A	N/A
5919141	12/1998	Money et al.	N/A	N/A
5925021	12/1998	Castellano et al.	N/A	N/A
5935224	12/1998	Svancarek et al.	N/A	N/A
5942979	12/1998	Luppino	N/A	N/A
5951485	12/1998	Cyrus et al.	N/A	N/A
5957854	12/1998	Besson et al.	N/A	N/A
5961451	12/1998	Reber et al.	N/A	N/A
5964993	12/1998	Blubaugh, Jr. et al.	N/A	N/A
5965380	12/1998	Heller et al.	N/A	N/A
5971922	12/1998	Arita et al.	N/A	N/A
5980708	12/1998	Champagne et al.	N/A	N/A
5995860	12/1998	Sun et al.	N/A	N/A
6001067	12/1998	Shults et al.	N/A	N/A
6024699	12/1999	Surwit et al.	N/A	N/A
6028413	12/1999	Brockmann	N/A	N/A
6049727	12/1999	Crothall	N/A	N/A
6052565	12/1999	Ishikura et al.	N/A	N/A
6066243	12/1999	Anderson et al.	N/A	N/A
6083710	12/1999	Heller et al.	N/A	N/A
6088608	12/1999	Schulman et al.	N/A	N/A
6091976	12/1999	Pfeiffer et al.	N/A	N/A
6091987	12/1999	Thompson	N/A	N/A
6093172	12/1999	Funderburk et al.	N/A	N/A
6096364	12/1999	Bok et al.	N/A	N/A
6103033	12/1999	Say et al.	N/A	N/A
6117290	12/1999	Say et al.	N/A	N/A
6119028	12/1999	Schulman et al.	N/A	N/A
6120676	12/1999	Heller et al.	N/A	N/A
6121009	12/1999	Heller et al.	N/A	N/A
6121611	12/1999	Lindsay et al.	N/A	N/A
6122351	12/1999	Schlueter, Jr. et al.	N/A	N/A
6130623	12/1999	MacLellan et al.	N/A	N/A
6134461	12/1999	Say et al.	N/A	N/A
6143164	12/1999	Heller et al.	N/A	N/A
6144871	12/1999	Saito et al.	N/A	N/A
6157850	12/1999	Diab et al.	N/A	N/A
6159147	12/1999	Lichter et al.	N/A	N/A
6162611	12/1999	Heller et al.	N/A	N/A
6175752	12/2000	Say	128/903	A61B 5/1495
6200265	12/2000	Walsh et al.	N/A	N/A
6212416	12/2000	Ward et al.	N/A	N/A
6219574	12/2000	Cormier et al.	N/A	N/A
6223283	12/2000	Chaiken et al.	N/A	N/A
6233471	12/2000	Berner et al.	N/A	N/A
6248067	12/2000	Causey, III et al.	N/A	N/A
6254586	12/2000	Mann et al.	N/A	N/A

6270455	12/2000	Brown	N/A	N/A
6275717	12/2000	Gross et al.	N/A	N/A
6283761	12/2000	Joao	N/A	N/A
6284478	12/2000	Heller et al.	N/A	N/A
6291200	12/2000	LeJeune et al.	N/A	N/A
6293925	12/2000	Safabash et al.	N/A	N/A
6294997	12/2000	Paratore et al.	N/A	N/A
6295506	12/2000	Heinonen et al.	N/A	N/A
6299347	12/2000	Pompei	N/A	N/A
6306104	12/2000	Cunningham et al.	N/A	N/A
6309884	12/2000	Cooper et al.	N/A	N/A
6314317	12/2000	Willis	N/A	N/A
6329161	12/2000	Heller et al.	N/A	N/A
6348640	12/2001	Navot et al.	N/A	N/A
6359270	12/2001	Bridson	N/A	N/A
6359444	12/2001	Grimes	N/A	N/A
6360888	12/2001	McIvor et al.	N/A	N/A
6366794	12/2001	Moussy et al.	N/A	N/A
6377828	12/2001	Chaiken et al.	N/A	N/A
6379301	12/2001	Worthington et al.	N/A	N/A
6387048	12/2001	Schulman et al.	N/A	N/A
6400974	12/2001	Lesho	N/A	N/A
6405066	12/2001	Essenpreis et al.	N/A	N/A
6413393	12/2001	Van Antwerp et al.	N/A	N/A
6416471	12/2001	Kumar et al.	N/A	N/A
6418346	12/2001	Nelson et al.	N/A	N/A
6424847	12/2001	Mastrototaro et al.	N/A	N/A
6427088	12/2001	Bowman, IV et al.	N/A	N/A
6440068	12/2001	Brown et al.	N/A	N/A
6471689	12/2001	Joseph et al.	N/A	N/A
6478736	12/2001	Mault	N/A	N/A
6484046	12/2001	Say et al.	N/A	N/A
6493069	12/2001	Nagashimada et al.	N/A	N/A
6496729	12/2001	Thompson	N/A	N/A
6497655	12/2001	Linberg et al.	N/A	N/A
6498043	12/2001	Schulman et al.	N/A	N/A
6514718	12/2002	Heller et al.	N/A	N/A
6520326	12/2002	McIvor et al.	N/A	N/A
6544212	12/2002	Galley et al.	N/A	N/A
6546268	12/2002	Ishikawa et al.	N/A	N/A
6549796	12/2002	Sohrab	N/A	N/A
6551494	12/2002	Feldman et al.	N/A	N/A
6554798	12/2002	Mann et al.	N/A	N/A
6558320	12/2002	Causey, III et al.	N/A	N/A
6558321	12/2002	Burd et al.	N/A	N/A
6558351	12/2002	Steil et al.	N/A	N/A
6560471	12/2002	Heller et al.	N/A	N/A
6561975	12/2002	Pool et al.	N/A	N/A
6561978	12/2002	Conn et al.	N/A	N/A
6562001	12/2002	Lebel et al.	N/A	N/A

6564105	12/2002	Starkweather et al.	N/A	N/A
6565509	12/2002	Say et al.	N/A	N/A
6571128	12/2002	Lebel et al.	N/A	N/A
6572545	12/2002	Knobbe et al.	N/A	N/A
6574490	12/2002	Abbink et al.	N/A	N/A
6574510	12/2002	Von Arx et al.	N/A	N/A
6576101	12/2002	Heller et al.	N/A	N/A
6577899	12/2002	Lebel et al.	N/A	N/A
6579231	12/2002	Phipps	N/A	N/A
6579690	12/2002	Bonnecaze et al.	N/A	N/A
6585644	12/2002	Lebel et al.	N/A	N/A
6591125	12/2002	Buse et al.	N/A	N/A
6595919	12/2002	Berner et al.	N/A	N/A
6605200	12/2002	Mao et al.	N/A	N/A
6605201	12/2002	Mao et al.	N/A	N/A
6607509	12/2002	Bobroff et al.	N/A	N/A
6610012	12/2002	Mault	N/A	N/A
6631281	12/2002	Kastle	N/A	N/A
6633772	12/2002	Ford et al.	N/A	N/A
6635014	12/2002	Starkweather et al.	N/A	N/A
6635167	12/2002	Batman et al.	N/A	N/A
6641533	12/2002	Causey, III et al.	N/A	N/A
6648821	12/2002	Lebel et al.	N/A	N/A
6654625	12/2002	Say et al.	N/A	N/A
6656114	12/2002	Poulsen et al.	N/A	N/A
6658396	12/2002	Tang et al.	N/A	N/A
6659948	12/2002	Lebel et al.	N/A	N/A
6668196	12/2002	Villegas et al.	N/A	N/A
6675030	12/2003	Ciurczak et al.	N/A	N/A
6676816	12/2003	Mao et al.	N/A	N/A
6687546	12/2003	Lebel et al.	N/A	N/A
6689056	12/2003	Kilcoyne et al.	N/A	N/A
6694191	12/2003	Starkweather et al.	N/A	N/A
6695860	12/2003	Ward et al.	N/A	N/A
6698269	12/2003	Baber et al.	N/A	N/A
6702857	12/2003	Brauker et al.	N/A	N/A
6721582	12/2003	Trepagnier et al.	N/A	N/A
6730025	12/2003	Platt	N/A	N/A
6731976	12/2003	Penn et al.	N/A	N/A
6733446	12/2003	Lebel et al.	N/A	N/A
6735183	12/2003	O'Toole et al.	N/A	N/A
6740075	12/2003	Lebel et al.	N/A	N/A
6740518	12/2003	Duong et al.	N/A	N/A
6741877	12/2003	Shults et al.	N/A	N/A
6746582	12/2003	Heller et al.	N/A	N/A
6758810	12/2003	Lebel et al.	N/A	N/A
6770030	12/2003	Schaupp et al.	N/A	N/A
6789195	12/2003	Prihoda et al.	N/A	N/A
6790178	12/2003	Mault et al.	N/A	N/A
6804558	12/2003	Haller et al.	N/A	N/A

6809653	12/2003	Mann et al.	N/A	N/A
6810290	12/2003	Lebel et al.	N/A	N/A
6811533	12/2003	Lebel et al.	N/A	N/A
6811534	12/2003	Bowman, IV et al.	N/A	N/A
6813519	12/2003	Lebel et al.	N/A	N/A
6850790	12/2004	Berner et al.	N/A	N/A
6862465	12/2004	Shults et al.	N/A	N/A
6865407	12/2004	Kimball et al.	N/A	N/A
6873268	12/2004	Lebel et al.	N/A	N/A
6878112	12/2004	Linberg et al.	N/A	N/A
6881551	12/2004	Heller et al.	N/A	N/A
6882940	12/2004	Potts et al.	N/A	N/A
6892085	12/2004	McIvor et al.	N/A	N/A
6895263	12/2004	Shin et al.	N/A	N/A
6895265	12/2004	Silver	N/A	N/A
6923763	12/2004	Kovatchev et al.	N/A	N/A
6923764	12/2004	Aceti et al.	N/A	N/A
6931327	12/2004	Goode, Jr. et al.	N/A	N/A
6932894	12/2004	Mao et al.	N/A	N/A
6936006	12/2004	Sabra	N/A	N/A
6940403	12/2004	Kail, IV	N/A	N/A
6941163	12/2004	Ford et al.	N/A	N/A
6942518	12/2004	Liamos et al.	N/A	N/A
6950708	12/2004	Bowman IV et al.	N/A	N/A
6954662	12/2004	Freger et al.	N/A	N/A
6958705	12/2004	Lebel et al.	N/A	N/A
6968294	12/2004	Gutta et al.	N/A	N/A
6971274	12/2004	Olin	N/A	N/A
6974437	12/2004	Lebel et al.	N/A	N/A
6983176	12/2005	Gardner et al.	N/A	N/A
6990366	12/2005	Say et al.	N/A	N/A
6997907	12/2005	Safabash et al.	N/A	N/A
6998247	12/2005	Monfre et al.	N/A	N/A
6999854	12/2005	Roth	N/A	N/A
7003336	12/2005	Holker et al.	N/A	N/A
7003340	12/2005	Say et al.	N/A	N/A
7003341	12/2005	Say et al.	N/A	N/A
7009511	12/2005	Mazar et al.	N/A	N/A
7011630	12/2005	Desai et al.	N/A	N/A
7015817	12/2005	Copley et al.	N/A	N/A
7016713	12/2005	Gardner et al.	N/A	N/A
7020508	12/2005	Stivoric et al.	N/A	N/A
7022072	12/2005	Fox et al.	N/A	N/A
7022219	12/2005	Mansouri et al.	N/A	N/A
7024236	12/2005	Ford et al.	N/A	N/A
7024245	12/2005	Lebel et al.	N/A	N/A
7025425	12/2005	Kovatchev et al.	N/A	N/A
7027848	12/2005	Robinson et al.	N/A	N/A
7027931	12/2005	Jones et al.	N/A	N/A
7029444	12/2005	Shin et al.	N/A	N/A

7041068	12/2005	Freeman et al.	N/A	N/A
7041468	12/2005	Drucker et al.	N/A	N/A
7043305	12/2005	KenKnight et al.	N/A	N/A
7046153	12/2005	Oja et al.	N/A	N/A
7052472	12/2005	Miller et al.	N/A	N/A
7052483	12/2005	Wojcik	N/A	N/A
7056302	12/2005	Douglas	N/A	N/A
7058453	12/2005	Nelson et al.	N/A	N/A
7060031	12/2005	Webb et al.	N/A	N/A
7074307	12/2005	Simpson et al.	N/A	N/A
7081195	12/2005	Simpson et al.	N/A	N/A
7082334	12/2005	Boute et al.	N/A	N/A
7092891	12/2005	Maus et al.	N/A	N/A
7098803	12/2005	Mann et al.	N/A	N/A
7108778	12/2005	Simpson et al.	N/A	N/A
7110803	12/2005	Shults et al.	N/A	N/A
7113821	12/2005	Sun et al.	N/A	N/A
7118667	12/2005	Lee	N/A	N/A
7123950	12/2005	Mannheimer	N/A	N/A
7125382	12/2005	Zhou et al.	N/A	N/A
7134999	12/2005	Brauker et al.	N/A	N/A
7136689	12/2005	Shults et al.	N/A	N/A
7153265	12/2005	Vachon	N/A	N/A
7155290	12/2005	Von Arx et al.	N/A	N/A
7155729	12/2005	Andrew et al.	N/A	N/A
7167818	12/2006	Brown	N/A	N/A
7171274	12/2006	Starkweather et al.	N/A	N/A
7179226	12/2006	Crothall et al.	N/A	N/A
7183102	12/2006	Monfre et al.	N/A	N/A
7190988	12/2006	Say et al.	N/A	N/A
7192450	12/2006	Brauker et al.	N/A	N/A
7198606	12/2006	Boecker et al.	N/A	N/A
7203549	12/2006	Schommer et al.	N/A	N/A
7207974	12/2006	Safabash et al.	N/A	N/A
7225535	12/2006	Feldman et al.	N/A	N/A
7226442	12/2006	Sheppard et al.	N/A	N/A
7226978	12/2006	Tapsak et al.	N/A	N/A
7228182	12/2006	Healy et al.	N/A	N/A
7237712	12/2006	DeRocco et al.	N/A	N/A
7258673	12/2006	Racchini et al.	N/A	N/A
7267665	12/2006	Steil et al.	N/A	N/A
7276029	12/2006	Goode, Jr. et al.	N/A	N/A
7278983	12/2006	Ireland et al.	N/A	N/A
7286894	12/2006	Grant et al.	N/A	N/A
7295867	12/2006	Berner et al.	N/A	N/A
7299082	12/2006	Feldman et al.	N/A	N/A
7301463	12/2006	Paterno	N/A	N/A
7310544	12/2006	Brister et al.	N/A	N/A
7317938	12/2007	Lorenz et al.	N/A	N/A
7318816	12/2007	Bobroff et al.	N/A	N/A

7324850	12/2007	Persen et al.	N/A	N/A
7335294	12/2007	Heller et al.	N/A	N/A
7344500	12/2007	Talbot et al.	N/A	N/A
7347819	12/2007	Lebel et al.	N/A	N/A
7354420	12/2007	Steil et al.	N/A	N/A
7364592	12/2007	Carr-Brendel et al.	N/A	N/A
7366556	12/2007	Brister et al.	N/A	N/A
7379765	12/2007	Petisce et al.	N/A	N/A
7384397	12/2007	Zhang et al.	N/A	N/A
7387010	12/2007	Sunshine et al.	N/A	N/A
7399277	12/2007	Saidara et al.	N/A	N/A
7402153	12/2007	Steil et al.	N/A	N/A
7404796	12/2007	Ginsberg	N/A	N/A
7419573	12/2007	Gundel	N/A	N/A
7424318	12/2007	Brister et al.	N/A	N/A
7460898	12/2007	Brister et al.	N/A	N/A
7467003	12/2007	Brister et al.	N/A	N/A
7468125	12/2007	Kraft et al.	N/A	N/A
7471972	12/2007	Rhodes et al.	N/A	N/A
7474992	12/2008	Ariyur	N/A	N/A
7492254	12/2008	Bandy et al.	N/A	N/A
7494465	12/2008	Brister et al.	N/A	N/A
7497827	12/2008	Brister et al.	N/A	N/A
7519408	12/2008	Rasdal et al.	N/A	N/A
7519478	12/2008	Bartkowiak et al.	N/A	N/A
7523004	12/2008	Bartkowiak et al.	N/A	N/A
7547281	12/2008	Hayes et al.	N/A	N/A
7565197	12/2008	Haubrich et al.	N/A	N/A
7569030	12/2008	Lebel et al.	N/A	N/A
7574266	12/2008	Dudding et al.	N/A	N/A
7583990	12/2008	Goode, Jr. et al.	N/A	N/A
7591801	12/2008	Brauker et al.	N/A	N/A
7599726	12/2008	Goode, Jr. et al.	N/A	N/A
7602310	12/2008	Mann et al.	N/A	N/A
7604178	12/2008	Stewart	N/A	N/A
7613491	12/2008	Boock et al.	N/A	N/A
7615007	12/2008	Shults et al.	N/A	N/A
7618369	12/2008	Hayter et al.	N/A	N/A
7630748	12/2008	Budiman	N/A	N/A
7632228	12/2008	Brauker et al.	N/A	N/A
7635594	12/2008	Holmes et al.	N/A	N/A
7637868	12/2008	Saint et al.	N/A	N/A
7640048	12/2008	Dobbles et al.	N/A	N/A
7643798	12/2009	Ljung	N/A	N/A
7651596	12/2009	Petisce et al.	N/A	N/A
7651845	12/2009	Doyle, III et al.	N/A	N/A
7653425	12/2009	Hayter et al.	N/A	N/A
7654956	12/2009	Brister et al.	N/A	N/A
7657297	12/2009	Simpson et al.	N/A	N/A
7659823	12/2009	Killian et al.	N/A	N/A

7668596	12/2009	Von Arx et al.	N/A	N/A
7699775	12/2009	Desai et al.	N/A	N/A
7699964	12/2009	Feldman et al.	N/A	N/A
7711402	12/2009	Shults et al.	N/A	N/A
7711493	12/2009	Bartkowiak et al.	N/A	N/A
7713574	12/2009	Brister et al.	N/A	N/A
7715893	12/2009	Kamath et al.	N/A	N/A
7736310	12/2009	Taub et al.	N/A	N/A
7741734	12/2009	Joannopoulos et al.	N/A	N/A
7751864	12/2009	Buck, Jr.	N/A	N/A
7766829	12/2009	Sloan et al.	N/A	N/A
7768386	12/2009	Hayter et al.	N/A	N/A
7768387	12/2009	Fennell	N/A	N/A
7771352	12/2009	Shults et al.	N/A	N/A
7774145	12/2009	Brauker et al.	N/A	N/A
7778680	12/2009	Goode, Jr. et al.	N/A	N/A
7779332	12/2009	Karr et al.	N/A	N/A
7782192	12/2009	Jeckelmann et al.	N/A	N/A
7783333	12/2009	Brister et al.	N/A	N/A
7791467	12/2009	Mazar et al.	N/A	N/A
7792562	12/2009	Shults et al.	N/A	N/A
7811231	12/2009	Jin et al.	N/A	N/A
7813809	12/2009	Strother et al.	N/A	N/A
7826382	12/2009	Sicurello et al.	N/A	N/A
7826981	12/2009	Goode, Jr. et al.	N/A	N/A
7831310	12/2009	Lebel et al.	N/A	N/A
7857760	12/2009	Brister et al.	N/A	N/A
7860574	12/2009	Von Arx et al.	N/A	N/A
7882611	12/2010	Shah et al.	N/A	N/A
7885697	12/2010	Brister et al.	N/A	N/A
7889069	12/2010	Fifolt et al.	N/A	N/A
7899511	12/2010	Shults et al.	N/A	N/A
7899545	12/2010	John	N/A	N/A
7905833	12/2010	Brister et al.	N/A	N/A
7912674	12/2010	Killoren Clark et al.	N/A	N/A
7914450	12/2010	Goode, Jr. et al.	N/A	N/A
7916013	12/2010	Stevenson	N/A	N/A
7920906	12/2010	Goode et al.	N/A	N/A
7928850	12/2010	Hayter et al.	N/A	N/A
7938797	12/2010	Estes	N/A	N/A
7941200	12/2010	Weinert et al.	N/A	N/A
7946984	12/2010	Brister et al.	N/A	N/A
7946985	12/2010	Mastrototaro et al.	N/A	N/A
7955258	12/2010	Goscha et al.	N/A	N/A
7970448	12/2010	Shults et al.	N/A	N/A
7972296	12/2010	Braig et al.	N/A	N/A
7974672	12/2010	Shults et al.	N/A	N/A
7976466	12/2010	Ward et al.	N/A	N/A
7978063	12/2010	Baldus et al.	N/A	N/A
7996158	12/2010	Hayter et al.	N/A	N/A

7999674	12/2010	Kamen	N/A	N/A
8005524	12/2010	Brauker et al.	N/A	N/A
8010174	12/2010	Goode et al.	N/A	N/A
8010256	12/2010	Oowada	N/A	N/A
8060173	12/2010	Goode, Jr. et al.	N/A	N/A
8072310	12/2010	Everhart	N/A	N/A
8090445	12/2011	Ginggen	N/A	N/A
8093991	12/2011	Stevenson et al.	N/A	N/A
8094009	12/2011	Allen et al.	N/A	N/A
8098159	12/2011	Batra et al.	N/A	N/A
8098160	12/2011	Howarth et al.	N/A	N/A
8098161	12/2011	Lavedas	N/A	N/A
8098201	12/2011	Choi et al.	N/A	N/A
8098208	12/2011	Ficker et al.	N/A	N/A
8102021	12/2011	Degani	N/A	N/A
8102154	12/2011	Bishop et al.	N/A	N/A
8102263	12/2011	Yeo et al.	N/A	N/A
8102789	12/2011	Rosar et al.	N/A	N/A
8103241	12/2011	Young et al.	N/A	N/A
8103325	12/2011	Swedlow et al.	N/A	N/A
8103471	12/2011	Hayter	N/A	N/A
8111042	12/2011	Bennett	N/A	N/A
8115488	12/2011	McDowell	N/A	N/A
8116681	12/2011	Baarman	N/A	N/A
8116683	12/2011	Baarman	N/A	N/A
8117481	12/2011	Anselmi et al.	N/A	N/A
8120493	12/2011	Burr	N/A	N/A
8124452	12/2011	Sheats	N/A	N/A
8130093	12/2011	Mazar et al.	N/A	N/A
8131351	12/2011	Kalgren et al.	N/A	N/A
8131365	12/2011	Zhang et al.	N/A	N/A
8131565	12/2011	Dicks et al.	N/A	N/A
8132037	12/2011	Fehr et al.	N/A	N/A
8135352	12/2011	Langsweirdt et al.	N/A	N/A
8136735	12/2011	Arai et al.	N/A	N/A
8138925	12/2011	Downie et al.	N/A	N/A
8140160	12/2011	Pless et al.	N/A	N/A
8140168	12/2011	Olson et al.	N/A	N/A
8140299	12/2011	Siess	N/A	N/A
8140312	12/2011	Hayter et al.	N/A	N/A
8150321	12/2011	Winter et al.	N/A	N/A
8150516	12/2011	Levine et al.	N/A	N/A
8170803	12/2011	Kamath et al.	N/A	N/A
8179266	12/2011	Hermle	N/A	N/A
8192394	12/2011	Estes et al.	N/A	N/A
8216138	12/2011	McGarraugh et al.	N/A	N/A
8239166	12/2011	Hayter et al.	N/A	N/A
8255026	12/2011	Al-Ali	N/A	N/A
8260558	12/2011	Hayter et al.	N/A	N/A
8282549	12/2011	Brauker et al.	N/A	N/A

8374668	12/2012	Hayter et al.	N/A	N/A
8376945	12/2012	Hayter et al.	N/A	N/A
8377271	12/2012	Mao et al.	N/A	N/A
8409093	12/2012	Bugler	N/A	N/A
8444560	12/2012	Hayter et al.	N/A	N/A
8461985	12/2012	Fennell et al.	N/A	N/A
8484005	12/2012	Hayter et al.	N/A	N/A
8543354	12/2012	Luo et al.	N/A	N/A
8560038	12/2012	Hayter et al.	N/A	N/A
8571808	12/2012	Hayter	N/A	N/A
8583205	12/2012	Budiman et al.	N/A	N/A
8597570	12/2012	Terashima et al.	N/A	N/A
8600681	12/2012	Hayter et al.	N/A	N/A
8612163	12/2012	Hayter et al.	N/A	N/A
8657746	12/2013	Roy	N/A	N/A
8682615	12/2013	Hayter et al.	N/A	N/A
8710993	12/2013	Hayter et al.	N/A	N/A
8834366	12/2013	Hayter et al.	N/A	N/A
8845536	12/2013	Brauker et al.	N/A	N/A
9000914	12/2014	Baker et al.	N/A	N/A
9060719	12/2014	Hayter et al.	N/A	N/A
9289179	12/2015	Hayter et al.	N/A	N/A
9398872	12/2015	Hayter et al.	N/A	N/A
9408566	12/2015	Hayter et al.	N/A	N/A
9439586	12/2015	Bugler	N/A	N/A
9483608	12/2015	Hayter et al.	N/A	N/A
9558325	12/2016	Hayter et al.	N/A	N/A
9743872	12/2016	Hayter et al.	N/A	N/A
9980140	12/2017	Spencer et al.	N/A	N/A
10375222	12/2018	Mandapaka et al.	N/A	N/A
10855788	12/2019	Arabo et al.	N/A	N/A
11076785	12/2020	Hayter	N/A	A61B 5/1473
2001/0037366	12/2000	Webb et al.	N/A	N/A
2002/0016534	12/2001	Trepagnier et al.	N/A	N/A
2002/0019022	12/2001	Dunn et al.	N/A	N/A
2002/0042090	12/2001	Heller et al.	N/A	N/A
2002/0054320	12/2001	Ogino	N/A	N/A
2002/0065454	12/2001	Lebel et al.	N/A	N/A
2002/0068860	12/2001	Clark	N/A	N/A
2002/0072784	12/2001	Sheppard et al.	N/A	N/A
2002/0095076	12/2001	Krausman et al.	N/A	N/A
2002/0103499	12/2001	Perez et al.	N/A	N/A
2002/0106709	12/2001	Potts et al.	N/A	N/A
2002/0117639	12/2001	Paolini et al.	N/A	N/A
2002/0120186	12/2001	Keimel	N/A	N/A
2002/0128594	12/2001	Das et al.	N/A	N/A
2002/0147135	12/2001	Schnell	N/A	N/A
2002/0150959	12/2001	Lejeune et al.	N/A	N/A
2002/0161288	12/2001	Shin et al.	N/A	N/A
2002/0169635	12/2001	Shillingburg	N/A	N/A

2003/0004403	12/2002	Drinan et al.	N/A	N/A
2003/0023317	12/2002	Brauker et al.	N/A	N/A
2003/0023461	12/2002	Quintanilla et al.	N/A	N/A
2003/0028089	12/2002	Galley et al.	N/A	N/A
2003/0028184	12/2002	Lebel et al.	N/A	N/A
2003/0032077	12/2002	Itoh et al.	N/A	N/A
2003/0032867	12/2002	Crothall et al.	N/A	N/A
2003/0032874	12/2002	Rhodes et al.	N/A	N/A
2003/0042137	12/2002	Mao et al.	N/A	N/A
2003/0050546	12/2002	Desai et al.	N/A	N/A
2003/0054428	12/2002	Monfre et al.	N/A	N/A
2003/0060692	12/2002	Ruchti et al.	N/A	N/A
2003/0060753	12/2002	Starkweather et al.	N/A	N/A
2003/0065308	12/2002	Lebel et al.	N/A	N/A
2003/0100040	12/2002	Bonnecaze et al.	N/A	N/A
2003/0100821	12/2002	Heller et al.	N/A	N/A
2003/0114897	12/2002	Von Arx et al.	N/A	N/A
2003/0125612	12/2002	Fox et al.	N/A	N/A
2003/0130616	12/2002	Steil et al.	N/A	N/A
2003/0134347	12/2002	Heller et al.	N/A	N/A
2003/0147515	12/2002	Kai et al.	N/A	N/A
2003/0168338	12/2002	Gao et al.	N/A	N/A
2003/0176933	12/2002	Lebel et al.	N/A	N/A
2003/0187338	12/2002	Say et al.	N/A	N/A
2003/0191377	12/2002	Robinson et al.	N/A	N/A
2003/0199744	12/2002	Buse et al.	N/A	N/A
2003/0199790	12/2002	Boecker et al.	N/A	N/A
2003/0208113	12/2002	Mault et al.	N/A	N/A
2003/0212317	12/2002	Kovatchev et al.	N/A	N/A
2003/0212379	12/2002	Bylund et al.	N/A	N/A
2003/0216630	12/2002	Jersey-Willuhn et al.	N/A	N/A
2003/0217966	12/2002	Tapsak et al.	N/A	N/A
2003/0235817	12/2002	Bartkowiak et al.	N/A	N/A
2004/0010186	12/2003	Kimball et al.	N/A	N/A
2004/0010207	12/2003	Flaherty et al.	N/A	N/A
2004/0011671	12/2003	Shults et al.	N/A	N/A
2004/0024553	12/2003	Monfre et al.	N/A	N/A
2004/0039298	12/2003	Abreu	N/A	N/A
2004/0040840	12/2003	Mao et al.	N/A	N/A
2004/0041749	12/2003	Dixon	N/A	N/A
2004/0045879	12/2003	Shults et al.	N/A	N/A
2004/0054263	12/2003	Moerman et al.	N/A	N/A
2004/0063435	12/2003	Sakamoto et al.	N/A	N/A
2004/0064068	12/2003	DeNuzzio et al.	N/A	N/A
2004/0099529	12/2003	Mao et al.	N/A	N/A
2004/0106858	12/2003	Say et al.	N/A	N/A
2004/0111017	12/2003	Say et al.	N/A	N/A
2004/0117204	12/2003	Mazar et al.	N/A	N/A
2004/0122353	12/2003	Shahmirian et al.	N/A	N/A
2004/0133164	12/2003	Funderburk et al.	N/A	N/A

2004/0133390	12/2003	Osorio et al.	N/A	N/A
2004/0135571	12/2003	Uutela et al.	N/A	N/A
2004/0135684	12/2003	Steinthal et al.	N/A	N/A
2004/0138588	12/2003	Saikley et al.	N/A	N/A
2004/0142403	12/2003	Hetzel et al.	N/A	N/A
2004/0146909	12/2003	Duong et al.	N/A	N/A
2004/0147872	12/2003	Thompson	N/A	N/A
2004/0152622	12/2003	Keith et al.	N/A	N/A
2004/0162678	12/2003	Hetzel et al.	N/A	N/A
2004/0167464	12/2003	Ireland et al.	N/A	N/A
2004/0167801	12/2003	Say et al.	N/A	N/A
2004/0171921	12/2003	Say et al.	N/A	N/A
2004/0176672	12/2003	Silver et al.	N/A	N/A
2004/0186362	12/2003	Brauker et al.	N/A	N/A
2004/0186365	12/2003	Jin et al.	N/A	N/A
2004/0193020	12/2003	Chiba et al.	N/A	N/A
2004/0193025	12/2003	Steil et al.	N/A	N/A
2004/0193090	12/2003	Lebel et al.	N/A	N/A
2004/0197846	12/2003	Hockersmith et al.	N/A	N/A
2004/0199056	12/2003	Husemann et al.	N/A	N/A
2004/0199059	12/2003	Brauker et al.	N/A	N/A
2004/0204687	12/2003	Mogensen et al.	N/A	N/A
2004/0204868	12/2003	Maynard et al.	N/A	N/A
2004/0219664	12/2003	Heller et al.	N/A	N/A
2004/0225338	12/2003	Lebel et al.	N/A	N/A
2004/0236200	12/2003	Say et al.	N/A	N/A
2004/0249253	12/2003	Racchini et al.	N/A	N/A
2004/0254433	12/2003	Bandis et al.	N/A	N/A
2004/0254434	12/2003	Goodnow et al.	N/A	N/A
2004/0260478	12/2003	Schwamm	N/A	N/A
2004/0267300	12/2003	Mace	N/A	N/A
2005/0001024	12/2004	Kusaka et al.	N/A	N/A
2005/0004439	12/2004	Shin et al.	N/A	N/A
2005/0004494	12/2004	Perez et al.	N/A	N/A
2005/0010269	12/2004	Lebel et al.	N/A	N/A
2005/0017864	12/2004	Tsoukalis	N/A	N/A
2005/0027177	12/2004	Shin et al.	N/A	N/A
2005/0027180	12/2004	Goode et al.	N/A	N/A
2005/0027181	12/2004	Goode et al.	N/A	N/A
2005/0027182	12/2004	Siddiqui et al.	N/A	N/A
2005/0027462	12/2004	Goode et al.	N/A	N/A
2005/0027463	12/2004	Goode et al.	N/A	N/A
2005/0031689	12/2004	Shults et al.	N/A	N/A
2005/0038332	12/2004	Saidara et al.	N/A	N/A
2005/0043598	12/2004	Goode, Jr. et al.	N/A	N/A
2005/0049179	12/2004	Davidson et al.	N/A	N/A
2005/0049473	12/2004	Desai et al.	N/A	N/A
2005/0070774	12/2004	Addison et al.	N/A	N/A
2005/0070777	12/2004	Cho et al.	N/A	N/A
2005/0090607	12/2004	Tapsak et al.	N/A	N/A

2005/0096511	12/2004	Fox et al.	N/A	N/A
2005/0096512	12/2004	Fox et al.	N/A	N/A
2005/0096516	12/2004	Soykan et al.	N/A	N/A
2005/0112169	12/2004	Brauker et al.	N/A	N/A
2005/0113648	12/2004	Yang et al.	N/A	N/A
2005/0113653	12/2004	Fox et al.	N/A	N/A
2005/0113886	12/2004	Fischell et al.	N/A	N/A
2005/0114068	12/2004	Chey et al.	N/A	N/A
2005/0115832	12/2004	Simpson et al.	N/A	N/A
2005/0116683	12/2004	Cheng et al.	N/A	N/A
2005/0121322	12/2004	Say et al.	N/A	N/A
2005/0131346	12/2004	Douglas	N/A	N/A
2005/0134731	12/2004	Lee et al.	N/A	N/A
2005/0137530	12/2004	Campbell et al.	N/A	N/A
2005/0143635	12/2004	Kamath et al.	N/A	N/A
2005/0148890	12/2004	Hastings	N/A	N/A
2005/0154271	12/2004	Rasdal et al.	N/A	N/A
2005/0176136	12/2004	Burd et al.	N/A	N/A
2005/0177398	12/2004	Watanabe et al.	N/A	N/A
2005/0182306	12/2004	Sloan	N/A	N/A
2005/0187442	12/2004	Cho et al.	N/A	N/A
2005/0187720	12/2004	Goode, Jr. et al.	N/A	N/A
2005/0192494	12/2004	Ginsberg	N/A	N/A
2005/0192557	12/2004	Brauker et al.	N/A	N/A
2005/0195930	12/2004	Spital et al.	N/A	N/A
2005/0196821	12/2004	Monfre et al.	N/A	N/A
2005/0197793	12/2004	Baker, Jr.	N/A	N/A
2005/0199494	12/2004	Say et al.	N/A	N/A
2005/0203360	12/2004	Brauker et al.	N/A	N/A
2005/0204134	12/2004	Von Arx et al.	N/A	N/A
2005/0209515	12/2004	Hockersmith et al.	N/A	N/A
2005/0214892	12/2004	Kovatchev et al.	N/A	N/A
2005/0239154	12/2004	Feldman et al.	N/A	N/A
2005/0239156	12/2004	Drucker et al.	N/A	N/A
2005/0241957	12/2004	Mao et al.	N/A	N/A
2005/0245795	12/2004	Goode, Jr. et al.	N/A	N/A
2005/0245799	12/2004	Brauker et al.	N/A	N/A
2005/0245839	12/2004	Stivoric et al.	N/A	N/A
2005/0245904	12/2004	Estes et al.	N/A	N/A
2005/0251033	12/2004	Scarantino et al.	N/A	N/A
2005/0272985	12/2004	Kotulla et al.	N/A	N/A
2005/0277164	12/2004	Drucker et al.	N/A	N/A
2005/0277912	12/2004	John	N/A	N/A
2005/0283208	12/2004	Von Arx et al.	N/A	N/A
2005/0287620	12/2004	Heller et al.	N/A	N/A
2006/0001538	12/2005	Kraft et al.	N/A	N/A
2006/0001551	12/2005	Kraft et al.	N/A	N/A
2006/0004270	12/2005	Bedard et al.	N/A	N/A
2006/0010098	12/2005	Goodnow et al.	N/A	N/A
2006/0015020	12/2005	Neale et al.	N/A	N/A

2006/0015024	12/2005	Brister et al.	N/A	N/A
2006/0016700	12/2005	Brister et al.	N/A	N/A
2006/0017923	12/2005	Ruchti et al.	N/A	N/A
2006/0019327	12/2005	Brister et al.	N/A	N/A
2006/0020186	12/2005	Brister et al.	N/A	N/A
2006/0020187	12/2005	Brister et al.	N/A	N/A
2006/0020188	12/2005	Kamath et al.	N/A	N/A
2006/0020189	12/2005	Brister et al.	N/A	N/A
2006/0020190	12/2005	Kamath et al.	N/A	N/A
2006/0020191	12/2005	Brister et al.	N/A	N/A
2006/0020192	12/2005	Brister et al.	N/A	N/A
2006/0020300	12/2005	Nghiem et al.	N/A	N/A
2006/0025663	12/2005	Talbot et al.	N/A	N/A
2006/0029177	12/2005	Cranford, Jr. et al.	N/A	N/A
2006/0031094	12/2005	Cohen et al.	N/A	N/A
2006/0036139	12/2005	Brister et al.	N/A	N/A
2006/0036140	12/2005	Brister et al.	N/A	N/A
2006/0036141	12/2005	Kamath et al.	N/A	N/A
2006/0036142	12/2005	Brister et al.	N/A	N/A
2006/0036143	12/2005	Brister et al.	N/A	N/A
2006/0036144	12/2005	Brister et al.	N/A	N/A
2006/0036145	12/2005	Brister et al.	N/A	N/A
2006/0058588	12/2005	Zdeblick	N/A	N/A
2006/0079740	12/2005	Silver et al.	N/A	N/A
2006/0091006	12/2005	Wang et al.	N/A	N/A
2006/0142651	12/2005	Brister et al.	N/A	N/A
2006/0154642	12/2005	Scannell	N/A	N/A
2006/0155180	12/2005	Brister et al.	N/A	N/A
2006/0156796	12/2005	Burke et al.	N/A	N/A
2006/0166629	12/2005	Reggiardo	N/A	N/A
2006/0173260	12/2005	Gaoni et al.	N/A	N/A
2006/0173406	12/2005	Hayes et al.	N/A	N/A
2006/0173444	12/2005	Choy et al.	N/A	N/A
2006/0183984	12/2005	Dobbles et al.	N/A	N/A
2006/0183985	12/2005	Brister	600/316	A61B 5/742
2006/0189851	12/2005	Tivig et al.	N/A	N/A
2006/0189863	12/2005	Peyser et al.	N/A	N/A
2006/0193375	12/2005	Lee et al.	N/A	N/A
2006/0202805	12/2005	Schulman et al.	N/A	N/A
2006/0211072	12/2005	Ryan et al.	N/A	N/A
2006/0222566	12/2005	Brauker et al.	N/A	N/A
2006/0224109	12/2005	Steil et al.	N/A	N/A
2006/0224141	12/2005	Rush et al.	N/A	N/A
2006/0229512	12/2005	Petisce et al.	N/A	N/A
2006/0247508	12/2005	Fennell	N/A	N/A
2006/0247710	12/2005	Goetz et al.	N/A	N/A
2006/0247985	12/2005	Liamos et al.	N/A	N/A
2006/0253296	12/2005	Liisberg et al.	N/A	N/A
2006/0258929	12/2005	Goode et al.	N/A	N/A
2006/0272652	12/2005	Stocker et al.	N/A	N/A

2006/0276771	12/2005	Galley et al.	N/A	N/A
2006/0281985	12/2005	Ward et al.	N/A	N/A
2006/0287691	12/2005	Drew	N/A	N/A
2006/0290496	12/2005	Peeters et al.	N/A	N/A
2006/0293607	12/2005	Alt et al.	N/A	N/A
2007/0010950	12/2006	Abensour et al.	N/A	N/A
2007/0016381	12/2006	Kamath et al.	N/A	N/A
2007/0017983	12/2006	Frank et al.	N/A	N/A
2007/0027381	12/2006	Stafford	N/A	N/A
2007/0027507	12/2006	Burdett et al.	N/A	N/A
2007/0032706	12/2006	Kamath et al.	N/A	N/A
2007/0032717	12/2006	Brister et al.	N/A	N/A
2007/0033074	12/2006	Nitzan et al.	N/A	N/A
2007/0038044	12/2006	Dobbles et al.	N/A	N/A
2007/0055799	12/2006	Koehler et al.	N/A	N/A
2007/0060803	12/2006	Liljeryd et al.	N/A	N/A
2007/0060814	12/2006	Stafford	N/A	N/A
2007/0060869	12/2006	Tolle et al.	N/A	N/A
2007/0060979	12/2006	Strother et al.	N/A	N/A
2007/0066873	12/2006	Kamath	600/300	A61B 5/1495
2007/0066956	12/2006	Finkel	N/A	N/A
2007/0071681	12/2006	Gadkar et al.	N/A	N/A
2007/0073129	12/2006	Shah et al.	N/A	N/A
2007/0078320	12/2006	Stafford	N/A	N/A
2007/0078321	12/2006	Mazza et al.	N/A	N/A
2007/0078322	12/2006	Stafford	N/A	N/A
2007/0078323	12/2006	Reggiardo et al.	N/A	N/A
2007/0078818	12/2006	Zivitz et al.	N/A	N/A
2007/0093786	12/2006	Goldsmith et al.	N/A	N/A
2007/0094216	12/2006	Mathias et al.	N/A	N/A
2007/0100222	12/2006	Mastrototaro et al.	N/A	N/A
2007/0106135	12/2006	Sloan et al.	N/A	N/A
2007/0118030	12/2006	Bruce et al.	N/A	N/A
2007/0118405	12/2006	Campbell et al.	N/A	N/A
2007/0124002	12/2006	Estes et al.	N/A	N/A
2007/0129621	12/2006	Kellogg et al.	N/A	N/A
2007/0149875	12/2006	Ouyang et al.	N/A	N/A
2007/0156033	12/2006	Causey, III et al.	N/A	N/A
2007/0163880	12/2006	Woo et al.	N/A	N/A
2007/0168224	12/2006	Letzt et al.	N/A	N/A
2007/0173706	12/2006	Neinast et al.	N/A	N/A
2007/0173709	12/2006	Petisce et al.	N/A	N/A
2007/0173710	12/2006	Petisce et al.	N/A	N/A
2007/0173761	12/2006	Kanderian et al.	N/A	N/A
2007/0179349	12/2006	Hoyme et al.	N/A	N/A
2007/0179352	12/2006	Randlov et al.	N/A	N/A
2007/0191701	12/2006	Feldman et al.	N/A	N/A
2007/0191702	12/2006	Yodfat et al.	N/A	N/A
2007/0202562	12/2006	Curry et al.	N/A	N/A
2007/0203407	12/2006	Hoss et al.	N/A	N/A

2007/0203966	12/2006	Brauker et al.	N/A	N/A
2007/0208244	12/2006	Brauker et al.	N/A	N/A
2007/0208246	12/2006	Brauker et al.	N/A	N/A
2007/0213657	12/2006	Jennewine et al.	N/A	N/A
2007/0228071	12/2006	Kamen et al.	N/A	N/A
2007/0232878	12/2006	Kovatchev et al.	N/A	N/A
2007/0232880	12/2006	Siddiqui et al.	N/A	N/A
2007/0235331	12/2006	Simpson et al.	N/A	N/A
2007/0244383	12/2006	Talbot et al.	N/A	N/A
2007/0249922	12/2006	Peyser et al.	N/A	N/A
2007/0253021	12/2006	Mehta et al.	N/A	N/A
2007/0255116	12/2006	Mehta et al.	N/A	N/A
2007/0255321	12/2006	Gerber et al.	N/A	N/A
2007/0255348	12/2006	Holtzclaw	N/A	N/A
2007/0255531	12/2006	Drew	N/A	N/A
2007/0258395	12/2006	Jollota et al.	N/A	N/A
2007/0270672	12/2006	Hayter	N/A	N/A
2007/0271285	12/2006	Eichorn et al.	N/A	N/A
2007/0282299	12/2006	Hellwig	N/A	N/A
2007/0285238	12/2006	Batra	N/A	N/A
2007/0299617	12/2006	Willis	N/A	N/A
2008/0004515	12/2007	Jennewine et al.	N/A	N/A
2008/0004601	12/2007	Jennewine et al.	N/A	N/A
2008/0009692	12/2007	Stafford	N/A	N/A
2008/0012701	12/2007	Kass et al.	N/A	N/A
2008/0017522	12/2007	Heller et al.	N/A	N/A
2008/0018433	12/2007	Pitt-Pladdy	N/A	N/A
2008/0021436	12/2007	Wolpert et al.	N/A	N/A
2008/0021666	12/2007	Goode, Jr. et al.	N/A	N/A
2008/0021972	12/2007	Huelskamp et al.	N/A	N/A
2008/0029391	12/2007	Mao et al.	N/A	N/A
2008/0030369	12/2007	Mann et al.	N/A	N/A
2008/0033254	12/2007	Kamath et al.	N/A	N/A
2008/0039702	12/2007	Hayter et al.	N/A	N/A
2008/0045824	12/2007	Tapsak et al.	N/A	N/A
2008/0058625	12/2007	McGarraugh et al.	N/A	N/A
2008/0058773	12/2007	John	N/A	N/A
2008/0060955	12/2007	Goodnow	N/A	N/A
2008/0061961	12/2007	John	N/A	N/A
2008/0064937	12/2007	McGarraugh et al.	N/A	N/A
2008/0064943	12/2007	Talbot et al.	N/A	N/A
2008/0071156	12/2007	Brister et al.	N/A	N/A
2008/0071157	12/2007	McGarraugh et al.	N/A	N/A
2008/0071158	12/2007	McGarraugh et al.	N/A	N/A
2008/0071328	12/2007	Haubrich et al.	N/A	N/A
2008/0081977	12/2007	Hayter et al.	N/A	N/A
2008/0083617	12/2007	Simpson et al.	N/A	N/A
2008/0086042	12/2007	Brister et al.	N/A	N/A
2008/0086044	12/2007	Brister et al.	N/A	N/A
2008/0086273	12/2007	Shults et al.	N/A	N/A

2008/0092638	12/2007	Brenneman et al.	N/A	N/A
2008/0097246	12/2007	Stafford	N/A	N/A
2008/0097289	12/2007	Steil et al.	N/A	N/A
2008/0103447	12/2007	Reggiardo et al.	N/A	N/A
2008/0108942	12/2007	Brister et al.	N/A	N/A
2008/0114228	12/2007	McCluskey et al.	N/A	N/A
2008/0119705	12/2007	Patel et al.	N/A	N/A
2008/0119710	12/2007	Reggiardo et al.	N/A	N/A
2008/0139910	12/2007	Mastrototaro et al.	N/A	N/A
2008/0154099	12/2007	Aspel et al.	N/A	N/A
2008/0154513	12/2007	Kovatchev et al.	N/A	N/A
2008/0161666	12/2007	Feldman et al.	N/A	N/A
2008/0167543	12/2007	Say et al.	N/A	N/A
2008/0172205	12/2007	Breton et al.	N/A	N/A
2008/0177149	12/2007	Weinert et al.	N/A	N/A
2008/0177165	12/2007	Blomquist et al.	N/A	N/A
2008/0182537	12/2007	Manku et al.	N/A	N/A
2008/0183060	12/2007	Steil et al.	N/A	N/A
2008/0183061	12/2007	Goode et al.	N/A	N/A
2008/0183399	12/2007	Goode et al.	N/A	N/A
2008/0188731	12/2007	Brister et al.	N/A	N/A
2008/0188796	12/2007	Steil et al.	N/A	N/A
2008/0189051	12/2007	Goode et al.	N/A	N/A
2008/0194934	12/2007	Ray et al.	N/A	N/A
2008/0194935	12/2007	Brister et al.	N/A	N/A
2008/0194936	12/2007	Goode et al.	N/A	N/A
2008/0194937	12/2007	Goode et al.	N/A	N/A
2008/0194938	12/2007	Brister et al.	N/A	N/A
2008/0195232	12/2007	Carr-Brendel et al.	N/A	N/A
2008/0195967	12/2007	Goode et al.	N/A	N/A
2008/0197024	12/2007	Simpson et al.	N/A	N/A
2008/0200788	12/2007	Brister et al.	N/A	N/A
2008/0200789	12/2007	Brister et al.	N/A	N/A
2008/0200791	12/2007	Simpson et al.	N/A	N/A
2008/0201325	12/2007	Doniger et al.	N/A	N/A
2008/0208025	12/2007	Shults et al.	N/A	N/A
2008/0208026	12/2007	Noujaim et al.	N/A	N/A
2008/0208113	12/2007	Damiano et al.	N/A	N/A
2008/0214900	12/2007	Fennell et al.	N/A	N/A
2008/0214910	12/2007	Buck	N/A	N/A
2008/0214915	12/2007	Brister et al.	N/A	N/A
2008/0214918	12/2007	Brister et al.	N/A	N/A
2008/0228051	12/2007	Shults et al.	N/A	N/A
2008/0228054	12/2007	Shults et al.	N/A	N/A
2008/0228055	12/2007	Sher	N/A	N/A
2008/0234663	12/2007	Yodfat et al.	N/A	N/A
2008/0234943	12/2007	Ray et al.	N/A	N/A
2008/0234992	12/2007	Ray et al.	N/A	N/A
2008/0235469	12/2007	Drew	N/A	N/A
2008/0242961	12/2007	Brister et al.	N/A	N/A

2008/0242963	12/2007	Essenpreis et al.	N/A	N/A
2008/0254544	12/2007	Modzelewski et al.	N/A	N/A
2008/0255434	12/2007	Hayter et al.	N/A	N/A
2008/0255437	12/2007	Hayter	N/A	N/A
2008/0255438	12/2007	Saidara et al.	N/A	N/A
2008/0255808	12/2007	Hayter	N/A	N/A
2008/0256048	12/2007	Hayter	N/A	N/A
2008/0262469	12/2007	Brister et al.	N/A	N/A
2008/0269714	12/2007	Mastrototaro et al.	N/A	N/A
2008/0269723	12/2007	Mastrototaro et al.	N/A	N/A
2008/0275313	12/2007	Brister et al.	N/A	N/A
2008/0278333	12/2007	Fennell et al.	N/A	N/A
2008/0287761	12/2007	Hayter	N/A	N/A
2008/0287762	12/2007	Hayter	N/A	N/A
2008/0287763	12/2007	Hayter	N/A	N/A
2008/0287764	12/2007	Rasdal et al.	N/A	N/A
2008/0287765	12/2007	Rasdal et al.	N/A	N/A
2008/0287766	12/2007	Rasdal et al.	N/A	N/A
2008/0288180	12/2007	Hayter	N/A	N/A
2008/0288204	12/2007	Hayter et al.	N/A	N/A
2008/0294024	12/2007	Cosentino et al.	N/A	N/A
2008/0296155	12/2007	Shults et al.	N/A	N/A
2008/0300572	12/2007	Rankers et al.	N/A	N/A
2008/0306368	12/2007	Goode et al.	N/A	N/A
2008/0306434	12/2007	Dobbles et al.	N/A	N/A
2008/0306435	12/2007	Kamath et al.	N/A	N/A
2008/0306444	12/2007	Brister et al.	N/A	N/A
2008/0312518	12/2007	Jina et al.	N/A	N/A
2008/0312841	12/2007	Hayter	N/A	N/A
2008/0312842	12/2007	Hayter	N/A	N/A
2008/0312844	12/2007	Hayter et al.	N/A	N/A
2008/0312845	12/2007	Hayter et al.	N/A	N/A
2008/0314395	12/2007	Kovatchev et al.	N/A	N/A
2008/0319085	12/2007	Wright et al.	N/A	N/A
2008/0319279	12/2007	Ramsay et al.	N/A	N/A
2009/0005665	12/2008	Hayter et al.	N/A	N/A
2009/0005666	12/2008	Shin et al.	N/A	N/A
2009/0005729	12/2008	Hendrixson et al.	N/A	N/A
2009/0006034	12/2008	Hayter et al.	N/A	N/A
2009/0006061	12/2008	Thukral et al.	N/A	N/A
2009/0006133	12/2008	Weinert et al.	N/A	N/A
2009/0012376	12/2008	Agus	N/A	N/A
2009/0012379	12/2008	Goode et al.	N/A	N/A
2009/0018424	12/2008	Kamath et al.	N/A	N/A
2009/0018425	12/2008	Ouyang et al.	N/A	N/A
2009/0030293	12/2008	Cooper et al.	N/A	N/A
2009/0030294	12/2008	Petisce et al.	N/A	N/A
2009/0030641	12/2008	Fjield et al.	N/A	N/A
2009/0033482	12/2008	Hayter et al.	N/A	N/A
2009/0036747	12/2008	Hayter et al.	N/A	N/A

2009/0036758	12/2008	Brauker et al.	N/A	N/A
2009/0036760	12/2008	Hayter	N/A	N/A
2009/0036763	12/2008	Brauker et al.	N/A	N/A
2009/0040022	12/2008	Finkenzeller	N/A	N/A
2009/0043181	12/2008	Brauker et al.	N/A	N/A
2009/0043182	12/2008	Brauker et al.	N/A	N/A
2009/0043525	12/2008	Brauker et al.	N/A	N/A
2009/0043541	12/2008	Brauker et al.	N/A	N/A
2009/0043542	12/2008	Brauker et al.	N/A	N/A
2009/0045055	12/2008	Rhodes et al.	N/A	N/A
2009/0048503	12/2008	Dalal et al.	N/A	N/A
2009/0054737	12/2008	Magar et al.	N/A	N/A
2009/0054745	12/2008	Jennewine et al.	N/A	N/A
2009/0054747	12/2008	Fennell	N/A	N/A
2009/0054748	12/2008	Feldman et al.	N/A	N/A
2009/0054753	12/2008	Robinson et al.	N/A	N/A
2009/0055149	12/2008	Hayter et al.	N/A	N/A
2009/0062633	12/2008	Brauker et al.	N/A	N/A
2009/0062635	12/2008	Brauker et al.	N/A	N/A
2009/0062767	12/2008	Van Antwerp et al.	N/A	N/A
2009/0063187	12/2008	Johnson et al.	N/A	N/A
2009/0063402	12/2008	Hayter	N/A	N/A
2009/0076356	12/2008	Simpson et al.	N/A	N/A
2009/0076360	12/2008	Brister et al.	N/A	N/A
2009/0076361	12/2008	Kamath et al.	N/A	N/A
2009/0082693	12/2008	Stafford	N/A	N/A
2009/0085768	12/2008	Patel et al.	N/A	N/A
2009/0085873	12/2008	Betts et al.	N/A	N/A
2009/0088614	12/2008	Taub et al.	N/A	N/A
2009/0093687	12/2008	Telfort et al.	N/A	N/A
2009/0099436	12/2008	Brister et al.	N/A	N/A
2009/0105554	12/2008	Stahmann et al.	N/A	N/A
2009/0105560	12/2008	Solomon	N/A	N/A
2009/0105568	12/2008	Bugler	N/A	N/A
2009/0105570	12/2008	Sloan et al.	N/A	N/A
2009/0105571	12/2008	Fennell et al.	N/A	N/A
2009/0105636	12/2008	Hayter et al.	N/A	N/A
2009/0112478	12/2008	Mueller, Jr. et al.	N/A	N/A
2009/0112626	12/2008	Talbot et al.	N/A	N/A
2009/0124877	12/2008	Goode et al.	N/A	N/A
2009/0124878	12/2008	Goode et al.	N/A	N/A
2009/0124879	12/2008	Brister et al.	N/A	N/A
2009/0124964	12/2008	Leach et al.	N/A	N/A
2009/0131768	12/2008	Simpson et al.	N/A	N/A
2009/0131769	12/2008	Leach et al.	N/A	N/A
2009/0131776	12/2008	Simpson et al.	N/A	N/A
2009/0131777	12/2008	Simpson et al.	N/A	N/A
2009/0137886	12/2008	Shariati et al.	N/A	N/A
2009/0137887	12/2008	Shariati et al.	N/A	N/A
2009/0143659	12/2008	Li et al.	N/A	N/A

2009/0143660	12/2008	Brister et al.	N/A	N/A
2009/0149717	12/2008	Brauer et al.	N/A	N/A
2009/0149728	12/2008	Van Antwerp et al.	N/A	N/A
2009/0150186	12/2008	Cohen et al.	N/A	N/A
2009/0156919	12/2008	Brister et al.	N/A	N/A
2009/0156924	12/2008	Shariati et al.	N/A	N/A
2009/0163790	12/2008	Brister et al.	N/A	N/A
2009/0163791	12/2008	Brister et al.	N/A	N/A
2009/0163855	12/2008	Shin et al.	N/A	N/A
2009/0164190	12/2008	Hayter	N/A	N/A
2009/0164239	12/2008	Hayter et al.	N/A	N/A
2009/0164251	12/2008	Hayter	N/A	N/A
2009/0177068	12/2008	Stivoric et al.	N/A	N/A
2009/0178459	12/2008	Li et al.	N/A	N/A
2009/0182217	12/2008	Li et al.	N/A	N/A
2009/0189738	12/2008	Hermle	N/A	N/A
2009/0192366	12/2008	Mensingher et al.	N/A	N/A
2009/0192380	12/2008	Shariati et al.	N/A	N/A
2009/0192722	12/2008	Shariati et al.	N/A	N/A
2009/0192724	12/2008	Brauker et al.	N/A	N/A
2009/0192745	12/2008	Kamath et al.	N/A	N/A
2009/0192751	12/2008	Kamath et al.	N/A	N/A
2009/0198118	12/2008	Hayter et al.	N/A	N/A
2009/0203981	12/2008	Brauker et al.	N/A	N/A
2009/0204341	12/2008	Brauker et al.	N/A	N/A
2009/0216100	12/2008	Ebner et al.	N/A	N/A
2009/0216103	12/2008	Brister et al.	N/A	N/A
2009/0221890	12/2008	Saffer et al.	N/A	N/A
2009/0227855	12/2008	Hill et al.	N/A	N/A
2009/0234200	12/2008	Husheer	N/A	N/A
2009/0240120	12/2008	Mensingher et al.	N/A	N/A
2009/0240128	12/2008	Mensingher et al.	N/A	N/A
2009/0240193	12/2008	Mensingher et al.	N/A	N/A
2009/0240440	12/2008	Shurabura et al.	N/A	N/A
2009/0242399	12/2008	Kamath et al.	N/A	N/A
2009/0242425	12/2008	Kamath et al.	N/A	N/A
2009/0247855	12/2008	Boock et al.	N/A	N/A
2009/0247856	12/2008	Boock et al.	N/A	N/A
2009/0247857	12/2008	Harper et al.	N/A	N/A
2009/0247931	12/2008	Damgaard-Sorensen	N/A	N/A
2009/0253973	12/2008	Bashan et al.	N/A	N/A
2009/0267765	12/2008	Greene et al.	N/A	N/A
2009/0275815	12/2008	Bickoff et al.	N/A	N/A
2009/0287073	12/2008	Boock et al.	N/A	N/A
2009/0287074	12/2008	Shults et al.	N/A	N/A
2009/0289796	12/2008	Blumberg	N/A	N/A
2009/0291634	12/2008	Saarisalo	N/A	N/A
2009/0292188	12/2008	Hoss et al.	N/A	N/A
2009/0296742	12/2008	Sicurello et al.	N/A	N/A
2009/0298182	12/2008	Schulat et al.	N/A	N/A

2009/0299155	12/2008	Yang et al.	N/A	N/A
2009/0299156	12/2008	Simpson et al.	N/A	N/A
2009/0299162	12/2008	Brauker et al.	N/A	N/A
2009/0299276	12/2008	Brauker et al.	N/A	N/A
2010/0010324	12/2009	Brauker et al.	N/A	N/A
2010/0010329	12/2009	Taub et al.	N/A	N/A
2010/0010331	12/2009	Brauker et al.	N/A	N/A
2010/0010332	12/2009	Brauker et al.	N/A	N/A
2010/0016687	12/2009	Brauker et al.	N/A	N/A
2010/0016698	12/2009	Rasdal et al.	N/A	N/A
2010/0022855	12/2009	Brauker et al.	N/A	N/A
2010/0022988	12/2009	Wochner et al.	N/A	N/A
2010/0030038	12/2009	Brauker et al.	N/A	N/A
2010/0030053	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0030484	12/2009	Brauker et al.	N/A	N/A
2010/0030485	12/2009	Brauker et al.	N/A	N/A
2010/0036215	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036216	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036222	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036223	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0036225	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0041971	12/2009	Goode, Jr. et al.	N/A	N/A
2010/0045425	12/2009	Chivallier	N/A	N/A
2010/0045465	12/2009	Brauker et al.	N/A	N/A
2010/0049024	12/2009	Saint et al.	N/A	N/A
2010/0057040	12/2009	Hayter	N/A	N/A
2010/0057041	12/2009	Hayter	N/A	N/A
2010/0057042	12/2009	Hayter	N/A	N/A
2010/0057044	12/2009	Hayter	N/A	N/A
2010/0057057	12/2009	Hayter et al.	N/A	N/A
2010/0063373	12/2009	Kamath et al.	N/A	N/A
2010/0064764	12/2009	Hayter et al.	N/A	N/A
2010/0076283	12/2009	Simpson et al.	N/A	N/A
2010/0081906	12/2009	Hayter et al.	N/A	N/A
2010/0081908	12/2009	Dobbles et al.	N/A	N/A
2010/0081909	12/2009	Budiman et al.	N/A	N/A
2010/0081910	12/2009	Brister et al.	N/A	N/A
2010/0081953	12/2009	Syeda-Mahmood et al.	N/A	N/A
2010/0087724	12/2009	Brauker et al.	N/A	N/A
2010/0094111	12/2009	Heller et al.	N/A	N/A
2010/0094251	12/2009	Estes et al.	N/A	N/A
2010/0096259	12/2009	Zhang et al.	N/A	N/A
2010/0099970	12/2009	Shults et al.	N/A	N/A
2010/0099971	12/2009	Shults et al.	N/A	N/A
2010/0105999	12/2009	Dixon et al.	N/A	N/A
2010/0119693	12/2009	Tapsak et al.	N/A	N/A
2010/0121167	12/2009	McGarraugh et al.	N/A	N/A
2010/0121169	12/2009	Petisce et al.	N/A	N/A
2010/0141656	12/2009	Krieffewirth	N/A	N/A

2010/0152554	12/2009	Steine et al.	N/A	N/A
2010/0160759	12/2009	Celentano et al.	N/A	N/A
2010/0168538	12/2009	Keenan et al.	N/A	N/A
2010/0168546	12/2009	Kamath et al.	N/A	N/A
2010/0174266	12/2009	Estes	N/A	N/A
2010/0185175	12/2009	Kamen et al.	N/A	N/A
2010/0190435	12/2009	Cook et al.	N/A	N/A
2010/0191082	12/2009	Brister et al.	N/A	N/A
2010/0191085	12/2009	Budiman	N/A	N/A
2010/0191472	12/2009	Doniger et al.	N/A	N/A
2010/0198142	12/2009	Sloan et al.	N/A	N/A
2010/0198314	12/2009	Wei	N/A	N/A
2010/0204557	12/2009	Kiaie et al.	N/A	N/A
2010/0213080	12/2009	Celentano et al.	N/A	N/A
2010/0230285	12/2009	Hoss et al.	N/A	N/A
2010/0234710	12/2009	Budiman et al.	N/A	N/A
2010/0240975	12/2009	Goode et al.	N/A	N/A
2010/0261987	12/2009	Kamath et al.	N/A	N/A
2010/0268157	12/2009	Wehba et al.	N/A	N/A
2010/0274111	12/2009	Say et al.	N/A	N/A
2010/0274515	12/2009	Hoss et al.	N/A	N/A
2010/0312176	12/2009	Lauer et al.	N/A	N/A
2010/0313105	12/2009	Nekoomaram et al.	N/A	N/A
2011/0004085	12/2010	Mensing et al.	N/A	N/A
2011/0004276	12/2010	Blair et al.	N/A	N/A
2011/0024043	12/2010	Boock et al.	N/A	N/A
2011/0024307	12/2010	Simpson et al.	N/A	N/A
2011/0027127	12/2010	Simpson et al.	N/A	N/A
2011/0027453	12/2010	Boock et al.	N/A	N/A
2011/0027458	12/2010	Boock et al.	N/A	N/A
2011/0028815	12/2010	Simpson et al.	N/A	N/A
2011/0028816	12/2010	Simpson et al.	N/A	N/A
2011/0031986	12/2010	Bhat et al.	N/A	N/A
2011/0040163	12/2010	Telson et al.	N/A	N/A
2011/0058485	12/2010	Sloan	N/A	N/A
2011/0077490	12/2010	Simpson et al.	N/A	N/A
2011/0077494	12/2010	Doniger et al.	N/A	N/A
2011/0106011	12/2010	Cinar et al.	N/A	N/A
2011/0112696	12/2010	Yodfat et al.	N/A	N/A
2011/0148905	12/2010	Simmons et al.	N/A	N/A
2011/0152637	12/2010	Kateraas et al.	N/A	N/A
2011/0173308	12/2010	Gutekunst	N/A	N/A
2011/0178717	12/2010	Goodnow et al.	N/A	N/A
2011/0184267	12/2010	Duke et al.	N/A	N/A
2011/0193704	12/2010	Harper et al.	N/A	N/A
2011/0202495	12/2010	Gawlick	N/A	N/A
2011/0208027	12/2010	Wagner et al.	N/A	N/A
2011/0210830	12/2010	Talty et al.	N/A	N/A
2011/0257895	12/2010	Brauker et al.	N/A	N/A
2011/0282327	12/2010	Kellogg et al.	N/A	N/A

2011/0287528	12/2010	Fern et al.	N/A	N/A
2011/0289497	12/2010	Kiaie et al.	N/A	N/A
2011/0320130	12/2010	Valdes et al.	N/A	N/A
2012/0078071	12/2011	Bohm et al.	N/A	N/A
2012/0084053	12/2011	Yuen et al.	N/A	N/A
2012/0108934	12/2011	Valdes et al.	N/A	N/A
2012/0165626	12/2011	Irina et al.	N/A	N/A
2012/0165640	12/2011	Galley et al.	N/A	N/A
2012/0173200	12/2011	Breton et al.	N/A	N/A
2012/0233679	12/2011	Shedrinsky	N/A	N/A
2012/0238851	12/2011	Kamen et al.	N/A	N/A
2012/0255875	12/2011	Vicente et al.	N/A	N/A
2012/0309302	12/2011	Buhot	N/A	N/A
2012/0313785	12/2011	Hanson et al.	N/A	N/A
2013/0035575	12/2012	Mayou et al.	N/A	N/A
2013/0225959	12/2012	Bugler	N/A	N/A
2013/0231541	12/2012	Hayter et al.	N/A	N/A
2013/0235166	12/2012	Jones et al.	N/A	N/A
2013/0324823	12/2012	Koski et al.	N/A	N/A
2014/0005499	12/2013	Catt et al.	N/A	N/A
2014/0046160	12/2013	Terashima et al.	N/A	N/A
2014/0266785	12/2013	Miller et al.	N/A	N/A
2014/0313052	12/2013	Yarger et al.	N/A	N/A
2014/0379273	12/2013	Pestice et al.	N/A	N/A
2015/0123810	12/2014	Hernandez-Rosas et al.	N/A	N/A
2015/0205947	12/2014	Berman et al.	N/A	N/A
2015/0207796	12/2014	Love et al.	N/A	N/A
2015/0241407	12/2014	Ou et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2143172	12/2004	CA	N/A
2396613	12/2007	CA	N/A
2413148	12/2009	CA	N/A
4401400	12/1994	DE	N/A
0098592	12/1983	EP	N/A
0127958	12/1983	EP	N/A
0320109	12/1988	EP	N/A
0353328	12/1989	EP	N/A
0390390	12/1989	EP	N/A
0396788	12/1989	EP	N/A
0286118	12/1994	EP	N/A
0724859	12/1995	EP	N/A
0678308	12/1999	EP	N/A
1048264	12/1999	EP	N/A
1292218	12/2002	EP	N/A
1077634	12/2002	EP	N/A
1568309	12/2004	EP	N/A
1666091	12/2005	EP	N/A

1703697	12/2005	EP	N/A
1704893	12/2005	EP	N/A
1897487	12/2008	EP	N/A
1897492	12/2008	EP	N/A
2113864	12/2008	EP	N/A
1897488	12/2008	EP	N/A
1681992	12/2009	EP	N/A
1448489	12/2009	EP	N/A
1971396	12/2009	EP	N/A
2201969	12/2010	EP	N/A
2153382	12/2011	EP	N/A
2284773	12/2011	EP	N/A
2 498 196	12/2011	EP	N/A
3 210 137	12/2020	EP	N/A
2939158	12/2021	EP	N/A
3831282	12/2021	EP	N/A
3988471	12/2022	EP	N/A
2409951	12/2004	GB	N/A
WO-1993/006237	12/1992	WO	N/A
WO-1996/025089	12/1995	WO	N/A
WO-1996/035370	12/1995	WO	N/A
WO 97/18639	12/1996	WO	N/A
WO-1997/033513	12/1996	WO	N/A
WO-1998/035053	12/1997	WO	N/A
WO-1999/056613	12/1998	WO	N/A
WO-2000/049940	12/1999	WO	N/A
WO-2000/059370	12/1999	WO	N/A
WO-2000/074753	12/1999	WO	N/A
WO-2000/078992	12/1999	WO	N/A
WO-2001/052935	12/2000	WO	N/A
WO-2001/054753	12/2000	WO	N/A
WO-2002/016905	12/2001	WO	N/A
WO-2002/058537	12/2001	WO	N/A
WO-2003/076893	12/2002	WO	N/A
WO-2003/082091	12/2002	WO	N/A
WO-2003/085372	12/2002	WO	N/A
WO 2004/006982	12/2003	WO	N/A
WO-2004/047445	12/2003	WO	N/A
WO-2004/061420	12/2003	WO	N/A
WO-2005/010756	12/2004	WO	N/A
WO-2005/040404	12/2004	WO	N/A
WO-2005/041766	12/2004	WO	N/A
WO-2005/045744	12/2004	WO	N/A
WO 2005/065538	12/2004	WO	N/A
WO-2005/089103	12/2004	WO	N/A
WO-2005/119238	12/2004	WO	N/A
WO 2005/121785	12/2004	WO	N/A
WO-2006/024671	12/2005	WO	N/A
WO-2006/032653	12/2005	WO	N/A
WO-2006/051466	12/2005	WO	N/A

WO-2006/064397	12/2005	WO	N/A
WO-2006/079114	12/2005	WO	N/A
WO-2006/085087	12/2005	WO	N/A
WO-2006/118947	12/2005	WO	N/A
WO-2006/124099	12/2005	WO	N/A
WO-2007/007459	12/2006	WO	N/A
WO-2007/016399	12/2006	WO	N/A
WO-2007/027788	12/2006	WO	N/A
WO-2007/041069	12/2006	WO	N/A
WO-2007/041070	12/2006	WO	N/A
WO-2007/041248	12/2006	WO	N/A
WO-2007/056638	12/2006	WO	N/A
WO-2007/097754	12/2006	WO	N/A
WO-2007/101223	12/2006	WO	N/A
WO-2007/120363	12/2006	WO	N/A
WO-2007/126444	12/2006	WO	N/A
WO-2007/053832	12/2006	WO	N/A
WO-2007/143225	12/2006	WO	N/A
WO-2008/021913	12/2007	WO	N/A
WO-2008/042760	12/2007	WO	N/A
WO-2008/086541	12/2007	WO	N/A
WO-2008/128210	12/2007	WO	N/A
WO-2008/130896	12/2007	WO	N/A
WO-2008/130897	12/2007	WO	N/A
WO-2008/130898	12/2007	WO	N/A
WO-2008/143943	12/2007	WO	N/A
WO-2008/151452	12/2007	WO	N/A
WO-2009/018058	12/2008	WO	N/A
WO-2009/049252	12/2008	WO	N/A
WO-2009/086216	12/2008	WO	N/A
WO-2009/096992	12/2008	WO	N/A
WO-2009/097594	12/2008	WO	N/A
WO 2009/136372	12/2008	WO	N/A
WO-2010/077329	12/2009	WO	N/A
WO-2011/022418	12/2010	WO	N/A
WO 2012/154286	12/2011	WO	N/A
WO 2013/019225	12/2012	WO	N/A
WO 2014/070456	12/2013	WO	N/A
WO 2014/105631	12/2013	WO	N/A
WO 2015/069797	12/2014	WO	N/A
WO 2016/092448	12/2015	WO	N/A

OTHER PUBLICATIONS

About Dexcom—Continuous Glucose Monitoring Company, 12 pages (2021). cited by applicant
About the Congressional Record, Congress.gov, Library of Congress, 3 (2022) pages. cited by applicant
Bindra, D.S., et al., Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring, Analytical Chemistry, vol. 63, No. 17, pp. 1692-1696 (1991). cited by applicant
Burton, H.D., Urging FDA to Act Promptly to Approve Artificial Pancreas Technologies, Congressional Record (Bound Edition), vol. 157, Part 13, 3 pages (2011). cited by applicant
Cass, A.E.G., et al., Ferrocene-Mediated Enzyme Electrode for Amperometric Determination of

Glucose, Analytical Chemistry, vol. 56, No. 4, 5 pages (1984). cited by applicant

Choudhary, P., et al., Insulin Pump Therapy with Automated Insulin Suspension in Response to Hypoglycemia, Reduction in nocturnal hypoglycemia in those at greatest risk, Diabetes Care, vol. 34, pp. 2023-2025 (2011). cited by applicant

Claims, Specification and Drawings for System and Methods for Providing Sensitive and Specific Alarms, 103 pages. cited by applicant

Clarke, W., et al., Statistical Tools to Analyze Continuous Glucose Monitor Data, Diabetes Technology & Therapeutics, vol. 11, Supplement 1, pp. S-45-S-54 (2009). cited by applicant

Cunningham, D.D., et al., In Vivo Glucose Sensing, Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley, 466 pages (2010). cited by applicant

Declaration of Duncan Hall (2021) including DexCom™ STS™ Continuous Glucose Monitoring System User's Guide (2006), 64 pages. cited by applicant

Decuir, "Bluetooth 4.0:Low Energy", Standards Architect, CSR Technology, Councilor, Bluetooth Architecture Review Board, IEEE Region 6 Northwest Area Chair, 104 pages (2012). cited by applicant

Dementyev, et al., "Power Consumption Analysis of Bluetooth Low Energy, ZigBee and ANT Sensor Nodes in a Cyclic Sleep Scenario", IEEE International Wireless Symposium (IWS), 5 pages (2013). cited by applicant

Facchinetti, A, et al., A New Index to Optimally Design and Compare Continuous Glucose Monitoring Glucose Prediction Algorithms, Diabetes Technology & Therapeutics, vol. 13, No. 2, pp. 111-119 (2011). cited by applicant

FDA PMA Approvals, 3 pages. cited by applicant

FDA Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor, 6 pages, Notice Date: Apr. 1, 2008. cited by applicant

Feature Analysis, 1 page. cited by applicant

Federal Register, vol. 76, No. 120, pp. 36542-36543 (2011). cited by applicant

FreeStyle Navigator® Continuous Glucose Monitoring System, User's Guide, Abbott, 196 pages (2008). cited by applicant

Garg, S.K., et al., Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults with Type 1 Diabetes, Diabetes Care, vol. 27, No. 3, pp. 734-738 (2004). cited by applicant

Guerra, S., et al., A Dynamic Risk Measure from Continuous Glucose Monitoring Data, Diabetes Technology & Therapeutics, vol. 13, No. 8, pp. 843-852 (2011). cited by applicant

Hayter, P.G. et al., Performance Standards for Continuous Glucose Monitors, Diabetes Technology & Therapeutics, vol. 7, No. 5, pp. 721-726 (2005). cited by applicant

Heller, A., et al., Electrochemical Glucose Sensors and Their Applications in Diabetes Management, Chemical Reviews, vol. 108, No. 7, pp. 2482-2505 (2008). cited by applicant

Instructions for Use DexCom™ STS™ Sensor, 1 page. cited by applicant

International Standard, IEC 60601-1-8, Medical Electrical Equipment, 166 pages (2006). cited by applicant

Klonoff, "A Review of Continuous Glucose Monitoring Technology", Diabetes Technology & Therapeutics, 7(5):770-775 (2005). cited by applicant

Klonoff, "Continuous Glucose Monitoring: Roadmap for 21st century diabetes therapy", Diabetes Care, 28(5):1231-1239 (2005). cited by applicant

Letter from Department of Health & Human Services re. FreeStyle Navigator Continuous Glucose Monitoring System, 7 pages (2008). cited by applicant

Letter to EPO re. Divisional Application of EP Application No. 13784079.9 in the name of Dexcom, Inc., 2 pages (2020). cited by applicant

McMurry Jr., The Artificial Pancreas Today, Henry Ford Hospital Medical Journal, vol. 31, No. 2, Article 4, 8 pages (1983). cited by applicant

Morak, et al., "Design and Evaluation of a Telemonitoring Concept Based on NFC-Enabled Mobile

Phones and Sensor Devices”, IEEE Transactions on Information Technology in Biomedicine, 16(1):17-23 (2012). cited by applicant

Movassaghi, et al., “Wireless Technologies for Body Area Networks: Characteristics and Challenges”, IEEE, International Symposium on Communications, and Information Technologies (ISCIT), pp. 42-47 (2012). cited by applicant

Palerm, C.C., et al., Hypoglycemia Detection and Prediction Using Continuous Glucose Monitoring—A Study on Hypoglycemic Clamp Data, Journal of Diabetes Science and Technology. vol. 1, Issue 5, pp. 624-629 (2007). cited by applicant

Sandham, W., et al., Blood Glucose Prediction for Diabetes Therapy Using a Recurrent Artificial Neural Network, 4 pages. cited by applicant

Sparacino, G., et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, IEEE Transaction on Biomedical Engineering, vol. 54, No. 5, pp. 931-937 (2007). cited by applicant

Specification of the Bluetooth System, Experience More, Specification vol. 0, Covered Core Package Version: 4.0, 2 302 pages (2010). cited by applicant

STS® Seven Continuous Glucose Monitoring System, User's Guide, 74 pages (2007). cited by applicant

Summary of Safety and Effectiveness Data for Continuous Glucose Monitor, 27 pages (2008). cited by applicant

Summary of Safety and Effectiveness Data for DexCom™ STS™ Continuous Glucose Monitoring System, 20 pages (2006). cited by applicant

Summary of Safety and Effectiveness Data for STS®-7 Continuous Glucose Monitoring System, 14 pages (2007). cited by applicant

Townsend, et al., “Getting Started with Bluetooth Low Energy [Book]”, O'Reilly, retrieved from <https://www.oreilly.com/library/view/getting-started-with/9781491900550/ch01.html> on (May 5, 2020), 26 pages. cited by applicant

Wikipedia, “Blood glucose monitoring” retrieved from “https://web.archive.org/web/20111215063153/http://en.wikipedia.org/wiki/Blood_glucose_monitoring” on Aug. 1, 2021, 6 pages. cited by applicant

Wikipedia, “Near field communication” retrieved from “http://en.wikipedia.org/w/index.php?title=Near_field_communication&oldid=543740757” on Jun. 27, 2014, 14 pages. cited by applicant

Certified Copy of U.S. Appl. No. 61/238,657, filed Aug. 31, 2009, 60 pages. cited by applicant

Declaration of Thomas Edward Foster of Taylor Wessing LLP, Hill House, 1 Little New St. London EC4A 3TR (“Taylor Wessing”), in Relation to STS-7 Use's Guide, Jan. 30, 2024, 160 pages. cited by applicant

DeXCom STS-7 Approval Order, Department of Health and Human Services, FDA, May 31, 2007, 7 pages. cited by applicant

FDA Premarket Approval PMA Order for the STS-7, 3 pages, May 31, 2007. cited by applicant

File History of U.S. Pat. No. 10,375,222, issued Aug. 6, 2019, 442 pages. cited by applicant

NFC Forum, Bluetooth® Secure Simple Pairing Using NFC Application Document NFC Forum™, NFCForum-AD-BTSSP_1_1, Jan. 9, 2014, 39 pages. cited by applicant

Omre, “Bluetooth Low Energy: Wireless Connectivity for Medical Monitoring,” Journal of Diabetes Science and Technology, vol. 4, Issue 2, 457-463, Mar. 2010. cited by applicant

Padgett et al., “Guide to Bluetooth Security, Recommendations of the National Institute of Standards and Technology,” National Institute of Standards and Technology, U.S. Department of Commerce, Special Publication 800-121 Revision 1, 48 pages, May 2007. cited by applicant

Specification Bluetooth System Experience More, 134 pages, Jun. 2010. cited by applicant

Specification Bluetooth System Wireless connections, 92 pages, Nov. 2003. cited by applicant

Strömmer et al., “Application of Near Field Communication for Health Monitoring in Daily Life,” Proceedings of the 28th IEEE FrC09.1 EMBS Annual International Conference New York City, USA, 3246-3249, Aug. 30-Sep. 3, 2006. cited by applicant

Wayback Machine internet archive of US FDA CDRH PMA Final Decisions Rendered, 21 pages, May 2007. cited by applicant

Wayback Machine internet archive of US FDA CDRH PMA for STS-7, May 31, 2007, 1 page. cited by applicant

Zhang et al., “Bluetooth Low Energy for Wearable Sensor-based Healthcare Systems,” 2014 Health Innovations and Point-of-Care Technologies Conference Seattle, Washington USA, 251-254, Oct. 8-10, 2014. cited by applicant

Exhibit CP-2, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Sparacino, et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, IEEE Transactions on Biomedical Engineering, vol. 54, No. 5, pp. 931-937 (2007). cited by applicant

Exhibit CP-3, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: In Vivo Glucose Sensing, Chemical Analysis, A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley (2010). cited by applicant

Exhibit CP-4, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Animas® Vibe™, the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval (2011). cited by applicant

Exhibit CP-6, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Bailey, et al., Reduction in Hemoglobin Alc with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study, Diabetes Technology & Therapeutics, vol. 9, No. 3, pp. 203-210 (2007). cited by applicant

Exhibit CP-7, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor, Diabetes Care, vol. 29, No. 1, pp. 44-50 (2006). cited by applicant

Exhibit CP-8, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Relationship of Fasting and Hourly Blood Glucose Levels to HbA_{1c} Values, Diabetes Care, vol. 29, No. 12, pp. 2644-2649 (2006). cited by applicant

Exhibit CP-9, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Welcome to Your FreeStyle Libre System, In-Service Guide, Abbott (2017). cited by applicant

Exhibit CP-10, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Standards of Medical Care in Diabetes—2009, American Diabetes Association, Diabetes Care, vol. 32, Supplement 1, pp. S13-S61 (2009). cited by applicant

Exhibit No. 2, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus, EMEA, The European Agency for the Evaluation of Medicinal Products (2002). cited by applicant

Exhibit No. 3, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Defining and Reporting Hypoglycemia in Diabetes, Diabetes Care, vol. 28, No. 5, pp. 1245-1249 (2005). cited by applicant

Exhibit No. 4, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Amiel, et al., Review Article, Hypoglycaemia in Type 2 diabetes, Diabetic Medicine, vol. 25, pp. 245-254 (2008). cited by applicant

Exhibit No. 5, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Swinnen, et al., Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia, Diabetologia, vol. 52, pp. 38-41 (2009). cited by applicant

Exhibit No. 6, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Frier, Defining hypoglycaemia: what level has clinical relevance?, Diabetologia, vol. 52, pp. 31-34 (2009). cited by applicant

Exhibit No. 7, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Cryer, Preventing hypoglycaemia: what is the appropriate glucose alert value?, Diabetologia, vol. 52, pp. 35-37 (2009). cited by applicant

Exhibit No. 8, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011). cited by applicant

Exhibit No. 9, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, European Medicines Agency, Science Medicines Health (2012). cited by applicant

Exhibit No. 10, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 Diabetes Research Roadmap, Identifying the strengths and weaknesses, gaps and opportunities of UK type 1 diabetes research; clearing a path to the cure, JDRF Improving Lives. Curing Type 1 Diabetes. Join us in finding the cure for type 1 diabetes (2013). cited by applicant

Exhibit No. 11, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, The New England Journal of Medicine, vol. 329, No. 14 (1993). cited by applicant

Exhibit No. 12, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Modern Standards and Service Models, Diabetes, National Service Framework for Diabetes: Standards, Department of Health (2000). cited by applicant

Exhibit No. 13, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Training in flexible, intensive, insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ, vol. 325 (2002). cited by applicant

Exhibit No. 14, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, Clinical Guideline 15, NHS, National Institute for Clinical Excellence (2004). cited by applicant

Exhibit No. 15, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011). cited by applicant

Exhibit No. 16, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Pickup, et al., Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data, BMJ (2011). cited by applicant

Exhibit No. 17, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Diabetes (type 1), NIHR (2011). cited by applicant

Exhibit No. 18, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Aleppo, et al., Replace-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes, Diabetes Care, vol. 40, pp. 538-545 (2017). cited by applicant

Exhibit No. 19, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol. 40, pp. 155-157 (2017). cited by applicant

Exhibit No. 20, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Continuous Glucose Sensors: Continuing Questions about Clinical Accuracy, J Diabetes Sci Technol vol. 1, Issue 5, pp. 669-675 (2007). cited by applicant

Exhibit No. 21, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: DeVries, Glucose Sensing Issues for the Artificial Pancreas, Journal of Diabetes Science and Technology, vol. 2, Issue 4, pp. 732-734 (2008). cited by applicant

Exhibit No. 22, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Innovation Milestones, et al. cited by applicant

Exhibit No. 23, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® System Gold™ Continuous Glucose Monitoring Overview, Medtronic MiniMed (2004). cited by applicant

Exhibit No. 24, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: GlucoWatch G2,

Automatic Glucose Biographer and Auto Sensors (2002). cited by applicant

Exhibit No. 25, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guardian® Real-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed (2006). cited by applicant

Exhibit No. 26, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® iPro™ Continuous Glucose Recorder, User Guide, Medtronic MiniMed (2007). cited by applicant

Exhibit No. 27, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator, Continuous Glucose Monitoring System, User Guide, Abbott (2008, 2010). cited by applicant

Exhibit No. 28, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator II, Continuous Glucose Monitoring System, User's Manual, Abbott (2011-2013). cited by applicant

Exhibit No. 29, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Dexcom G4, Continuous Glucose Monitoring System, User's Guide (2013). cited by applicant

Exhibit No. 30, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for US 2007/208244A1. cited by applicant

Exhibit No. 31, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for EP625. cited by applicant

Exhibit No. 32, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Puhr, et al., Real-World Hypoglycemia Avoidance with a Predictive Low Glucose Alert Does Not Depend on Frequent Screen Views, *Journal of Diabetes Science and Technology*, vol. 14(1), pp. 83-86 (2020). cited by applicant

Exhibit No. 33, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Rilstone, et al., The impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for people with type 1 diabetes: Pace study (2022). cited by applicant

Exhibit No. 34, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 2, Flash Glucose Monitoring System, User's Manual, Abbott (2019-2021). cited by applicant

Exhibit No. 35, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 3, Continuous Glucose Monitoring System, User's Manual, Abbott (2022). cited by applicant

Exhibit No. 37, to the Second Expert Report of Professor Nick Oliver, Oct. 21, 2022: Oliver, et al., Review Article, Glucose sensors, a review of current and emerging technology, *Diabetic Medicine*, vol. 26, pp. 197-210 (2009). cited by applicant

File History of U.S. Appl. No. 61/551,773, filed Oct. 26, 2011, 27 pages. cited by applicant

Harvey, et al., Clinically Relevant Hypoglycemia Prediction Metrics for Event Mitigation, *Diabetes Technology & Therapeutics*. vol. 14, No. 8, pp. 719-727 (2012). cited by applicant

Hughes, et al., Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data, *Journal of Diabetes Science and Technology*, vol. 4, Issue 5, pp. 1146-1155 (2010). cited by applicant

Premarket Approval Letter with Summary of Safety and Effectiveness Data for the Freestyle Navigator Continuous Glucose Monitor, Mar. 12, 2008 [34 pgs.]. cited by applicant

Schiavon, An online method for prevention of the risk of glycemic shock in diabetic patients from continuous glucose monitoring data, 117 pages (2010) with English translation of summary attached. cited by applicant

User Guide for the Navigator Freestyle (Mar. 2008) [38 pgs.]. cited by applicant

“DexCom's 7-Day STS Continuous Glucose Monitoring System”, Jun. 1, 2007
<https://newatlas.com/dexcoms-7-day-sts-continuous-glucose-monitoring-system/7376/> 1 page. cited by applicant

Chuang et al., “Pilot Studies of Transdermal Continuous Glucose Measurement in Outpatient Diabetic Patients and in Patients during and after Cardiac Surgery,” *Journal of Diabetes Science and Technology*, 595-602 (2008). cited by applicant

Exhibit B-22.pdf—Opponent's Written Response in Opposition of EP 3 730 045, Sep. 27, 2023, 43 pages. cited by applicant

McCartney et al., “In vivo glucose sensing for diabetes management: progress towards non-invasive monitoring,” *BMJ*, vol. 319, 4 pages (1999). cited by applicant

Townsend et al., "Getting Started with Bluetooth Low Energy—Tools and Techniques for Low-Power Networking," O'Reilly Media, Inc., 180 pages (2014). cited by applicant

Wang et al. "A Feasible IMD Communication Protocol: Security without Obscurity," School of Engineering and Computing Sciences, NYIT Research Experience for Undergraduates (REU), May 26-Jul. 30, 2015, 1 page. cited by applicant

Alva et al., "Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System with Advanced Algorithm in Pediatric and Adult Population with Diabetes," Journal of Diabetes Science and Technology, vol. 16(1) 70-77 (2022). cited by applicant

Campbell et al., "Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study," Pediatric Diabetes, 1294-1301 (2018). cited by applicant

Deshmuk et al., "Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit," <https://doi.org/10.2337/dc20-0738>, Diabetes Care, 8 pages (2020). cited by applicant

Deutscher Gesundheitsbericht, Diabetes 2021, Die Bestandsaufnahme , German Diabetes Society, with English Abstract, 15 pages (2021). cited by applicant

DexCom™ STS™ Continuous Glucose Monitoring System, User's Guide, 2006, 57 pages. cited by applicant

FDA, STS-7 Continuous Glucose Monitoring System, P050012/S001, May 31, 2007, 95 pages. cited by applicant

Haak et al., "Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes," Diabetes Ther., 14 pages (2017). cited by applicant

Roussel et al., "Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The Relief Study," American Diabetes Association, Diabetes Care, 1368-1376 (2021). cited by applicant

U.S. Appl. No. 15/681,345 (U.S. Pat. No. 11,076,785), filed Aug. 19, 2017 (Aug. 3, 2021). cited by applicant

U.S. Appl. No. 14/741,457 (U.S. Pat. No. 9,737,249), filed Jun. 17, 2015 (Aug. 22, 2015). cited by applicant

U.S. Appl. No. 14/106,000 (U.S. Pat. No. 9,060,719), filed Dec. 13, 2013 (Jun. 23, 2015). cited by applicant

U.S. Appl. No. 13/599,847 (U.S. Pat. No. 8,612,163), filed Aug. 30, 2012 (Dec. 17, 2013). cited by applicant

U.S. Appl. No. 12/152,636 (U.S. Pat. No. 8,260,558), filed May 14, 2008 (Sep. 4, 2012). cited by applicant

U.S. Appl. No. 15/681,345, Jun. 30, 2021 Issue Fee Payment. cited by applicant

U.S. Appl. No. 15/681,345, Mar. 31, 2021 Notice of Allowance. cited by applicant

U.S. Appl. No. 15/681,345, Jan. 22, 2021 Request for Continued Examination. cited by applicant

U.S. Appl. No. 15/681,345, Jan. 19, 2021 Response to Final Office Action. cited by applicant

U.S. Appl. No. 15/681,345, Oct. 20, 2020 Final Office Action. cited by applicant

U.S. Appl. No. 15/681,345, Jul. 2, 2020 Response to Non-Final Office Action. cited by applicant

U.S. Appl. No. 15/681,345, Apr. 6, 2020 Non-Final Office Action. cited by applicant

Armour, J. C., et al., "Application of Chronic Intravascular Blood Glucose Sensor in Dogs", Diabetes, vol. 39, 1990, pp. 1519-1526. cited by applicant

Arnold, M. A., et al., "Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors", Journal of Diabetes Science and Technology, vol. 1, No. 4, 2007, pp. 454-462. cited by applicant

Aussedat, B., et al., "A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycemic Alarm", Biosensors & Bioelectronics, vol. 12, No. 11, 1997, pp. 1061-1070. cited by

applicant

Bennion, N., et al., "Alternate Site Glucose Testing: A Crossover Design", *Diabetes Technology & Therapeutics*, vol. 4, No. 1, 2002, pp. 25-33. cited by applicant

Blank, T. B., et al., "Clinical Results From a Non-Invasive Blood Glucose Monitor", *Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II*, *Proceedings of SPIE*, vol. 4624, 2002, pp. 1-10. cited by applicant

Boyne, M. S., et al., "Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor", *Diabetes*, vol. 52, Nov. 2003, pp. 2790-2794. cited by applicant

Bremer, T. M., et al., "Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies", *Diabetes Technology & Therapeutics*, vol. 3, No. 3, 2001, pp. 409-418. cited by applicant

Brooks, S. L., et al., "Development of an On-Line Glucose Sensor for Fermentation Monitoring", *Biosensors*, vol. 3, 1987/88, pp. 45-56. cited by applicant

Cass, A. E., et al., "Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose", *Analytical Chemistry*, vol. 56, No. 4, 1984, 667-671. cited by applicant

Cheyne, E. H., et al., "Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers", *Diabetes Technology & Therapeutics*, vol. 4, No. 5, 2002, pp. 607-613. cited by applicant

Csoregi, E., et al., "Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on 'Wired' Glucose Oxidase", *Analytical Chemistry*, vol. 67, No. 7, 1995, pp. 1240-1244. cited by applicant

El-Khatib, F. H., et al., "Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine", *Journal of Diabetes Science and Technology*, vol. 1, No. 2, 2007, pp. 181-192. cited by applicant

Eren-Oruklu, M., et al., "Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models", *Diabetes Technology & Therapeutics* vol. 11(4), 2009, pp. 243-253. cited by applicant

Feldman, B., et al., "A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes", *Diabetes Technology & Therapeutics*, vol. 5, No. 5, 2003, pp. 769-779. cited by applicant

Feldman, B., et al., "Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change", *Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet*, 2004. cited by applicant

Garg, S., et al., "Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor", *Diabetes Care*, vol. 29, No. 1, 2006, pp. 44-50. cited by applicant

Hovorka, R., et al., "Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes", *Physiological Measurement*, vol. 55, Jul. 2004, pp. 905-920. cited by applicant

Isermann, R., "Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction", *Control Engineering Practice*, vol. 5, No. 5, 1997, pp. 639-652. cited by applicant

Isermann, R., et al., "Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes", *Control Engineering Practice*, vol. 5, No. 5, 1997, pp. 709-719. cited by applicant

Johnson, p. C., "Peripheral Circulation", *John Wiley & Sons*, 1978, pp. 198. cited by applicant

Jungheim, K., et al., "How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?", 2002, pp. 250. cited by applicant

Jungheim, K., et al., "Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm", *Diabetes Care*, vol. 24, No. 7, 2001, pp. 1303-1304. cited by applicant

Kaplan, S. M., "Wiley Electrical and Electronics Engineering Dictionary", *IEEE Press*, 2004, pp. 141, 142, 548, 549. cited by applicant

Kovatchev, B. P., et al., "Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag", *Diabetes Technology & Therapeutics*, vol. 11, No. 3, 2009, pp. 139-143. cited by applicant

Kuure-Kinsey, M., et al., "A Dual-Rate Kalman Filter for Continuous Glucose Monitoring", Proceedings of the 28th IEEE, EMBS Annual International Conference, New York City, 2006, pp. 63-66. cited by applicant

Li, Y., et al., "In Vivo Release From a Drug Delivery MEMS Device", Journal of Controlled Release, vol. 100, 2004, pp. 211-219. cited by applicant

Lo, B., et al., "Key Technical Challenges and Current Implementations of Body Sensor Networks", Body Sensor Networks, 2005, pp. 1-5. cited by applicant

Lodwig, V., et al., "Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria", Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 573-587. cited by applicant

Lortz, J., et al., "What is Bluetooth? We Explain The Newest Short-Range Connectivity Technology", Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74. cited by applicant

Malin, S. F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy", Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658. cited by applicant

McGarraugh, G., et al., "Glucose Measurements Using Blood Extracted from the Forearm and the Finger", TheraSense, Inc., 2001, 16 Pages. cited by applicant

McGarraugh, G., et al., "Physiological Influences on Off-Finger Glucose Testing", Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376. cited by applicant

McKean, B. D., et al., "A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors", IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532. cited by applicant

Morbiducci, U, et al., "Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation", Clinical Science, vol. 112, 2007, pp. 257-263. cited by applicant

Mougiakakou, et al., "A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients", Proceedings of the 2005 IEEE, 2005, pp. 298-301. cited by applicant

Panteleon, A. E., et al., "The Role of the Independent Variable to Glucose Sensor Calibration", Diabetes Technology & Therapeutics, vol. 5, No. 3, 2003, pp. 401-410. cited by applicant

Parker, R., et al., "Robust H_{∞} Glucose Control in Diabetes Using a Physiological Model", AIChE Journal, vol. 46, No. 12, 2000, pp. 2537-2549. cited by applicant

Pickup, J., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy", Biosensors, vol. 3, 1987/88, pp. 335-346. cited by applicant

Pickup, J., et al., "In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer", Diabetologia, vol. 32, 1989, pp. 213-217. cited by applicant

Pishko, M. V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels", Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272. cited by applicant

Quinn, C. P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors", The American Physiological Society, 1995, E155-E161. cited by applicant

Rodriguez, N., et al., "Flexible Communication and Control Protocol for Injectable Neuromuscular Interfaces", IEEE Transactions on Biomedical Circuits and Systems, vol. 1, No. 1, 2007, pp. 19-27. cited by applicant

Roe, J. N., et al., "Bloodless Glucose Measurements", Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241. cited by applicant

Sakakida, M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations", Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158. cited by applicant

Sakakida, M., et al., "Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane", Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322. cited by applicant

Salehi, C., et al., "A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors", *Analytical Letters*, vol. 29, No. 13, 1996, pp. 2289-2308. cited by applicant

Schmidtke, D. W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin", *Proceedings of the National Academy of Sciences*, vol. 95, 1998, pp. 294-299. cited by applicant

Shaw, G. W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients", *Biosensors & Bioelectronics*, vol. 6, 1991, pp. 401-406. cited by applicant

Shichiri, M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas", *Diabetologia*, vol. 24, 1983, pp. 179-184. cited by applicant

Shichiri, M., et al., "In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers", *Hormone and Metabolic Research Supplement Series*, vol. 20, 1988, pp. 17-20. cited by applicant

Shichiri, M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor", *Diabetes Nutrition and Metabolism*, vol. 2, 1989, pp. 309-313. cited by applicant

Shichiri, M., et al., "Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas", *Implantable Sensors for Closed-Loop Prosthetic Systems*, Chapter 15, 1985, pp. 197-210. cited by applicant

Shichiri, M., et al., "Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals", *Diabetes Care*, vol. 9, No. 3, 1986, pp. 298-301. cited by applicant

Shichiri, M., et al., "Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor", *The Lancet*, 1982, pp. 1129-1131. cited by applicant

Shults, M. C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors", *IEEE Transactions on Biomedical Engineering*, vol. 41, No. 10, 1994, pp. 937-942. cited by applicant

Steil, G. M., et al., "Closed-Loop Insulin Delivery—the Path of Physiological Glucose Control", *Advanced Drug Delivery Reviews*, vol. 56, 2004, pp. 125-144. cited by applicant

Steil, G. M., et al., "Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor", *Diabetes Technology & Therapeutics*, vol. 5, No. 1, 2003, pp. 27-31. cited by applicant

Sternberg, R., et al., "Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors", *Biosensors*, vol. 4, 1988, pp. 27-40. cited by applicant

Thompson, M., et al., "In Vivo Probes: Problems and Perspectives", *Clinical Biochemistry*, vol. 19, 1986, pp. 255-261. cited by applicant

Turner, A., et al., "Diabetes Mellitus: Biosensors for Research and Management", *Biosensors*, vol. 1, 1985, pp. 85-115. cited by applicant

Updike, S. J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)", *Biosensors in the Body: Continuous in vivo Monitoring*, Chapter 4, 1997, pp. 117-137. cited by applicant

Velho, G., et al., "Strategies for Calibrating a Subcutaneous Glucose Sensor", *Biomedica Biochimica Acta*, vol. 48, 1989, pp. 957-964. cited by applicant

Wilson, G. S., et al., "Progress Toward the Development of an Implantable Sensor for Glucose", *Clinical Chemistry*, vol. 38, No. 9, 1992, pp. 1613-1617. cited by applicant

Canadian Patent Application No. 2,683,930, Examiner's Report mailed Aug. 17, 2015. cited by applicant

Canadian Patent Application No. 2,683,930, Examiner's Report mailed Jul. 22, 2014. cited by applicant

European Patent Application No. 08745803.0, Extended European Search Report mailed Sep. 27, 2012. cited by applicant

European Patent Application No. 08745805.5, Examination Report mailed Jan. 30, 2015. cited by

applicant

European Patent Application No. 08745805.5, Extended European Search Report mailed May 23, 2012.

cited by applicant

European Patent Application No. 08745807.1, Extended European Search Report mailed Oct. 8, 2012.

cited by applicant

European Patent Application No. 08745809.7, Examination Report mailed Aug. 16, 2016. cited by applicant

European Patent Application No. 08745809.7, Extended European Search Report mailed Jul. 2, 2012.

cited by applicant

European Patent Application No. 08754499.5, Extended European Search Report mailed Sep. 20, 2012.

cited by applicant

European Patent Application No. 08796500.0, Examination Report mailed Dec. 4, 2014. cited by applicant

European Patent Application No. 08796500.0, Extended European Search Report mailed Jan. 14, 2014.

cited by applicant

European Patent Application No. 08871628.7, Extended European Search Report mailed Oct. 15, 2012.

cited by applicant

PCT Application No. PCT/US2008/006247, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Nov. 26, 2009. cited by applicant

PCT Application No. PCT/US2008/006247, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 5, 2008. cited by applicant

PCT Application No. PCT/US2008/060277, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009. cited by applicant

PCT Application No. PCT/US2008/060277, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 22, 2008. cited by applicant

PCT Application No. PCT/US2008/060279, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009. cited by applicant

PCT Application No. PCT/US2008/060279, International Search Report and Written Opinion of the International Searching Authority mailed Jul. 14, 2008. cited by applicant

PCT Application No. PCT/US2008/060281, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009. cited by applicant

PCT Application No. PCT/US2008/060281, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 23, 2008. cited by applicant

PCT Application No. PCT/US2008/060282, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009. cited by applicant

PCT Application No. PCT/US2008/060282, International Search Report and Written Opinion of the International Searching Authority mailed Jun. 18, 2009. cited by applicant

PCT Application No. PCT/US2008/060284, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009. cited by applicant

PCT Application No. PCT/US2008/060284, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 23, 2008. cited by applicant

PCT Application No. PCT/US2008/070923, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, mailed Feb. 11, 2010. cited by applicant

PCT Application No. PCT/US2008/070923, International Search Report and Written Opinion of the International Searching Authority mailed Oct. 1, 2008. cited by applicant

PCT Application No. PCT/US2009/032756, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, mailed Aug. 12, 2010. cited by applicant

PCT Application No. PCT/US2009/032756, International Search Report and Written Opinion of the International Searching Authority mailed Apr. 7, 2009. cited by applicant

U.S. Appl. No. 11/831,866, Notice of Allowance mailed May 26, 2010. cited by applicant

U.S. Appl. No. 11/831,866, Office Action mailed Jun. 25, 2009. cited by applicant
U.S. Appl. No. 11/831,866, Supplemental Office Action mailed Dec. 9, 2009. cited by applicant
U.S. Appl. No. 11/831,881, Advisory Action mailed Aug. 23, 2013. cited by applicant
U.S. Appl. No. 11/831,881, Notice of Allowance mailed Jun. 20, 2014. cited by applicant
U.S. Appl. No. 11/831,881, Office Action mailed Jun. 21, 2011. cited by applicant
U.S. Appl. No. 11/831,881, Office Action mailed Mar. 13, 2014. cited by applicant
U.S. Appl. No. 11/831,881, Office Action mailed May 23, 2013. cited by applicant
U.S. Appl. No. 11/831,881, Office Action mailed Nov. 17, 2011. cited by applicant
U.S. Appl. No. 11/831,881, Office Action mailed Oct. 1, 2012. cited by applicant
U.S. Appl. No. 11/831,895, Advisory Action mailed Apr. 22, 2015. cited by applicant
U.S. Appl. No. 11/831,895, Advisory Action mailed Aug. 5, 2013. cited by applicant
U.S. Appl. No. 11/831,895, Advisory Action mailed Jan. 18, 2012. cited by applicant
U.S. Appl. No. 11/831,895, Advisory Action mailed Jan. 25, 2012. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed Feb. 13, 2015. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed Jul. 17, 2014. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed Jul. 20, 2012. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed Mar. 21, 2016. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed May 16, 2013. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed May 25, 2011. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed Oct. 1, 2013. cited by applicant
U.S. Appl. No. 11/831,895, Office Action mailed Oct. 14, 2011. cited by applicant
U.S. Appl. No. 12/024,101, Notice of Allowance Jan. 9, 2012. cited by applicant
U.S. Appl. No. 12/024,101, Office Action mailed Feb. 17, 2011. cited by applicant
U.S. Appl. No. 12/024,101, Office Action mailed Oct. 17, 2011. cited by applicant
U.S. Appl. No. 12/102,839, Advisory Action mailed May 1, 2013. cited by applicant
U.S. Appl. No. 12/102,839, Notice of Allowance mailed Oct. 30, 2015. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Aug. 1, 2013. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Aug. 5, 2010. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Dec. 14, 2009. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Dec. 14, 2012. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Dec. 5, 2013. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Jan. 25, 2011. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Jul. 17, 2015. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed May 25, 2012. cited by applicant
U.S. Appl. No. 12/102,839, Office Action mailed Oct. 27, 2011. cited by applicant
U.S. Appl. No. 12/102,844, Notice of Allowance mailed Jan. 10, 2012. cited by applicant
U.S. Appl. No. 12/102,844, Office Action mailed Aug. 17, 2011. cited by applicant
U.S. Appl. No. 12/102,847, Advisory Action mailed Aug. 27, 2014. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Apr. 24, 2014. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Aug. 18, 2011. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Aug. 3, 2015. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Dec. 31, 2015. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Feb. 12, 2015. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Jan. 10, 2012. cited by applicant
U.S. Appl. No. 12/102,847, Office Action mailed Jun. 16, 2014. cited by applicant
U.S. Appl. No. 12/102,855, Office Action mailed Aug. 24, 2011. cited by applicant
U.S. Appl. No. 12/102,855, Office Action mailed Jan. 10, 2012. cited by applicant
U.S. Appl. No. 12/102,855, Office Action mailed Jun. 11, 2014. cited by applicant
U.S. Appl. No. 12/102,855, Office Action mailed Mar. 23, 2016. cited by applicant
U.S. Appl. No. 12/102,855, Office Action mailed May 13, 2015. cited by applicant

U.S. Appl. No. 12/102,855, Office Action mailed Oct. 24, 2014. cited by applicant
U.S. Appl. No. 12/102,855, Office Action mailed Sep. 2, 2015. cited by applicant
U.S. Appl. No. 12/102,856, Notice of Allowance mailed Feb. 25, 2015. cited by applicant
U.S. Appl. No. 12/102,856, Office Action mailed Aug. 17, 2011. cited by applicant
U.S. Appl. No. 12/102,856, Office Action mailed Jan. 10, 2012. cited by applicant
U.S. Appl. No. 12/102,856, Office Action mailed May 7, 2014. cited by applicant
U.S. Appl. No. 12/102,856, Office Action mailed Nov. 25, 2014. cited by applicant
U.S. Appl. No. 12/152,623, Notice of Allowance Mailed Nov. 3, 2011. cited by applicant
U.S. Appl. No. 12/152,623, Office Action mailed May 26, 2011. cited by applicant
U.S. Appl. No. 12/152,636, Advisory Action mailed Jan. 19, 2012. cited by applicant
U.S. Appl. No. 12/152,636, Advisory Action mailed Jan. 6, 2012. cited by applicant
U.S. Appl. No. 12/152,636, Notice of Allowance mailed Jun. 19, 2012. cited by applicant
U.S. Appl. No. 12/152,636, Office Action mailed Dec. 27, 2010. cited by applicant
U.S. Appl. No. 12/152,636, Office Action mailed Sep. 20, 2011. cited by applicant
U.S. Appl. No. 12/152,648, Notice of Allowance mailed Aug. 2, 2013. cited by applicant
U.S. Appl. No. 12/152,648, Office Action mailed Aug. 12, 2011. cited by applicant
U.S. Appl. No. 12/152,648, Office Action mailed Aug. 29, 2012. cited by applicant
U.S. Appl. No. 12/152,648, Office Action mailed Jan. 27, 2012. cited by applicant
U.S. Appl. No. 12/152,648, Office Action mailed Mar. 13, 2013. cited by applicant
U.S. Appl. No. 12/152,649, Notice of Allowance mailed Jul. 1, 2013. cited by applicant
U.S. Appl. No. 12/152,649, Office Action mailed Aug. 5, 2011. cited by applicant
U.S. Appl. No. 12/152,649, Office Action mailed Jan. 27, 2012. cited by applicant
U.S. Appl. No. 12/152,649, Office Action mailed Nov. 5, 2012. cited by applicant
U.S. Appl. No. 12/152,650, Notice of Allowance mailed Jan. 22, 2013. cited by applicant
U.S. Appl. No. 12/152,650, Office Action mailed Aug. 11, 2011. cited by applicant
U.S. Appl. No. 12/152,650, Office Action mailed Jan. 26, 2012. cited by applicant
U.S. Appl. No. 12/152,650, Office Action mailed Jul. 25, 2012. cited by applicant
U.S. Appl. No. 12/152,652, Advisory Action mailed Jan. 13, 2012. cited by applicant
U.S. Appl. No. 12/152,652, Notice of Allowance mailed May 3, 2012. cited by applicant
U.S. Appl. No. 12/152,652, Office Action mailed Jun. 23, 2011. cited by applicant
U.S. Appl. No. 12/152,652, Office Action mailed Nov. 1, 2011. cited by applicant
U.S. Appl. No. 12/152,657, Notice of Allowance mailed Jul. 10, 2015. cited by applicant
U.S. Appl. No. 12/152,657, Office Action mailed Apr. 24, 2015. cited by applicant
U.S. Appl. No. 12/152,657, Office Action mailed Aug. 11, 2011. cited by applicant
U.S. Appl. No. 12/152,657, Office Action mailed Jan. 26, 2012. cited by applicant
U.S. Appl. No. 12/152,657, Office Action mailed Sep. 18, 2014. cited by applicant
U.S. Appl. No. 12/152,662, Advisory Action mailed Sep. 3, 2014. cited by applicant
U.S. Appl. No. 12/152,662, Office Action mailed Aug. 19, 2011. cited by applicant
U.S. Appl. No. 12/152,662, Office Action mailed Aug. 19, 2015. cited by applicant
U.S. Appl. No. 12/152,662, Office Action mailed Jan. 11, 2012. cited by applicant
U.S. Appl. No. 12/152,662, Office Action mailed Jan. 23, 2015. cited by applicant
U.S. Appl. No. 12/152,662, Office Action mailed Jun. 12, 2014. cited by applicant
U.S. Appl. No. 12/152,662, Office Action mailed Mar. 9, 2016. cited by applicant
U.S. Appl. No. 12/152,670, Notice of Allowance mailed Jun. 20, 2011. cited by applicant
U.S. Appl. No. 12/152,670, Office Action mailed Jan. 7, 2011. cited by applicant
U.S. Appl. No. 12/152,673, Advisory Action mailed Apr. 9, 2013. cited by applicant
U.S. Appl. No. 12/152,673, Office Action mailed Aug. 26, 2011. cited by applicant
U.S. Appl. No. 12/152,673, Office Action mailed Jan. 30, 2013. cited by applicant
U.S. Appl. No. 12/152,673, Office Action mailed Jan. 5, 2012. cited by applicant
U.S. Appl. No. 12/152,673, Office Action mailed Jul. 11, 2012. cited by applicant

U.S. Appl. No. 13/356,598, Notice of Allowance mailed Jul. 11, 2013. cited by applicant
U.S. Appl. No. 13/356,598, Office Action mailed Aug. 30, 2012. cited by applicant
U.S. Appl. No. 13/356,598, Office Action mailed May 2, 2013. cited by applicant
U.S. Appl. No. 13/424,291, Notice of Allowance mailed Apr. 24, 2013. cited by applicant
U.S. Appl. No. 13/424,291, Office Action mailed Feb. 6, 2013. cited by applicant
U.S. Appl. No. 13/424,291, Office Action mailed Jul. 31, 2012. cited by applicant
U.S. Appl. No. 13/567,038, Notice of Allowance Nov. 22, 2013. cited by applicant
U.S. Appl. No. 13/567,038, Office Action mailed Jun. 6, 2013. cited by applicant
U.S. Appl. No. 13/567,038, Office Action mailed Oct. 10, 2013. cited by applicant
U.S. Appl. No. 13/599,847, Notice of Allowance mailed Aug. 21, 2013. cited by applicant
U.S. Appl. No. 13/599,847, Office Action mailed Jan. 29, 2013. cited by applicant
U.S. Appl. No. 13/898,139, Notice of Allowance mailed Sep. 15, 2016. cited by applicant
U.S. Appl. No. 13/898,139, Office Action mailed Jan. 21, 2016. cited by applicant
U.S. Appl. No. 13/925,685, Notice of Allowance mailed Sep. 20, 2016. cited by applicant
U.S. Appl. No. 13/925,685, Office Action mailed May 16, 2016. cited by applicant
U.S. Appl. No. 14/028,358, Notice of Allowance mailed Jul. 19, 2017. cited by applicant
U.S. Appl. No. 14/028,358, Office Action mailed Mar. 22, 2017. cited by applicant
U.S. Appl. No. 14/028,358, Office Action mailed Nov. 2, 2016. cited by applicant
U.S. Appl. No. 14/052,381, Advisory Action mailed May 10, 2017. cited by applicant
U.S. Appl. No. 14/052,381, Notice of Allowance mailed Jun. 16, 2017. cited by applicant
U.S. Appl. No. 14/052,381, Office Action mailed Feb. 21, 2017. cited by applicant
U.S. Appl. No. 14/052,381, Office Action mailed Oct. 3, 2016. cited by applicant
U.S. Appl. No. 14/077,004, Office Action mailed Jul. 26, 2016. cited by applicant
U.S. Appl. No. 14/094,721, Advisory Action mailed Sep. 28, 2016. cited by applicant
U.S. Appl. No. 14/094,721, Office Action mailed Feb. 25, 2016. cited by applicant
U.S. Appl. No. 14/094,721, Office Action mailed Jun. 30, 2016. cited by applicant
U.S. Appl. No. 14/094,721, Office Action mailed Mar. 17, 2107. cited by applicant
U.S. Appl. No. 14/094,721, Office Action mailed Nov. 17, 2016. cited by applicant
U.S. Appl. No. 14/094,721, Office Action mailed Nov. 16, 2017. cited by applicant
U.S. Appl. No. 14/106,000, Notice of Allowance mailed Apr. 24, 2015. cited by applicant
U.S. Appl. No. 14/106,000, Office Action mailed Aug. 26, 2014. cited by applicant
U.S. Appl. No. 14/106,000, Office Action mailed Jun. 17, 2014. cited by applicant
U.S. Appl. No. 14/106,000, Office Action mailed Nov. 26, 2014. cited by applicant
U.S. Appl. No. 14/223,893, Notice of Allowance mailed Aug. 11, 2017. cited by applicant
U.S. Appl. No. 14/223,893, Office Action mailed Mar. 28, 2017. cited by applicant
U.S. Appl. No. 14/223,893, Office Action mailed Nov. 14, 2016. cited by applicant
U.S. Appl. No. 14/223,893, Office Action mailed Nov. 7, 2016. cited by applicant
U.S. Appl. No. 14/472,341, Notice of Allowance mailed Mar. 28, 2016. cited by applicant
U.S. Appl. No. 14/472,341, Office Action mailed Apr. 10, 2015. cited by applicant
U.S. Appl. No. 14/472,341, Office Action mailed Dec. 23, 2014. cited by applicant
U.S. Appl. No. 14/472,341, Office Action mailed Oct. 9, 2015. cited by applicant
U.S. Appl. No. 14/741,457, Notice of Allowance mailed Apr. 12, 2017. cited by applicant
U.S. Appl. No. 14/741,457, Office Action mailed Apr. 8, 2016. cited by applicant
U.S. Appl. No. 14/741,457, Office Action mailed Oct. 28, 2016. cited by applicant
U.S. Appl. No. 14/846,986, Office Action mailed Aug. 3, 2017. cited by applicant
U.S. Appl. No. 15/294,683, Office Action mailed Feb. 10, 2017. cited by applicant
U.S. Appl. No. 15/461,459, Office Action mailed Dec. 11, 2017. cited by applicant
U.S. Appl. No. 15/796,262, Office Action mailed Jan. 11, 2018. cited by applicant
U.S. Appl. No. 15/796,274, Office Action mailed Dec. 29, 2017. cited by applicant
Select pages from OneTouch UltraVue User Manual published on Oct. 1, 2009 (with English

Translation), 4 pages. cited by applicant

Annex A2 Documents relating to the Patent Extract from the EP Register for the Patent, EP 3988471, 6 pages (2023). cited by applicant

Annex B1 Evidence relating to infringing products Dexcom G6 Start Here Guide, 21 pages (2023). cited by applicant

Annex B3 User Guide LibreLinkUp, 28 pages (2023). cited by applicant

Annex B4 Extract from the privacy notice for Libre View, 7 pages (2024). cited by applicant

Annex D1 UPC Court of Appeal Feb. 26, 2024, 335/2023, 38 pages (2024). cited by applicant

Annex E3 Excerpts from the “German Health Report Diabetes 2023” of the German Diabetes Society, 24 pages (2023) with English translation. cited by applicant

Annex F5 Application to amend the Patent under R30 RoP, 5 pages (2024). cited by applicant

Annex G2 Case law of the Boards of Appeal, I.C-4.3, 3 pages (2024). cited by applicant

Annex G3 European Patent Guide, 23rd ed., chapter 3 (“Patentability”), 3.4, 6 pages (2023). cited by applicant

Annex G5 Case Law of the Boards of Appeal, I-D, 4.2.0, 2 pages (2023). cited by applicant

Annex G6 UPC Court of Appeal Feb. 26, 2024 *NanoString Technologies v. 10x Genomics*, 38 pages (2024). cited by applicant

Annex G7 Decision of the Enlarged Board of the EPO, G 3/14, 97 pages (2015). cited by applicant

Annex G8 Willem Hoyng, “The Unified Patent Court (UPC) opens its doors! Some observations”, 42 pages (2023). cited by applicant

Annex G10 Düsseldorf Local Division Oct. 18, 2023, UPC_CFI_177 2023 (*MyStromer v Revolt Zycling*), 19 pages (2023). cited by applicant

Annex G11 Munich Local Division Apr. 23, 2024, UPC CFI 514/2023 (*Volkswagen AG, Audi AG, Texas Instruments Inc. and Texas Instruments Deutschland GmbH v. Network system Technologies LLC*), 10 pages (2024). cited by applicant

Annex G12 Munich Local Division, Sep. 19, 2023, UPC_CFI_2/2023 (*NanoString Technologies v. 10x Genomics*), 107 pages (2023). cited by applicant

Annex G13 Regulation 2017/745 (EU), 176 pages (2017). cited by applicant

Annex G14 P. England, ‘A Practitioner's Guide to the Unified Patent Court and Unitary Patent’, Hart Publishing 2022, p. 159, 7 pages (2022). cited by applicant

Ballard, User Interface Design Guidelines for J2ME MIDP 2.0, 9 pages (2005). cited by applicant

Cunningham et al., “In Vivo Glucose Sensing,” Wiley & Sons, 111 pages (2010). cited by applicant

Cunningham et al., “In Vivo Glucose Sensing Chemical Analysis: A Series of Monographs on Analytical chemistry and Its Applications,” Wiley & Sons, 1 page (2010). cited by applicant

Custodio et al., “A Review on Architectures and Communications Technologies for Wearable Health-Monitoring Systems,” *Sensors* 12, 13907-13946 (2012). cited by applicant

D26 Microsoft Applications for Windows Moblie 6, User Guide, Part 1 92 pages, Part 2 92 pages (2008). cited by applicant

D29 Medtronic, Paradigm Real-Time Revel™ Minimed, Part 1 132 pages, Part 2 133 pages (2009). cited by applicant

Dexcom, Seven Plus CGMS Users Guide, Part 1, 72 pages, Part 2, 72 pages (2008). cited by applicant

FreeStyle Navigator® CGMS Indications for Use, 96 pages (2008). cited by applicant

FreeStyle Navigator® CGMS Indications for Use, Part 1, 65 pages, Part 2, 65 pages, Part 3, 66 pages (2008). cited by applicant

Huizinga et al., “Automated Defect Prevention, Best Practices in Software Management,” 6 pages (2007). cited by applicant

Medronic, The MiniMed Paradigm® Real-time System, Insulin Pump and CGMS, 8 pages (2008). cited by applicant

Medronic, The MiniMed Paradigm® Real-Time Insulin Pump User Guide, Paradigm® 522 and 722 Insulin Pumps, 176 pages (2006). cited by applicant

Medtronic, Guardian® Real-Time Continuous Glucose Monitoring System, User Guide, 184 pages (2006). cited by applicant
Medtronic, The MiniMed Paradigm® Real-Time Sensor Features User Guide, Paradigm® 522 and 722 Insulin Pumps, 76 pages (2006). cited by applicant
Medtronic, Paradigm® Real-Time, Revel™ Insulin Pump User Guide, 132 pages (2009). cited by applicant
Mosa et al., “A Systematic Review of Healthcare Applications for Smartphones,” BMC Medical Informatics and Decision Making, 32 pages (2012). cited by applicant
Section 10 Response to Alarms, Errors, and Problems, 96 pages (2008). cited by applicant
Seven Plus continuous glucose monitoring system User's Guide, Dexcom, 72 pages (2008). cited by applicant
Sommerville, “Software Engineering,” 7 pages (2007). cited by applicant
Stone et al., “User Interface Design and Evaluation,” The Open University, 153 pages (2005). cited by applicant
Stoodley et al., “The Automatic Detection of Transients, Step Changes and Slope Changes in the Monitoring of Medical Time Series,” The Statistician, vol. 28, No. 3, 163-170 (1979). cited by applicant

Primary Examiner: Sims; Jason M

Assistant Examiner: Kretzer; Kyle W.

Attorney, Agent or Firm: WORKMAN NYDEGGER

Background/Summary

RELATED APPLICATION (1) The present application is a continuation of U.S. patent application Ser. No. 15/681,345, filed Aug. 19, 2017, which is U.S. patent application Ser. No. 14/741,457, filed Jun. 17, 2015, now U.S. Pat. No. 9,737,249, which is a continuation of U.S. patent application Ser. No. 14/106,000 filed Dec. 13, 2013, now U.S. Pat. No. 9,060,719, which is a continuation of U.S. patent application Ser. No. 13/599,847 filed Aug. 30, 2012, now U.S. Pat. No. 8,612,163, which is a continuation of U.S. patent application Ser. No. 12/152,636 filed May 14, 2008, now U.S. Pat. No. 8,260,558, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/917,889 filed May 14, 2007, entitled “Method and Apparatus for Providing Data Processing and Control in a Medical Communication System,” the disclosures of each of which are incorporated herein by reference for all purposes.

BACKGROUND

(1) Analyte, e.g., glucose monitoring systems including continuous and discrete monitoring systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer, and RF signals to transmit the collected data. One aspect of certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored. The sensor cell may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.

(2) The analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to detect the analyte levels of the patient, and another portion or segment of the analyte sensor that is in communication with the transmitter unit. The transmitter unit is configured

to transmit the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit. The receiver/monitor unit performs data analysis, among others on the received analyte levels to generate information pertaining to the monitored analyte levels. To provide flexibility in analyte sensor manufacturing and/or design, among others, tolerance of a larger range of the analyte sensor sensitivities for processing by the transmitter unit is desirable.

(3) In view of the foregoing, it would be desirable to have a method and system for providing data processing and control for use in medical telemetry systems such as, for example, analyte monitoring systems.

SUMMARY

(4) In one embodiment, method and apparatus for receiving a plurality of signals associated with a monitored analyte level detected by an in vivo sensor for a predetermined time period, comparing each of the plurality of the received signals to a predefined signal range, and modifying a parameter associated with a trend information determined based on comparing the plurality of the received signals to the predefined signal range, is disclosed.

(5) These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 illustrates a block diagram of a data monitoring and management system for practicing one or more embodiments of the present disclosure;

(2) FIG. 2 is a block diagram of the transmitter unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure;

(3) FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure;

(4) FIGS. 4A-4B illustrate a perspective view and a cross sectional view, respectively of an analyte sensor in accordance with one embodiment of the present disclosure;

(5) FIG. 5 is a flowchart illustrating ambient temperature compensation routine for determining on-skin temperature information in accordance with one embodiment of the present disclosure;

(6) FIG. 6 is a flowchart illustrating digital anti-aliasing filtering routing in accordance with one embodiment of the present disclosure;

(7) FIG. 7 is a flowchart illustrating actual or potential sensor insertion or removal detection routine in accordance with one embodiment of the present disclosure;

(8) FIG. 8 is a flowchart illustrating receiver unit processing corresponding to the actual or potential sensor insertion or removal detection routine of FIG. 7 in accordance with one embodiment of the present disclosure;

(9) FIG. 9 is a flowchart illustrating data processing corresponding to the actual or potential sensor insertion or removal detection routine in accordance with another embodiment of the present disclosure;

(10) FIG. 10 is a flowchart illustrating a concurrent passive notification routine in the data receiver/monitor unit of the data monitoring and management system of FIG. 1 in accordance with one embodiment of the present disclosure;

(11) FIG. 11 is a flowchart illustrating a data quality verification routine in accordance with one embodiment of the present disclosure;

(12) FIG. 12 is a flowchart illustrating a rate variance filtering routine in accordance with one embodiment of the present disclosure;

- (13) FIG. 13 is a flowchart illustrating a composite sensor sensitivity determination routine in accordance with one embodiment of the present disclosure;
- (14) FIG. 14 is a flowchart illustrating an outlier data point verification routine in accordance with one embodiment of the present disclosure;
- (15) FIG. 15 is a flowchart illustrating a sensor stability verification routine in accordance with one embodiment of the present disclosure;
- (16) FIG. 16 illustrates analyte sensor code determination in accordance with one embodiment of the present disclosure;
- (17) FIG. 17 illustrates an early user notification function associated with the analyte sensor condition in one aspect of the present disclosure;
- (18) FIG. 18 illustrates uncertainty estimation associated with glucose level rate of change determination in one aspect of the present disclosure;
- (19) FIG. 19 illustrates glucose trend determination in accordance with one embodiment of the present disclosure; and
- (20) FIG. 20 illustrates glucose trend determination in accordance with another embodiment of the present disclosure.

DETAILED DESCRIPTION

- (21) As described in further detail below, in accordance with the various embodiments of the present disclosure, there is provided a method and apparatus for providing data processing and control for use in a medical telemetry system. In particular, within the scope of the present disclosure, there are provided method and system for providing data communication and control for use in a medical telemetry system such as, for example, a continuous glucose monitoring system.
- (22) FIG. 1 illustrates a data monitoring and management system such as, for example, analyte (e.g., glucose) monitoring system **100** in accordance with one embodiment of the present disclosure. The subject invention is further described primarily with respect to a glucose monitoring system for convenience and such description is in no way intended to limit the scope of the invention. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes, e.g., lactate, and the like.
- (23) Analytes that may be monitored include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored.
- (24) The analyte monitoring system **100** includes a sensor **101**, a transmitter unit **102** coupled to the sensor **101**, and a primary receiver unit **104** which is configured to communicate with the transmitter unit **102** via a communication link **103**. The primary receiver unit **104** may be further configured to transmit data to a data processing terminal **105** for evaluating the data received by the primary receiver unit **104**. Moreover, the data processing terminal in one embodiment may be configured to receive data directly from the transmitter unit **102** via a communication link which may optionally be configured for bi-directional communication.
- (25) Also shown in FIG. 1 is a secondary receiver unit **106** which is operatively coupled to the communication link **103** and configured to receive data transmitted from the transmitter unit **102**. Moreover, as shown in the Figure, the secondary receiver unit **106** is configured to communicate with the primary receiver unit **104** as well as the data processing terminal **105**. Indeed, the secondary receiver unit **106** may be configured for bi-directional wireless communication with each of the primary receiver unit **104** and the data processing terminal **105**. As discussed in further detail below, in one embodiment of the present disclosure, the secondary receiver unit **106** may be configured to include a limited number of functions and features as compared with the primary receiver unit **104**. As such, the secondary receiver unit **106** may be configured substantially in a

smaller compact housing or embodied in a device such as a wrist watch, for example. Alternatively, the secondary receiver unit **106** may be configured with the same or substantially similar functionality as the primary receiver unit **104**, and may be configured to be used in conjunction with a docking cradle unit for placement by bedside, for night time monitoring, and/or bi-directional communication device.

(26) Only one sensor **101**, transmitter unit **102**, communication link **103**, and data processing terminal **105** are shown in the embodiment of the analyte monitoring system **100** illustrated in FIG. **1**. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system **100** may include one or more sensor **101**, transmitter unit **102**, communication link **103**, and data processing terminal **105**. Moreover, within the scope of the present disclosure, the analyte monitoring system **100** may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each device is configured to be uniquely identified by each of the other devices in the system so that communication conflict is readily resolved between the various components within the analyte monitoring system **100**.

(27) In one embodiment of the present disclosure, the sensor **101** is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor **101** may be configured to continuously sample the analyte level of the user and convert the sampled analyte level into a corresponding data signal for transmission by the transmitter unit **102**. In one embodiment, the transmitter unit **102** is coupled to the sensor **101** so that both devices are positioned on the user's body, with at least a portion of the analyte sensor **101** positioned transcutaneously under the skin layer of the user. The transmitter unit **102** performs data processing such as filtering and encoding on data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit **104** via the communication link **103**.

(28) In one embodiment, the analyte monitoring system **100** is configured as a one-way RF communication path from the transmitter unit **102** to the primary receiver unit **104**. In such embodiment, the transmitter unit **102** transmits the sampled data signals received from the sensor **101** without acknowledgement from the primary receiver unit **104** that the transmitted sampled data signals have been received. For example, the transmitter unit **102** may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals) after the completion of the initial power on procedure. Likewise, the primary receiver unit **104** may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, the analyte monitoring system **100** may be configured with a bi-directional RF (or otherwise) communication between the transmitter unit **102** and the primary receiver unit **104**.

(29) Additionally, in one aspect, the primary receiver unit **104** may include two sections. The first section is an analog interface section that is configured to communicate with the transmitter unit **102** via the communication link **103**. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the transmitter unit **102**, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of the primary receiver unit **104** is a data processing section which is configured to process the data signals received from the transmitter unit **102** such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery.

(30) In operation, upon completing the power-on procedure, the primary receiver unit **104** is configured to detect the presence of the transmitter unit **102** within its range based on, for example, the strength of the detected data signals received from the transmitter unit **102** or a predetermined transmitter identification information. Upon successful synchronization with the corresponding transmitter unit **102**, the primary receiver unit **104** is configured to begin receiving from the transmitter unit **102** data signals corresponding to the user's detected analyte level. More specifically, the primary receiver unit **104** in one embodiment is configured to perform synchronized time hopping with the corresponding synchronized transmitter unit **102** via the communication link **103** to obtain the user's detected analyte level.

(31) Referring again to FIG. 1, the data processing terminal **105** may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal **105** may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected analyte level of the user.

(32) Within the scope of the present disclosure, the data processing terminal **105** may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the receiver unit **104** for receiving, among others, the measured analyte level. Alternatively, the receiver unit **104** may be configured to integrate an infusion device therein so that the receiver unit **104** is configured to administer insulin therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the transmitter unit **102**.

(33) Additionally, the transmitter unit **102**, the primary receiver unit **104** and the data processing terminal **105** may each be configured for bi-directional wireless communication such that each of the transmitter unit **102**, the primary receiver unit **104** and the data processing terminal **105** may be configured to communicate (that is, transmit data to and receive data from) with each other via a wireless communication link. More specifically, the data processing terminal **105** may in one embodiment be configured to receive data directly from the transmitter unit **102** via a communication link, where the communication link, as described above, may be configured for bi-directional communication.

(34) In this embodiment, the data processing terminal **105** which may include an insulin pump, may be configured to receive the analyte signals from the transmitter unit **102**, and thus, incorporate the functions of the receiver unit **104** including data processing for managing the patient's insulin therapy and analyte monitoring. In one embodiment, the communication link **103** may include one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, a Zigbee® transmission protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference.

(35) FIG. 2 is a block diagram of the transmitter of the data monitoring and detection system shown in FIG. 1 in accordance with one embodiment of the present disclosure. Referring to the Figure, the transmitter unit **102** in one embodiment includes an analog interface **201** configured to communicate with the sensor **101** (FIG. 1), a user input **202**, and a temperature detection section **203**, each of which is operatively coupled to a transmitter processor **204** such as a central processing unit (CPU).

(36) Further shown in FIG. 2 are a transmitter serial communication section **205** and an RF transmitter **206**, each of which is also operatively coupled to the transmitter processor **204**. Moreover, a power supply **207** such as a battery is also provided in the transmitter unit **102** to provide the necessary power for the transmitter unit **102**. Additionally, as can be seen from the Figure, clock **208** is provided to, among others, supply real time information to the transmitter processor **204**.

(37) As can be seen from FIG. 2, the sensor **101** (FIG. 1) is provided four contacts, three of which are electrodes—work electrode (W) **210**, guard contact (G) **211**, reference electrode (R) **212**, and counter electrode (C) **213**, each operatively coupled to the analog interface **201** of the transmitter unit **102**. In one embodiment, each of the work electrode (W) **210**, guard contact (G) **211**, reference electrode (R) **212**, and counter electrode (C) **213** may be made using a conductive material that is either printed or etched, for example, such as carbon which may be printed, or metal foil (e.g., gold) which may be etched, or alternatively provided on a substrate material using laser or

photolithography.

(38) In one embodiment, a unidirectional input path is established from the sensor **101** (FIG. 1) and/or manufacturing and testing equipment to the analog interface **201** of the transmitter unit **102**, while a unidirectional output is established from the output of the RF transmitter **206** of the transmitter unit **102** for transmission to the primary receiver unit **104**. In this manner, a data path is shown in FIG. 2 between the aforementioned unidirectional input and output via a dedicated link **209** from the analog interface **201** to serial communication section **205**, thereafter to the processor **204**, and then to the RF transmitter **206**. As such, in one embodiment, via the data path described above, the transmitter unit **102** is configured to transmit to the primary receiver unit **104** (FIG. 1), via the communication link **103** (FIG. 1), processed and encoded data signals received from the sensor **101** (FIG. 1). Additionally, the unidirectional communication data path between the analog interface **201** and the RF transmitter **206** discussed above allows for the configuration of the transmitter unit **102** for operation upon completion of the manufacturing process as well as for direct communication for diagnostic and testing purposes.

(39) As discussed above, the transmitter processor **204** is configured to transmit control signals to the various sections of the transmitter unit **102** during the operation of the transmitter unit **102**. In one embodiment, the transmitter processor **204** also includes a memory (not shown) for storing data such as the identification information for the transmitter unit **102**, as well as the data signals received from the sensor **101**. The stored information may be retrieved and processed for transmission to the primary receiver unit **104** under the control of the transmitter processor **204**. Furthermore, the power supply **207** may include a commercially available battery.

(40) The transmitter unit **102** is also configured such that the power supply section **207** is capable of providing power to the transmitter for a minimum of about three months of continuous operation after having been stored for about eighteen months in a low-power (non-operating) mode. In one embodiment, this may be achieved by the transmitter processor **204** operating in low power modes in the non-operating state, for example, drawing no more than approximately 1 μ A of current. Indeed, in one embodiment, the final step during the manufacturing process of the transmitter unit **102** may place the transmitter unit **102** in the lower power, non-operating state (i.e., post-manufacture sleep mode). In this manner, the shelf life of the transmitter unit **102** may be significantly improved. Moreover, as shown in FIG. 2, while the power supply unit **207** is shown as coupled to the processor **204**, and as such, the processor **204** is configured to provide control of the power supply unit **207**, it should be noted that within the scope of the present disclosure, the power supply unit **207** is configured to provide the necessary power to each of the components of the transmitter unit **102** shown in FIG. 2.

(41) Referring back to FIG. 2, the power supply section **207** of the transmitter unit **102** in one embodiment may include a rechargeable battery unit that may be recharged by a separate power supply recharging unit (for example, provided in the receiver unit **104**) so that the transmitter unit **102** may be powered for a longer period of usage time. Moreover, in one embodiment, the transmitter unit **102** may be configured without a battery in the power supply section **207**, in which case the transmitter unit **102** may be configured to receive power from an external power supply source (for example, a battery) as discussed in further detail below.

(42) Referring yet again to FIG. 2, the temperature detection section **203** of the transmitter unit **102** is configured to monitor the temperature of the skin near the sensor insertion site. The temperature reading is used to adjust the analyte readings obtained from the analog interface **201**. The RF transmitter **206** of the transmitter unit **102** may be configured for operation in the frequency band of 315 MHz to 322 MHz, for example, in the United States. Further, in one embodiment, the RF transmitter **206** is configured to modulate the carrier frequency by performing Frequency Shift Keying and Manchester encoding. In one embodiment, the data transmission rate is 19,200 symbols per second, with a minimum transmission range for communication with the primary receiver unit **104**.

(43) Referring yet again to FIG. 2, also shown is a leak detection circuit **214** coupled to the guard contact (G) **211** and the processor **204** in the transmitter unit **102** of the data monitoring and management system **100**. The leak detection circuit **214** in accordance with one embodiment of the present disclosure may be configured to detect leakage current in the sensor **101** to determine whether the measured sensor data is corrupt or whether the measured data from the sensor **101** is accurate.

(44) FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure. Referring to FIG. 3, the primary receiver unit **104** includes a blood glucose test strip interface **301**, an RF receiver **302**, a user input **303**, a temperature detection section **304**, and a clock **305**, each of which is operatively coupled to a receiver processor **307**. As can be further seen from the Figure, the primary receiver unit **104** also includes a power supply **306** operatively coupled to a power conversion and monitoring section **308**. Further, the power conversion and monitoring section **308** is also coupled to the receiver processor **307**. Moreover, also shown are a receiver serial communication section **309**, and an output **310**, each operatively coupled to the receiver processor **307**.

(45) In one embodiment, the test strip interface **301** includes a glucose level testing portion to receive a manual insertion of a glucose test strip, and thereby determine and display the glucose level of the test strip on the output **310** of the primary receiver unit **104**. This manual testing of glucose can be used to calibrate sensor **101**. The RF receiver **302** is configured to communicate, via the communication link **103** (FIG. 1) with the RF transmitter **206** of the transmitter unit **102**, to receive encoded data signals from the transmitter unit **102** for, among others, signal mixing, demodulation, and other data processing. The input **303** of the primary receiver unit **104** is configured to allow the user to enter information into the primary receiver unit **104** as needed. In one aspect, the input **303** may include one or more keys of a keypad, a touch-sensitive screen, or a voice-activated input command unit. The temperature detection section **304** is configured to provide temperature information of the primary receiver unit **104** to the receiver processor **307**, while the clock **305** provides, among others, real time information to the receiver processor **307**.

(46) Each of the various components of the primary receiver unit **104** shown in FIG. 3 is powered by the power supply **306** which, in one embodiment, includes a battery. Furthermore, the power conversion and monitoring section **308** is configured to monitor the power usage by the various components in the primary receiver unit **104** for effective power management and to alert the user, for example, in the event of power usage which renders the primary receiver unit **104** in sub-optimal operating conditions. An example of such sub-optimal operating condition may include, for example, operating the vibration output mode (as discussed below) for a period of time thus substantially draining the power supply **306** while the processor **307** (thus, the primary receiver unit **104**) is turned on. Moreover, the power conversion and monitoring section **308** may additionally be configured to include a reverse polarity protection circuit such as a field effect transistor (FET) configured as a battery activated switch.

(47) The serial communication section **309** in the primary receiver unit **104** is configured to provide a bi-directional communication path from the testing and/or manufacturing equipment for, among others, initialization, testing, and configuration of the primary receiver unit **104**. Serial communication section **309** can also be used to upload data to a computer, such as time-stamped blood glucose data. The communication link with an external device (not shown) can be made, for example, by cable, infrared (IR) or RF link. The output **310** of the primary receiver unit **104** is configured to provide, among others, a graphical user interface (GUI) such as a liquid crystal display (LCD) for displaying information. Additionally, the output **310** may also include an integrated speaker for outputting audible signals as well as to provide vibration output as commonly found in handheld electronic devices, such as mobile telephones presently available. In a further embodiment, the primary receiver unit **104** also includes an electro-luminescent lamp

configured to provide backlighting to the output **310** for output visual display in dark ambient surroundings.

(48) Referring back to FIG. **3**, the primary receiver unit **104** in one embodiment may also include a storage section such as a programmable, non-volatile memory device as part of the processor **307**, or provided separately in the primary receiver unit **104**, operatively coupled to the processor **307**. The processor **307** is further configured to perform Manchester decoding as well as error detection and correction upon the encoded data signals received from the transmitter unit **102** via the communication link **103**.

(49) In a further embodiment, the one or more of the transmitter unit **102**, the primary receiver unit **104**, secondary receiver unit **106**, or the data processing terminal/infusion section **105** may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a glucose meter. In still a further embodiment, the user or patient manipulating or using the analyte monitoring system **100** (FIG. **1**) may manually input the blood glucose value using, for example, a user interface (for example, a keyboard, keypad, and the like) incorporated in the one or more of the transmitter unit **102**, the primary receiver unit **104**, secondary receiver unit **106**, or the data processing terminal/infusion section **105**.

(50) Additional detailed description of the continuous analyte monitoring system, and its various components including the functional descriptions of the transmitter are provided in U.S. Pat. No. 6,175,752 issued Jan. 16, 2001 entitled "Analyte Monitoring Device and Methods of Use", and in application Ser. No. 10/745,878 filed Dec. 26, 2003 entitled "Continuous Glucose Monitoring System and Methods of Use", each assigned to the Assignee of the present application, and each of which are incorporated herein by reference for all purposes.

(51) FIGS. **4A-4B** illustrate a perspective view and a cross sectional view, respectively of an analyte sensor in accordance with one embodiment of the present disclosure. Referring to FIG. **4A**, a perspective view of a sensor **400**, the major portion of which is above the surface of the skin **410**, with an insertion tip **430** penetrating through the skin and into the subcutaneous space **420** in contact with the user's biofluid such as interstitial fluid. Contact portions of a working electrode **401**, a reference electrode **402**, and a counter electrode **403** can be seen on the portion of the sensor **400** situated above the skin surface **410**. Working electrode **401**, a reference electrode **402**, and a counter electrode **403** can be seen at the end of the insertion tip **430**.

(52) Referring now to FIG. **4B**, a cross sectional view of the sensor **400** in one embodiment is shown. In particular, it can be seen that the various electrodes of the sensor **400** as well as the substrate and the dielectric layers are provided in a stacked or layered configuration or construction. For example, as shown in FIG. **4B**, in one aspect, the sensor **400** (such as the sensor **101** FIG. **1**), includes a substrate layer **404**, and a first conducting layer **401** such as a carbon trace disposed on at least a portion of the substrate layer **404**, and which may comprise the working electrode. Also shown disposed on at least a portion of the first conducting layer **401** is a sensing layer **408**.

(53) Referring back to FIG. **4B**, a first insulation layer such as a first dielectric layer **405** is disposed or stacked on at least a portion of the first conducting layer **401**, and further, a second conducting layer **409** such as another carbon trace may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) **405**. As shown in FIG. **4B**, the second conducting layer **409** may comprise the reference electrode **402**, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl).

(54) Referring still again to FIG. **4B**, a second insulation layer **406** such as a dielectric layer in one embodiment may be disposed or stacked on at least a portion of the second conducting layer **409**. Further, a third conducting layer **403** which may include carbon trace and that may comprise the counter electrode **403** may in one embodiment be disposed on at least a portion of the second insulation layer **406**. Finally, a third insulation layer **407** is disposed or stacked on at least a portion of the third conducting layer **403**. In this manner, the sensor **400** may be configured in a stacked or

layered construction or configuration such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).

(55) Additionally, within the scope of the present disclosure, some or all of the electrodes **401**, **402**, **403** may be provided on the same side of the substrate **404** in a stacked construction as described above, or alternatively, may be provided in a co-planar manner such that each electrode is disposed on the same plane on the substrate **404**, however, with a dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in still another aspect of the present disclosure, the one or more conducting layers such as the electrodes **401**, **402**, **403** may be disposed on opposing sides of the substrate **404**.

(56) Referring back to the Figures, in one embodiment, the transmitter unit **102** (FIG. 1) is configured to detect the current signal from the sensor **101** (FIG. 1) and the skin temperature near the sensor **101**, which are preprocessed by, for example, the transmitter processor **204** (FIG. 2) and transmitted to the receiver unit (for example, the primary receiver unit **104** (FIG. 1)) periodically at a predetermined time interval, such as for example, but not limited to, once per minute, once every two minutes, once every five minutes, or once every ten minutes. Additionally, the transmitter unit **102** may be configured to perform sensor insertion detection and data quality analysis, information pertaining to which are also transmitted to the receiver unit **104** periodically at the predetermined time interval. In turn, the receiver unit **104** may be configured to perform, for example, skin temperature compensation as well as calibration of the sensor data received from the transmitter unit **102**.

(57) For example, in one aspect, the transmitter unit **102** may be configured to oversample the sensor signal at a nominal rate of four samples per second, which allows the analyte anti-aliasing filter in the transmitter unit **102** to attenuate noise (for example, due to effects resulting from motion or movement of the sensor after placement) at frequencies above 2 Hz. More specifically, in one embodiment, the transmitter processor **204** may be configured to include a digital filter to reduce aliasing noise when decimating the four Hz sampled sensor data to once per minute samples for transmission to the receiver unit **104**. As discussed in further detail below, in one aspect, a two stage Kaiser FIR filter may be used to perform the digital filtering for anti-aliasing. While Kaiser FIR filter may be used for digital filtering of the sensor signals, within the scope of the present disclosure, other suitable filters may be used to filter the sensor signals.

(58) In one aspect, the temperature measurement section **203** of the transmitter unit **102** may be configured to measure once per minute the on skin temperature near the analyte sensor at the end of the minute sampling cycle of the sensor signal. Within the scope of the present disclosure, different sample rates may be used which may include, for example, but not limited to, measuring the on skin temperature for each 30 second periods, each two minute periods, and the like. Additionally, as discussed above, the transmitter unit **102** may be configured to detect sensor insertion, sensor signal settling after sensor insertion, and sensor removal, in addition to detecting for sensor—transmitter system failure modes and sensor signal data integrity. Again, this information is transmitted periodically by the transmitter unit **102** to the receiver unit **104** along with the sampled sensor signals at the predetermined time intervals.

(59) Referring again to the Figures, as the analyte sensor measurements are affected by the temperature of the tissue around the transcutaneously positioned sensor **101**, in one aspect, compensation of the temperature variations and effects on the sensor signals are provided for determining the corresponding glucose value. Moreover, the ambient temperature around the sensor **101** may affect the accuracy of the on skin temperature measurement and ultimately the glucose value determined from the sensor signals. Accordingly, in one aspect, a second temperature sensor is provided in the transmitter unit **102** away from the on skin temperature sensor (for example, physically away from the temperature measurement section **203** of the transmitter unit **102**), so as to provide compensation or correction of the on skin temperature measurements due to the ambient temperature effects. In this manner, the accuracy of the estimated glucose value corresponding to

the sensor signals may be attained.

(60) In one aspect, the processor **204** of the transmitter unit **102** may be configured to include the second temperature sensor, and which is located closer to the ambient thermal source within the transmitter unit **102**. In other embodiments, the second temperature sensor may be located at a different location within the transmitter unit **102** housing where the ambient temperature within the housing of the transmitter unit **102** may be accurately determined.

(61) Referring now to FIG. 5, in one aspect, an ambient temperature compensation routine for determining the on-skin temperature level for use in the glucose estimation determination based on the signals received from the sensor **101**. Referring to FIG. 5, for each sampled signal from the sensor **101**, a corresponding measured temperature information is received (**510**), for example, by the processor **204** from the temperature measurement section **203** (which may include, for example, a thermistor provided in the transmitter unit **102**). In addition, a second temperature measurement is obtained (**520**), for example, including a determination of the ambient temperature level using a second temperature sensor provided within the housing the transmitter unit **102**.

(62) In one aspect, based on a predetermined ratio of thermal resistances between the temperature measurement section **203** and the second temperature sensor (located, for example, within the processor **204** of the transmitter unit **102**), and between the temperature measurement section **203** and the skin layer on which the transmitter unit **102** is placed and coupled to the sensor **101**, ambient temperature compensation may be performed (**530**), to determine the corresponding ambient temperature compensated on skin temperature level (**540**). In one embodiment, the predetermined ratio of the thermal resistances may be approximately 0.2. However, within the scope of the present disclosure, this thermal resistance ratio may vary according to the design of the system, for example, based on the size of the transmitter unit **102** housing, the location of the second temperature sensor within the housing of the transmitter unit **102**, and the like.

(63) With the ambient temperature compensated on-skin temperature information, the corresponding glucose value from the sampled analyte sensor signal may be determined.

(64) Referring again to FIG. 2, the processor **204** of the transmitter unit **102** may include a digital anti-aliasing filter. Using analog anti-aliasing filters for a one minute measurement data sample rate would require a large capacitor in the transmitter unit **102** design, and which in turn impacts the size of the transmitter unit **102**. As such, in one aspect, the sensor signals may be oversampled (for example, at a rate of 4 times per second), and then the data is digitally decimated to derive a one-minute sample rate.

(65) As discussed above, in one aspect, the digital anti-aliasing filter may be used to remove, for example, signal artifacts or otherwise undesirable aliasing effects on the sampled digital signals received from the analog interface **201** of the transmitter unit **102**. For example, in one aspect, the digital anti-aliasing filter may be used to accommodate decimation of the sensor data from approximately four Hz samples to one-minute samples. In one aspect, a two stage FIR filter may be used for the digital anti-aliasing filter, which includes improved response time, pass band and stop band properties.

(66) Referring to FIG. 6, a routine for digital anti-aliasing filtering is shown in accordance with one embodiment. As shown, in one embodiment, at each predetermined time period such as every minute, the analog signal from the analog interface **201** corresponding to the monitored analyte level received from the sensor **101** (FIG. 1) is sampled (**610**). For example, at every minute, in one embodiment, the signal from the analog interface **201** is over-sampled at approximately 4 Hz. Thereafter, the first stage digital filtering on the over-sampled data is performed (**620**), where, for example, a $\frac{1}{6}$ down-sampling from 246 samples to 41 samples is performed, and the resulting 41 samples is further down-sampled at the second stage digital filtering (**630**) such that, for example, a $\frac{1}{41}$ down-sampling is performed from 41 samples (from the first stage digital filtering), to a single sample. Thereafter, the filter is reset (**640**), and the routine returns to the beginning for the next minute signal received from the analog interface **201**.

(67) While the use of FIR filter, and in particular the use of Kaiser FIR filter, is within the scope of the present disclosure, other suitable filters, such as FIR filters with different weighting schemes or IIR filters, may be used.

(68) Referring yet again to the Figures, the transmitter unit **102** may be configured in one embodiment to periodically perform data quality checks including error condition verifications and potential error condition detections, and also to transmit the relevant information related to one or more data quality, error condition or potential error condition detection to the receiver unit **104** with the transmission of the monitored sensor data. For example, in one aspect, a state machine may be used in conjunction with the transmitter unit **102** and which may be configured to be updated four times per second, the results of which are transmitted to the receiver unit **104** every minute.

(69) In particular, using the state machine, the transmitter unit **102** may be configured to detect one or more states that may indicate when a sensor is inserted, when a sensor is removed from the user, and further, may additionally be configured to perform related data quality checks so as to determine when a new sensor has been inserted or transcutaneously positioned under the skin layer of the user and has settled in the inserted state such that the data transmitted from the transmitter unit **102** does not compromise the integrity of signal processing performed by the receiver unit **104** due to, for example, signal transients resulting from the sensor insertion.

(70) That is, when the transmitter unit **102** detects low or no signal from the sensor **101** which is followed by detected signals from the sensor **101** that is above a given signal, the processor **204** may be configured to identify such transition is monitored signal levels and associate with a potential sensor insertion state. Alternatively, the transmitter unit **102** may be configured to detect the signal level above another predetermined threshold level, which is followed by the detection of the signal level from the sensor **101** that falls below the predetermined threshold level. In such a case, the processor **204** may be configured to associate or identify such transition or condition in the monitored signal levels as a potential sensor removal state.

(71) Accordingly, when either of potential sensor insertion state or potential sensor removal state is detected by the transmitter unit **102**, this information is transmitted to the receiver unit **104**, and in turn, the receiver unit may be configured to prompt the user for confirmation of either of the detected potential sensor related state. In another aspect, the sensor insertion state or potential sensor removal state may be detected or determined by the receiver unit based on one or more signals received from the transmitter unit **102**. For example, similar to an alarm condition or a notification to the user, the receiver unit **104** may be configured to display a request or a prompt on the display or an output unit of the receiver unit **104** a text and/or other suitable notification message to inform the user to confirm the state of the sensor **101**.

(72) For example, the receiver unit **104** may be configured to display the following message: "New Sensor Inserted?" or a similar notification in the case where the receiver unit **104** receives one or more signals from the transmitter unit **102** associated with the detection of the signal level below the predetermined threshold level for the predefined period of time, followed by the detection of the signal level from the sensor **101** above another predetermined threshold level for another predefined period of time. Additionally, the receiver unit **104** may be configured to display the following message: "Sensor Removed?" or a similar notification in the case where the receiver unit **104** received one or more signals from the transmitter unit **102** associated with the detection of the signal level from the sensor **101** that is above another predetermined threshold level for another predefined period of time, which is followed by the detection of the signal level from the sensor **101** that falls below the predetermined threshold level for the predefined period of time.

(73) Based on the user confirmation received, the receiver unit **104** may be further configured to execute or perform additional related processing and routines in response to the user confirmation or acknowledgement. For example, when the user confirms, using the user interface input/output mechanism of the receiver unit **104**, for example, that a new sensor has been inserted, the receiver unit **104** may be configured to initiate new sensor insertion related routines including, such as, for

example, a sensor calibration routine including, for example, calibration timer, sensor expiration timer and the like. Alternatively, when the user confirms or it is determined that the sensor **101** is not properly positioned or otherwise removed from the insertion site, the receiver unit **104** may be accordingly configured to perform related functions such as, for example, stop displaying of the glucose values/levels, or deactivating the alarm monitoring conditions.

(74) On the other hand, in response to the potential sensor insertion notification generated by the receiver unit **104**, if the user confirms that no new sensor has been inserted, then the receiver unit **104** in one embodiment is configured to assume that the sensor **101** is in acceptable operational state, and continues to receive and process signals from the transmitter unit **102**.

(75) In this manner, in cases, for example, when there is momentary movement or temporary dislodging of the sensor **101** from the initially positioned transcutaneous state, or when one or more of the contact points between sensor **101** and the transmitter unit **102** are temporarily disconnected, but otherwise, the sensor **101** is operational and within its useful life, the routine above provides an option to the user to maintain the usage of the sensor **101**, without replacing the sensor **101** prior to the expiration of its useful life. In this manner, in one aspect, false positive indications of sensor **101** failure may be identified and addressed.

(76) For example, FIG. 7 is a flowchart illustrating actual or potential sensor insertion or removal detection routine in accordance with one embodiment of the present disclosure. Referring to the Figure, the current analyte related signal is first compared to a predetermined signal characteristic (**710**). In one aspect, the predetermined signal characteristic may include one of a signal level transition from below a first predetermined level (for example, but not limited to 18 ADC (analog to digital converter) counts) to above the first predetermined level, a signal level transition from above a second predetermined level (for example, but not limited to 9 ADC counts) to below the second predetermined level, a transition from below a predetermined signal rate of change threshold to above the predetermined signal rate of change threshold, and a transition from above the predetermined signal rate of change threshold to below the predetermined signal rate of change threshold.

(77) In this manner, in one aspect of the present disclosure, based on a transition state of the received analyte related signals, it may be possible to determine the state of the analyte sensor (**720**), and based on which, the user or the patient may confirm whether the analyte sensor is in the desired or proper position, has been temporarily dislocated, or otherwise, removed from the desired insertion site so as to require a new analyte sensor. A prior signal associated with the analyte level is compared with the current analyte related signal (**730**). An output data is generated which is associated with the operational state (**740**).

(78) In this manner, in one aspect, when the monitored signal from the sensor **101** crosses a transition level (for example, from no or low signal level to a high signal level, or vice versa), the transmitter unit **102** may be configured to generate an appropriate output data associated with the sensor signal transition, for transmission to the receiver unit **104** (FIG. 1). Additionally, as discussed in further detail below, in another embodiment, the determination of whether the sensor **101** has crossed a transition level may be determined by the receiver/monitor unit **104/106** based, at least in part on the one or more signals received from the transmitter unit **102**.

(79) FIG. 8 is a flowchart illustrating receiver unit processing corresponding to the actual or potential sensor insertion or removal detection routine of FIG. 7 in accordance with one embodiment of the present disclosure. Referring now to FIG. 8, when the receiver unit **104** receives the generated output data from the transmitter unit **102** (**810**), a corresponding operation state is associated with the received output data (**820**), for example, related to the operational state of the sensor **101**. Moreover, a notification associated with the sensor operation state is generated and output to the user on the display unit or any other suitable output segment of the receiver unit **104** (**830**). When a user input signal is received in response to the notification associated with the sensor state operation state (**840**), the receiver unit **104** is configured to execute one or more

routines associated with the received user input signal (850).

(80) That is, as discussed above, in one aspect, if the user confirms that the sensor **101** has been removed, the receiver unit **104** may be configured to terminate or deactivate alarm monitoring and glucose displaying functions. On the other hand, if the user confirms that a new sensor **101** has been positioned or inserted into the user, then the receiver unit **104** may be configured to initiate or execute routines associated with the new sensor insertion, such as, for example, calibration procedures, establishing calibration timer, and establishing sensor expiration timer.

(81) In a further embodiment, based on the detected or monitored signal transition, the receiver/monitor unit may be configured to determine the corresponding sensor state without relying upon the user input or confirmation signal associated with whether the sensor is dislocated or removed from the insertion site, or otherwise, operating properly.

(82) FIG. **9** is a flowchart illustrating data processing corresponding to the actual or potential sensor insertion or removal detection routine in accordance with another embodiment of the present disclosure. Referring to FIG. **9**, a current analyte related signal is received and compared to a predetermined signal characteristic (**910**). Thereafter, an operational state associated with an analyte monitoring device such as, for example, the sensor **101** (FIG. **1**) is retrieved (**920**) from a storage unit or otherwise resident in, for example, a memory of the receiver/monitor unit.

Additionally, a prior analyte related signal is also retrieved from the storage unit, and compared to the current analyte related signal received (**930**). An output data is generated which is associated with the operational state (**940**), and which at least in part is based on the one or more of the received current analyte related signal and the retrieved prior analyte related signal.

(83) Referring again to FIG. **9**, when the output data is generated, a corresponding user input command or signal is received in response to the generated output data (**950**), which may include one or more of a confirmation, verification, or rejection of the operational state related to the analyte monitoring device.

(84) FIG. **10** is a flowchart illustrating a concurrent passive notification routine in the data receiver/monitor unit of the data monitoring and management system of FIG. **1** in accordance with one embodiment of the present disclosure. Referring to FIG. **10**, a predetermined routine is executed for a predetermined time period to completion (**1010**). During the execution of the predetermined routine, an alarm condition is detected (**1020**), and when the alarm or alert condition is detected, a first indication associated with the detected alarm or alert condition is output concurrent to the execution of the predetermined routine (**1030**).

(85) That is, in one embodiment, when a predefined routine is being executed, and an alarm or alert condition is detected, a notification is provided to the user or patient associated with the detected alarm or alert condition, but which does not interrupt or otherwise disrupt the execution of the predefined routine. Referring back to FIG. **10**, upon termination of the predetermined routine, another output or second indication associated with the detected alarm condition is output or displayed (**1040**).

(86) More specifically, in one aspect, the user interface notification feature associated with the detected alarm condition is output to the user only upon the completion of an ongoing routine which was in the process of being executed when the alarm condition is detected. As discussed above, when such alarm condition is detected during the execution of a predetermined routine, a temporary alarm notification such as, for example, a backlight indicator, a text output on the user interface display or any other suitable output indication may be provided to alert the user or the patient of the detected alarm condition substantially in real time, but which does not disrupt an ongoing routine.

(87) Within the scope of the present disclosure, the ongoing routine or the predetermined routine being executed may include one or more of performing a finger stick blood glucose test (for example, for purposes of periodically calibrating the sensor **101**), or any other processes that interface with the user interface, for example, on the receiver/monitor unit **104/106** (FIG. **1**)

including, but not limited to the configuration of device settings, review of historical data such as glucose data, alarms, events, entries in the data log, visual displays of data including graphs, lists, and plots, data communication management including RF communication administration, data transfer to the data processing terminal **105** (FIG. **1**), or viewing one or more alarm conditions with a different priority in a preprogrammed or determined alarm or notification hierarchy structure. (88) In this manner, in one aspect of the present disclosure, the detection of one or more alarm conditions may be presented or notified to the user or the patient, without interrupting or disrupting an ongoing routine or process in, for example, the receiver/monitor unit **104/106** of the data monitoring and management system **100** (FIG. **1**).

(89) Referring now back to the Figures, FIG. **11** is a flowchart illustrating a data quality verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. **11**, initially the data quality status flags are cleared or initialized or reset (**1110**). Thereafter, data quality checks or verifications are performed, for example, as described above (**1120**). Thereafter, data quality flag is generated and associated with the data packet when data quality check has failed (**1130**). In one aspect, the generated data quality flag may be based on data quality verification such that when the underlying condition being verified is determined to be acceptable, the data quality flag may return a value of zero (or one or more predetermined value). Alternatively, in the case where the underlying condition being verified is determined to be not within the acceptable criteria (or above the acceptable level), the associated data quality flag may return a value of one (or one or more predetermined value associated with the determination of such condition).

(90) Referring to FIG. **11**, the data packet including the raw glucose data as well as the data quality flags are transmitted, for example, to the receiver/monitor unit **104/106** for further processing (**1140**). As described above, the data quality checks may be performed in the transmitter unit **102** (FIG. **1**) and/or in the receiver/monitor unit **104/106** in the data monitoring and management system **100** (FIG. **1**) in one aspect of the present disclosure.

(91) FIG. **12** is a flowchart illustrating a rate variance filtering routine in accordance with one embodiment of the present disclosure. Referring to FIG. **12**, when glucose related data is detected or received (**1210**), for example, for each predetermined time intervals such as every minute, every five minutes or any other suitable time intervals, a plurality of filtered values based on the received or detected glucose related data is determined (**1220**). For example, as discussed above, in one aspect, using, for example, an FIR filter, or based on a weighted average, a plurality of filtered values for a 15 minute and two minute glucose related data including the currently received or detected glucose related are determined.

(92) Referring back to FIG. **12**, weighting associated with the plurality of filtered values is determined (**1230**). Thereafter, a rate of change of the glucose level based in part on the detected or received glucose related data is determined as well as a standard deviation of the rate of change based on the glucose related data (**1240**). Further, a weighted average associated with the current detected or monitored glucose related data is determined based on the plurality of filtered values and the determined standard deviation of the rate of change and/or the rate of change of the glucose level (**1250**). For example, when the rate of change is determined to be high relative to the rate of change variation, the filtered value based on the two minute data is weighted more heavily. On the other hand, when the rate of change is determined to be low relative to the rate of change variation, the filtered glucose related data includes the one of the plurality of filtered values based on the 15 minute data which is weighted more heavily. In this manner, in one aspect, there is provided a rate variance filtering approach which may be configured to dynamically modify the weighting function or data filtering to, for example, reduce undesirable variation in glucose related signals due to factors such as noise.

(93) FIG. **13** is a flowchart illustrating a composite sensor sensitivity determination routine in accordance with one embodiment of the present disclosure. Referring to FIG. **13**, during scheduled calibration time periods or otherwise manual calibration routines to calibrate the analyte sensor,

when a current blood glucose value is received or detected (**1310**), a current or present sensitivity is determined based on the detected blood glucose value (**1320**). For example, the current sensitivity may be determined by taking a ratio of the current glucose sensor value and the detected blood glucose value.

(94) Referring to FIG. **13**, a prior sensitivity previously determined is retrieved, for example, from the storage unit (**1330**). In one aspect, the prior sensitivity may include a previous sensitivity determined during a prior sensor calibration event, or may be based on the nominal sensor sensitivity based on the sensor code from manufacturing, for example. Returning again to FIG. **13**, a first weighted parameter is applied to the current sensitivity, and a second weighted parameter is applied to the retrieved prior sensitivity (**1340**). For example, based on the time lapsed between the calibration event associated with the retrieved prior sensitivity value and the current calibration event (associated with the current or received blood glucose value), the first and second weighted parameters may be modified (e.g., increased or decreased in value) to improve accuracy.

(95) Referring back to FIG. **13**, based on applying the first and the second weighted parameters to the current sensitivity and the retrieved prior sensitivity, a composite sensitivity associated with the analyte sensor for the current calibration event is determined (**1350**). For example, using a time based approach, in one embodiment, the sensitivity associated with the analyte sensor for calibration may be determined to, for example, reduce calibration errors or accommodate sensitivity drift.

(96) FIG. **14** is a flowchart illustrating an outlier data point verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. **14**, and as discussed in detail above, in determining composite sensitivity associated with the analyte sensor calibration, in one aspect, an outlier data point may be detected and accordingly corrected. For example, in one aspect, two successive sensitivities associated with two successive calibration events for the analyte sensor is compared (**1410**). If it is determined that the comparison between the two sensitivities are within a predetermined range (**1420**), the composite sensitivity for the current calibration of the analyte sensor is determined based on the two successive sensitivity values (**1430**), using, for example, the weighted approach described above.

(97) Referring back to FIG. **14**, if it is determined that the comparison of the two successive sensitivities results in the compared value being outside of the predetermined range, then the user may be prompted to enter or provide a new current blood glucose value (for example, using a blood glucose meter) (**1440**). Based on the new blood glucose value received, an updated or new sensitivity associated with the analyte sensor is determined (**1450**). Thereafter, the new or updated sensitivity determined is compared with the two prior sensitivities compared (at **1420**) to determine whether the new or updated sensitivity is within a predefined range of either of the two prior sensitivities (**1460**). If it is determined that the new or updated sensitivity of the analyte sensor is within the predefined range of either of the two prior successive sensitivities, a composite sensitivity is determined based on the new or updated sensitivity and the one of the two prior successive sensitivities within the defined range of which the new or updated sensitivity is determined (**1470**). On the other hand, if it is determined that the new or updated sensitivity is not within the predefined range of either of the two prior sensitivities, then the routine repeats and prompts the user to enter a new blood glucose value (**1440**).

(98) FIG. **15** is a flowchart illustrating a sensor stability verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. **15**, and as discussed above, between predetermined or scheduled baseline calibration events to calibrate the sensor, the analyte sensor sensitivity stability may be verified, to determine, for example, if additional stability calibrations may be needed prior to the subsequent scheduled baseline calibration event.

(99) For example, referring to FIG. **15**, in one embodiment, after the second baseline calibration event to calibrate the analyte sensor, the user may be prompted to provide a new blood glucose value. With the current blood glucose value received (**1510**), the current sensor sensitivity is

determined (1520). Thereafter, the most recent stored sensor sensitivity value from prior calibration event is retrieved (for example, from a storage unit) (1530), and the determined current sensor sensitivity is compared with the retrieved stored sensor sensitivity value to determine whether the difference, if any, between the two sensitivity values are within a predefined range (1540).

(100) Referring back to FIG. 15, if it is determined that the difference between the current and retrieved sensitivity values are within the predefined range, then the stability associated with the sensor sensitivity is confirmed (1550), and no additional calibration is required prior to the subsequent scheduled baseline calibration event. On the other hand, if it is determined that the difference between the current sensitivity and the retrieved prior sensitivity is not within the predefined range, then after a predetermined time period has lapsed (1560), the routine returns to the beginning and prompts the user to enter a new blood glucose value to perform the stability verification routine.

(101) In this manner, in one aspect, the stability checks may be performed after the outlier check is performed, and a new composite sensitivity determined as described above. Accordingly, in one aspect, analyte sensor sensitivity may be monitored as the sensitivity attenuation is dissipating to, among others, improve accuracy of the monitored glucose data and sensor stability.

(102) FIG. 16 illustrates analyte sensor code determination in accordance with one embodiment. Referring to the Figure, a batch of predetermined number of analyte sensors, for example, glucose sensors are selected during the manufacturing process (1610). The batch of predetermined number of glucose sensors may be a set number, or a variable number depending upon other manufacturing or post-manufacturing parameters (for example, such as testing, quality control verification, or packaging).

(103) Referring to FIG. 16, the sensitivity of each selected glucose sensor is determined (1620). For example, in one aspect, in vitro sensitivity determination is performed for each selected glucose sensor to determine the corresponding sensitivity. Thereafter, a variation between the determined sensitivity of each glucose sensor is determined (1630). That is, in one aspect, the determined in vitro sensitivity associated with each selected glucose sensor is compared to a predefined variation tolerance level (1640).

(104) In one aspect, if the variation of the sensitivity is greater than the predefined variation tolerance level for one of the selected glucose sensors in the selected batch of predetermined number of glucose sensors (1660), then the entire batch or lot may be rejected and not used. In another aspect, the rejection of the selected batch of predetermined number of glucose sensors may be based on a predetermined number of sensors within the selected batch that are associated with a sensitivity value that exceeds the predefined variation tolerance level. For example, in a batch of 30 glucose sensors, if 10 percent (or 3 sensors) has sensitivity that exceeds the predefined variation tolerance level, then the entire batch of 30 glucose sensors is rejected and not further processed during the manufacturing routine, for example, for use. Within the scope of the present disclosure, the number of sensors in the selected batch, or the number of sensors within the selected batch that exceeds the predefined variation tolerance level to result in a failed batch may be varied depending upon, for example, but not limited to, sensor manufacturing process, sensor testing routines, quality control verification, or other parameters associated with sensor performance integrity.

(105) Referring back to FIG. 16, if it is determined that the sensitivity of the selected glucose sensors are within the predefined variation tolerance level, a nominal sensitivity is determined for the batch of the predetermined number of glucose sensors (1650). Further, a sensor code is associated with the determined nominal sensitivity for the batch of predetermined number of analyte sensors (1670).

(106) In one aspect, the sensor code may be provided on the labeling for the batch of glucose sensors for use by the patient or the user. For example, in one aspect, the analyte monitoring system may prompt the user to enter the sensor code into the system (for example, to the receiver unit 104/106 FIG. 1) after the sensor has been initially positioned in the patient and prior to the first

sensor calibration event. In a further aspect, based on the sensor code, the analyte monitoring system may be configured to retrieve the nominal sensitivity associated with the batch of predetermined number of sensors for, for example, calibration of the transcutaneously positioned glucose sensor.

(107) FIG. **17** illustrates an early user notification function associated with the analyte sensor condition in one aspect of the present disclosure. Referring to FIG. **17**, upon detection of the sensor insertion (**1710**), for example, in fluid contact with the patient or user's analyte (e.g., interstitial fluid), one or more adverse data condition occurrence associated with the patient or the user's analyte level is monitored (**1720**). Examples of the adverse data condition occurrence may include, for example, a persistent low sensor signal (for example, continuous for a predefined time period), identified data quality flags or identifiers associated with erroneous or potentially inaccurate sensor signal level or sensor condition (for example, dislodged or improperly positioned sensor).

(108) Referring to FIG. **17**, when it is determined that the monitored adverse data condition occurrence exceeds a predetermined number of occurrences during a predefined time period (**1730**), a notification is generated and provided to the user to either replace the sensor, or to perform one or more verifications to confirm, for example, but not limited to, that the sensor is properly inserted and positioned, so the transmitter unit is in proper contact with the sensor (**1740**).

(109) On the other hand, if the number of adverse data condition occurrence has not occurred during the predefined time period, in one aspect, the routine continues to monitor for the occurrence of such condition during the set time period. In one aspect, the predetermined time period during which the occurrence of adverse data condition occurrence may be approximately one hour from the initial sensor positioning. Alternatively, this time period may be shorter or longer, depending upon the particular system configuration.

(110) In this manner, in the event that adverse condition related to the sensor is determined and persists for a given time period from the initial sensor insertion, the user or the patient is notified to either replace the sensor or to perform one or more troubleshooting steps to make sure that the components of the analyte monitoring system are functioning properly. Indeed, in one aspect, when an adverse condition related to the sensor is identified early on, the user is not inconvenienced by continuing to maintain the sensor in position even though the sensor may be defective or improperly positioned, or is associated with one or more other adverse conditions that will not allow the sensor to function properly.

(111) FIG. **18** illustrates uncertainty estimation associated with glucose level rate of change determination in one aspect of the present disclosure. Referring to FIG. **18**, based on the monitored glucose level from the glucose sensor, a rate of change estimate of the glucose level fluctuation is determined (**1810**). Further, an estimation of an uncertainty range or level associated with the determined rate of change of the glucose level is determined (**1820**). That is, in one aspect, a predefined rate of uncertainty determination may be performed, such as for example, a rate of change variance calculation. If the uncertainty determination is within a predetermined threshold level (**1830**), then an output is generated and/or provided to the user (**1840**).

(112) For example, when it is determined that the determined uncertainty measure is within the threshold level, the analyte monitoring system may be configured to display or output an indication to the user or the patient, such as a glucose level trend indicator (for example, a visual trend arrow or a distinctive audible alert (increasing or decreasing tone, etc)). On the other hand, if it is determined that the uncertainty measure related to the rate of change estimate exceeds the predetermined threshold, the determined rate of change of glucose level may be rejected or discarded (or stored but not output to the user or the patient). In one aspect, the uncertainty measure may include a predefined tolerance parameter associated with the accuracy of the determined rate of change of the monitored glucose level.

(113) In one aspect, the uncertainty measure or the tolerance level related to the rate of change of monitored glucose level may include, for example, but not limited to, corrupt or erroneous data

associated with the monitored glucose level, unacceptably large number of missing data associated with the monitored glucose level, rate of acceleration or deceleration of the monitored glucose level that exceeds a defined or acceptable threshold level, or any other parameters that may contribute to potential inaccuracy in the determined rate of change of the monitored glucose level.

(114) Accordingly, in one aspect, the accuracy of the analyte monitoring system may be maintained by, for example, disabling the output function associated with the rate of change determination related to the monitored glucose level, so that the user or the patient does not take corrective actions based on potentially inaccurate information. That is, as discussed above, in the event when it is determined that the determined uncertainty measure or parameter exceeds an acceptable tolerance range, the output function on the receiver unit **104/106** in the analyte monitoring system **100** may be disabled temporarily, or until the uncertainty measure of parameter related to the rate of change of the glucose level being monitored is within the acceptable tolerance range.

(115) When the monitored rate of change of the glucose level is steady (or within a defined range) and medically significant with respect to the monitored glucose measurement, a prediction of future or anticipated glucose level may be considered reliable based on the determined rate of change level. However, the monitored glucose level time series is such that the determined rate of change estimate may be less certain.

(116) Accordingly, in one aspect, the present disclosure accounts for the rate of change estimates having varying degrees of certainty. Since clinical treatment decisions may be made based on these estimates, it is important to discount, or not display or output to the user, the determined rate of change estimates with a high degree of uncertainty.

(117) In one aspect, the rate of change value and its uncertainty determine a probability distribution. This distribution may be assumed to be Gaussian, for example. Within the scope of the present disclosure, the uncertainty measure may be calculated in various ways. In one embodiment, it may include a standard deviation determination. Another possibility is to use the coefficient of variation (CV), which is the standard deviation of the rate of change divided by the rate of change. A combination of these uncertainty measures may also be used.

(118) In one aspect, various ranges of rates of change may be combined into bins. For example, bin edges at ± 2 mg/dL and at ± 1 mg/dL may be defined in one embodiment resulting in five bins. Each bin may be represented by a position of a trend arrow indicator, associated with the monitored glucose level. When the rate of change is included in one of the determined bins, the associated trend arrow position may be displayed.

(119) Further, the presence of uncertainty may modify the trend arrow position that is displayed to the user or the patient. In one aspect, a determination that involves the uncertainty measure results in a metric value which may be a simple comparison of the uncertainty value to a predefined threshold. There are also other possible metrics. Another approach may use a different predefined threshold value for each bin.

(120) In one aspect, an unacceptable metric value may cause no trend arrow indicator to be displayed. Alternatively, this condition may be indicated by a change in the characteristics of the display to the user or the patient. For example, the trend arrow indicator may flash, change color, change shape, change size, change length or change width, among others. A further embodiment may include the trend arrow indicator showing no significant rate-of-change. Within the scope of the present disclosure, other user output configurations including audible and/or vibratory output are contemplated.

(121) In one aspect, the uncertainty measure may be characterized a number of ways. One is the standard deviation of the monitored glucose levels over the period in which the rate of change is estimated. Another is the coefficient of variation (CV), which, as discussed above, is the standard deviation of the monitored glucose trend divided by the rate of change value. A further characterization may include a probabilistic likelihood estimate. Yet a further characterization is the output of a statistical filter or estimator such as a Kalman filter. The uncertainty comparison may be

based on one of these techniques or a combination of two or more of these techniques. Also, different uncertainty characteristics may be used for different rate-of-change results. For instance, in one embodiment, a CV formulation may be used for high glucose values and a standard deviation formulation may be used for low glucose values.

(122) FIG. **19** illustrates glucose trend determination in accordance with one embodiment of the present disclosure. Referring to FIG. **19**, a current value associated with a monitored glucose level is received (**1910**). One or more prior values associated with the monitored glucose level (previously stored, for example) is retrieved (**1920**). With the current and prior values associated with the monitored glucose level, a most recent calibration scale factor is applied to the current and prior values associated with the monitored glucose level (**1930**). After applying the calibration scale factor to the current and prior values, the trend associated with the monitored glucose level is determined (**1940**).

(123) In this manner, in one aspect, with the updated calibration of the glucose sensor including a newly determined sensitivity, buffered or stored values associated with the monitored glucose level may be updated using, for example, the updated calibration information, resulting, for example, in revised or modified prior values associated with the monitored glucose level. As such, in one embodiment, stored or buffered values associated with the monitored glucose level may be updated and, the updated values may be used to determine glucose trend information or rate of change of glucose level calculation. In this manner, accuracy of the glucose trend information may be improved by applying the most recent calibration parameters to previously detected and stored values associated with the monitored glucose level, when, for example, the previously detected and stored values are used for further analysis, such as, glucose trend determination or rate of change of glucose level calculation.

(124) FIG. **20** illustrates glucose trend determination in accordance with another embodiment of the present disclosure. Referring to FIG. **20**, a current value associated with a monitored glucose level is received (**2010**). One or more prior values associated with the monitored glucose level (previously stored, for example) is retrieved (**2020**). With the current and prior values associated with the monitored glucose level, a rate of change estimate of the monitored glucose level is determined (**2030**). Referring back to FIG. **20**, an uncertainty parameter associated with the rate of change estimate is determined (**2040**).

(125) In one aspect, an uncertainty parameter may be predetermined and programmed into the analyte monitoring system **100** (for example, in the receiver unit **104/106**). Alternatively, the uncertainty parameter may be dynamically configured to vary depending upon the number of data available for determination of the glucose level rate of change determination, or upon other programmable parameters that may include user specified uncertainty parameters. Within the scope of the present disclosure, the uncertainty parameter may include the number of acceptable missing or unavailable values when performing the monitored glucose level rate of change estimation. Referring back to FIG. **20**, when it is determined that the uncertainty parameter is within an acceptable predetermined tolerance range, the rate of change of the monitored glucose level is determined and output to the user or the patient (**2050**).

(126) In one embodiment, the uncertainty parameter may be associated with the time spacing of the current and prior values, such that when the rate of change estimation requires a preset number of values, and no more than a predetermined number of values (optionally consecutively, or non consecutively) are unavailable, the rate of change estimation is performed. In this manner, for example, when a large number of values associated with the monitored glucose level (for example, 5 consecutive one minute data—tolerance range) are unavailable, corrupt or otherwise unusable for purposes of rate of change determination, the uncertainty parameter is deemed to exceed the predetermined tolerance range, and the rate of change calculation may not be performed, or may be postponed.

(127) As discussed, the rate of change in glucose for a patient or a user may be used by glucose

monitoring devices to direct glucose trend indicators for display to the patient or the user such that the patient or the user may base treatment decisions not only on the current glucose levels but also on the current direction or change in the glucose level. The rate of change estimate may also be used to project into the future if a predetermined glucose threshold (upper or lower range or limit) is not exceeded within a specific time period based on the current glucose level and rate of change information. Within the scope of the present disclosure, other projection approaches may be based on higher order derivatives of the rate of change, and/or other statistical likelihood formulations that can be contemplated for prediction of a future event.

(128) One approach to determine the rate of change is to calculate the difference between two glucose samples and dividing the result by the time difference between the samples. Another approach may be to fit a time series of glucose readings to a function, such as a polynomial, using techniques such as the least squares techniques. The number of samples and the time period of the samples may impact the accuracy of the rate of change estimate in the form of a trade off between noise reduction properties and lag introduced.

(129) Referring again to the Figures, in one aspect, the transmitter unit **102** may be configured to perform one or more periodic or routine data quality checks or verification before transmitting the data packet to the receiver/monitor unit **104/106**. For example, in one aspect, for each data transmission (e.g., every 60 seconds, or some other predetermined transmission time interval), the transmitter data quality flags in the data packet are reset, and then it is determined whether any data field in the transmission data packet includes an error flag. If one error flag is detected, then in one aspect, the entire data packet may be considered corrupt, and this determination is transmitted to the receiver/monitor unit **104/106**. Alternatively, the determination that the entire data packet is corrupt may be performed by the receiver/monitor unit **104/106**. Accordingly, in one aspect, when at least one data quality check fails in the transmitter data packet, the entire packet is deemed to be in error, and the associated monitored analyte level is discarded, and not further processed by the receiver/monitor unit **104/106**.

(130) In another aspect, the data quality check in the transmitter unit **102** data packet may be performed so as to identify each error flag in the data packet, and those identified error flag are transmitted to the receiver/monitor unit **104/106** in addition to the associated monitored analyte level information. In this manner, in one aspect, if the error flag is detected in the transmitter data packet which is not relevant to the accuracy of the data associated with the monitored analyte level, the error indication is flagged and transmitted to the receiver/monitor unit **104/106** in addition to the data indicating the monitored analyte level.

(131) In one aspect, examples of error condition that may be detected or flagged in the transmitter unit **102** data packet include sensor connection fault verification by, for example, determining, among others, whether the counter electrode voltage signal is within a predetermined range, resolution of the data associated with the monitored analyte level, transmitter unit temperature (ambient and/or on-skin temperature) out of range, and the like. As discussed above, the data quality check in the transmitter unit **102** may be performed serially, such that detection of an error condition or an error flag renders the entire data packet invalid or deemed corrupt. In this case, such data is reported as including error to the receiver/monitor unit **104/106**, but not used to process the associated monitored analyte level. In another aspect, all data quality fields in the data packet of the transmitter unit **102** may be checked for error flags, and if there are error flags detected, the indication of the detected error flags is transmitted with the data packet to the receiver/monitor unit **104/106** for further processing.

(132) In one embodiment, on the receiver/monitor unit **104/106** side, for each periodic data packet received (for example every 60 seconds or some other predetermined time interval), the receiver/monitor unit **104/106** may be configured to receive the raw glucose data including any data quality check flags from the transmitter unit **102**, and to apply temperature compensation and/or calibration to the raw data to determine the corresponding glucose data (with any data

quality flags as may have been identified). The unfiltered, temperature compensated and/or calibrated glucose data is stored along with any data quality flags in a FIFO buffer (including, for example, any invalid data identifier). Alternatively, a further data quality check may be performed on the temperature compensated and calibrated glucose data to determine the rate of change or variance of the measured glucose data. For example, in one embodiment, a high variance check or verification is performed on 30 minutes of glucose data stored in the FIFO buffer. If it is determined that the rate of variance exceeds a predetermined threshold, then the data packet in process may be deemed invalid. On the other hand, if the rate of variance does not exceed the predetermined threshold, the results including the glucose data and any associated validity or error flags are stored in the FIFO buffer.

(133) Thereafter, the data processing is performed on the stored data to determine, for example, the respective glucose level estimation or calculation. That is, the stored data in the FIFO buffer in one embodiment is filtered to reduce unwanted variation in signal measurements due to noise or time delay, among others. In one aspect, when the rate of change or variance of glucose data stored in the FIFO buffer, for example, is within a predetermined limit, the glucose measurements are filtered over a 15 minute period. On the other hand, if it is determined that the rate of change is greater than the predetermined limit, a more responsive 2 minute filtering is performed. In one aspect, the filtering is performed for each 60 second glucose data. In this manner, in one embodiment, a rate variance filter is provided that may be configured to smooth out the variation in the glucose measurement when the glucose level is relatively stable, and further, that can respond quickly when the glucose level is changing rapidly. The rate variance filter may be implemented in firmware as an FIR filter which is stable and easy to implement in integer-based firmware, for example, implemented in fixed point math processor.

(134) In one embodiment, for each 60 second glucose data received, two filtered values and two additional parameters are determined. That is, using an FIR filter, for example, a weighted average for a 15 minute filtered average glucose value and a 2 minute average filtered glucose value are determined. In addition, a rate of change based on 15 minutes of data as well as a standard deviation associated with the rate estimate is determined. To determine the final filtered glucose value for output and/or display to the user, a weighted average of the two determined filtered glucose values is determined, where when the rate of change of the glucose values is high, then weighting is configured to tend towards the 2 minute filtered value, while when the rate of change of the glucose value is low the weighting tends towards the 15 minute filtered value. In this manner, when the rate of change is high, the 2 minute filtered value is weighted more heavily (as the 15 minute filtered average value potentially introduces lag, which at higher rates of change, likely results in large error).

(135) Referring back, during the calibration routine, in one embodiment, when the discrete blood glucose value is received for purposes of calibration of the glucose data from the sensor **101** (FIG. **1**), the processing unit of the receiver/monitor unit **104/106** is configured to retrieve from the FIFO buffer two of the last five valid transmitter data packets that do not include any data quality flags associated with the respective data packets. In this manner, in one aspect, the calibration validation check may be performed when the blood glucose value is provided to the receiver/monitor unit **104/106** determined using, for example, a blood glucose meter. In the event that two valid data packets from the last five data packets cannot be determined, the receiver/monitor unit **104/106** is configured to alarm or notify the user, and the calibration routine is terminated.

(136) On the other hand, if the calibration validation check is successful, the sensitivity associated with the sensor **101** (FIG. **1**) is determined, and its range verified. In one aspect, if the sensitivity range check fails, again, the receiver/monitor unit **104/106** may be configured to alarm or otherwise notify the user and terminate the calibration routine. Otherwise, the determined sensitivity is used for subsequent glucose data measurement and processing (until a subsequent calibration is performed).

(137) Referring back to the Figures, in one aspect, determination of optimal sensitivity evaluates one or more potential error sources or conditions present in blood glucose value for calibration and the potential sensitivity drift. Accordingly, using a weighted average of the current sensitivity determined for calibration and previously determined sensitivity, the sensitivity accuracy may be optimized. For example, in one embodiment, a weighted average of the two most recent sensitivities determined used for calibration may be used to determine a composite sensitivity determination to improve accuracy and reduce calibration errors. In this aspect, earlier blood glucose values used for calibration are discarded to accommodate for sensitivity drift. In one embodiment, the number of blood glucose values used for determining the weighted average, and also, the weighting itself may be varied using one or more approaches including, for example, a time based technique.

(138) For example, for each sensor calibration routine, the sensitivity derived from the current blood glucose value from the current blood glucose test and the stored sensitivity value associated with the most recent prior stored blood glucose value may be used to determine a weighted average value that is optimized for accuracy. Within the scope of the present disclosure, as discussed above, the weighting routine may be time based such that if the earlier stored blood glucose value used for prior calibration is greater than a predetermined number of hours, then the weighting value assigned to the earlier stored blood glucose may be less heavy, and a more significant weighting value may be given to the current blood glucose value to determine the composite sensitivity value.

(139) In one embodiment, a lookup table may be provided for determining the composite sensitivity determination based on a variable weighting average which provides a non-linear correction to reduce errors and improve accuracy of the sensor sensitivity.

(140) The determined composite sensitivity in one embodiment may be used to convert the sensor ADC counts to the corresponding calibrated glucose value. In one aspect, the composite sensitivity determined may be used to minimize outlier calibrations and unstable sensitivity during, for example, the initial use periods. That is, during the data validation routines, an outlier check may be performed to determine whether the sensitivity associated with each successive calibration is within a predetermined threshold or range.

(141) For example, the sensor **101** (FIG. **1**) may require a predetermined number of baseline calibrations during its use. For a five day operational lifetime of a sensor, four calibrations may be required at different times during the five day period. Moreover, during this time period, additional stability related calibrations may be required if the sensor sensitivity is determined to be unstable after the second baseline calibration is performed, for example, at the 12.sup.th hour (or other suitable time frame) of the sensor usage after the initial calibration within the first 10 hours of sensor deployment.

(142) In one aspect, during the outlier check routine, it is determined whether the sensitivity variance between two successive calibrations is within a predetermined acceptable range. If it is determined that the variance is within the predetermined range, then the outlier check is confirmed, and a new composite sensitivity value is determined based on a weighted average of the two sensitivity values. As discussed above, the weighted average may include a time based function or any other suitable discrete weighting parameters.

(143) If on the other hand, the variance between the two sensitivities is determined to be outside of the predetermined acceptable range, then the second (more recent) sensitivity value is considered to be an outlier (for example, due to ESA, change in sensitivity or due to bad or erroneous blood glucose value), and the user is prompted to perform another fingerstick testing to enter a new blood glucose value (for example, using a blood glucose meter). If the second current sensitivity associated with the new blood glucose value is determined to be within the predetermined acceptable range from the prior sensitivity, then the earlier current sensitivity value is discarded, and the composite sensitivity is determined based on applying a weighting function or parameter on the prior sensitivity value, and the second current sensitivity value (discarding the first current

sensitivity value which is outside the predetermined acceptable range and considered to be an outlier).

(144) On the other hand, when the second current sensitivity value is determined to be within the predetermined acceptable range of the first current sensitivity value, but not within the predetermined acceptable range of the prior sensitivity value (of the two successive calibrations described above), then it is determined in one embodiment that a sensitivity shift, rather than an outlier, has occurred or is detected from the first current sensitivity value to the second current sensitivity value. Accordingly, the composite sensitivity may be determined based, in this case, on the first and second current sensitivity values (and discarding the prior sensitivity).

(145) If, for example, the second current sensitivity value is determined to be outside the predetermined range of both of the two successive sensitivities described above, then the user in one embodiment is prompted to perform yet another blood glucose test to input another current blood glucose value, and the routine described above is repeated.

(146) Furthermore, in accordance with another aspect, the determination of the sensitivity variance between two successive calibrations are within a predetermined acceptable range may be performed prior to the outlier check routine.

(147) Referring to the Figures, during the period of use, as discussed above, the sensor **101** (FIG. 1) is periodically calibrated at predetermined time intervals. In one aspect, after the second baseline calibration (for example, at 12.sup.th hour of sensor **101** transcutaneously positioned in fluid contact with the user's analyte), sensor sensitivity stability verifications may be performed to determine whether, for example, additional stability calibrations may be necessary before the third baseline calibration is due. In one aspect, the sensitivity stability verification may be performed after the outlier checks as described above is performed, and a new composite sensitivity is determined, and prior to the third scheduled baseline calibration at the 24.sup.th hour (or at another suitable scheduled time period).

(148) That is, the sensor sensitivity may be attenuated (e.g., ESA) early in the life of the positioned sensor **101** (FIG. 1), and if not sufficiently dissipated by the time of the first baseline calibration, for example, at the 10.sup.th hour (or later), and even by the time of the second calibration at the 12.sup.th hour. As such, in one aspect, a relative difference between the two sensitivities associated with the two calibrations is determined. If the determined relative difference is within a predefined threshold or range (for example, approximately 26% variation), then it is determined that the sufficient stability point has reached. On the other hand, if the relative difference determined is beyond the predefined threshold, then the user is prompted to perform additional calibrations at a timed interval (for example, at each subsequent 2 hour period) to determine the relative difference in the sensitivity and compared to the predefined range. This may be repeated for each two hour interval, for example, until acceptable stability point has been reached, or alternatively, until the time period for the third baseline calibration is reached, for example, at the 24.sup.th hour of sensor **101** (FIG. 1) use.

(149) In this manner, in one aspect, the stability verification may be monitored as the sensitivity attenuation is dissipating over a given time period. While the description above is provided with particular time periods for baseline calibrations and additional calibration prompts for stability checks, for example, within the scope of the present disclosure, other time periods or calibration schedule including stability verifications may be used. In addition, other suitable predefined threshold or range of the relative sensitivity difference to determine acceptable attenuation dissipation other than approximately 26% may be used. Moreover, as discussed above, the predetermined calibration schedule for each sensor **101** (FIG. 1) may be modified from the example provided above, based on, for example, the system design and/or sensor **101** (FIG. 1) configuration.

(150) Additionally, in one aspect, the user may be prompted to perform the various scheduled calibrations based on the calibration schedule provided. In the case where the scheduled calibration

is not performed, in one embodiment, the glucose value determination for user display or output (on the receiver/monitor unit **104/106**, for example) based on the received sensor data may be disabled after a predetermined time period has lapsed. Further, the glucose value determination may be configured to resume when the prompted calibration is successfully completed.

(151) In a further aspect, the scheduled calibration timing may be relative to the prior calibration time periods, starting with the initial sensor positioning. That is, after the initial transcutaneous positioning of the sensor **101** (FIG. **1**) and the scheduled time period has elapsed to allow the sensor **101** to reach a certain stability point, the user may be prompted to perform the first baseline calibration as described above (for example, at the 10.sup.th hour since the initial sensor placement). Thereafter, in the case when the user waits until the 11.sup.th hour to perform the initial baseline calibration, the second scheduled calibration at the 12.sup.th hour, for example, may be performed at the 13.sup.th hour, so that the two hour spacing between the two calibrations are maintained, and the second calibration timing is based on the timing of the first successful baseline calibration performed. In an alternate embodiment, each scheduled calibration time period may be based on the timing of the initial sensor positioning. That is, rather than determining the appropriate subsequent calibration time periods based on the prior calibration performed, the timing of the scheduled calibration time periods may be made to be absolute and based from the time of the initial sensor placement.

(152) Furthermore, in one aspect, when the scheduled calibration is not performed at the scheduled time periods, the glucose values may nevertheless be determined based on the sensor data for display to the user for a limited time period (for example, for no more than two hours from when the scheduled calibration time period is reached). In this manner, a calibration time window may be established or provided to the user with flexibility in performing the scheduled calibration and during which the glucose values are determined for output display to the user, for example. In one aspect, if within the calibration time window, the scheduled calibrations are not performed, the glucose values may be deemed in error, and thus not provided to the user or determined until the calibration is performed.

(153) For example, after the initial successful baseline calibration at the 10.sup.th hour, for example, or at any other suitable scheduled initial baseline calibration time, glucose values are displayed or output to the user and stored in a memory. Thereafter, at the next scheduled calibration time period (for example, at the 12.sup.th hour), the user may be prompted to perform the second calibration. If the user does not perform the second calibration, a grace period of two hours, for example, is provided during which valid glucose values are provided to the user (for example, on the display unit of the receiver/monitor unit **104/106**) based on the prior calibration parameters (for example, the initial baseline calibration performed at the 10.sup.th hour). However, if the second calibration is still not performed after the grace period, in one aspect, no additional glucose values are provided to user, and until the scheduled calibration is performed.

(154) In still another aspect, the user may supplement the scheduled calibrations, and perform manual calibration based on the information that the user has received. For example, in the case that the user determines that the calibration performed and determined to be successful by the receiver/monitor unit **104/106**, for example, is not sufficiently accurate, rather than replacing the sensor, the user may recalibrate the sensor even if the scheduled calibration time has not been reached. For example, based on a blood glucose test result, if the determined blood glucose level is not close to or within an acceptable range as compared to the sensor data, the user may determine that additional calibration may be needed.

(155) Indeed, as the sensitivity value of a given sensor tends to stabilize over time, a manual user forced calibration later in the sensor's life may provide improved accuracy in the determined glucose values, as compared to the values based on calibrations performed in accordance with the prescribed or predetermined calibration schedule. Accordingly, in one aspect, additional manual calibrations may be performed in addition to the calibrations based on the predetermined

calibration schedule.

(156) In a further aspect, user notification functions may be programmed in the receiver/monitor unit **104/106**, or in the transmitter unit **102** (FIG. **1**) to notify the user of initial conditions associated with the sensor **101** (FIG. **1**) performance or integrity. That is, alarms or alerts, visual, auditory, and/or vibratory may be configured to be triggered when conditions related to the performance of the sensor are detected. For example, during the initial one hour period (or some other suitable time period) from the sensor insertion, in the case where data quality flags/conditions (described above) are detected, or in the case where low or no signal from the sensor is detected from a given period of time, an associated alarm or notification may be initiated or triggered to notify the user to verify the sensor position, the sensor contacts with the transmitter unit **102** (FIG. **1**), or alternatively, to replace the sensor with a new sensor. In this manner, rather than waiting a longer period until the acceptable sensor stability point has been reached, the user may be provided at an early stage during the sensor usage that the positioned sensor may be defective or has failed.

(157) In addition, other detected conditions related to the performance of the sensor, calibration, and detected errors associated with the glucose value determination may be provided to the user using one or more alarm or alert features. For example, when the scheduled calibration has been timely performed, and the grace period as described above has expired, in one embodiment, the glucose value is not processed for display or output to the user anymore. In this case, an alarm or alert notifying the user that the glucose value cannot be calculated is provided so that the user may timely take corrective actions such as performing the scheduled calibration. In addition, when other parameters that are monitored such as the temperature, sensor data, and other variables that are used to determine the glucose value, include error or otherwise is deemed to be corrupt, the user may be notified that the associated glucose value cannot be determined, so that the user may take corrective actions such as, for example, replacing the sensor, verifying the contacts between the sensor and the transmitter unit, and the like.

(158) In this manner, in one embodiment, there is provided an alarm or notification function that detects or monitors one or more conditions associated with the glucose value determination, and notifies the user of the same when such condition is detected. Since the alarms or notifications associated with the glucose levels (such as, for example, alarms associated with potential hyperglycemic, hypoglycemic, or programmed trend or rate of change glucose level conditions) will be inactive if the underlying glucose values cannot be determined, by providing a timely notification or alarm to the user that the glucose value cannot be determined, the user can determine or be prompted/notified that these alarms associated with glucose levels are inactive.

(159) In one aspect of the present disclosure, glucose trend information may be determined and provided to the user, for example, on the receiver/monitor unit **104/106**. For example, trend information in one aspect is based on the prior monitored glucose levels. When calibration is performed, the scaling used to determine the glucose levels may change. If the scaling for the prior glucose data (for example, one minute prior) is not changed, then in one aspect, the trend determination may be deemed more error prone. Accordingly, in one aspect, to determine accurate and improved trend determination, the glucose level determination is performed retrospectively for a 15 minute time interval based on the current glucose data when each successive glucose level is determined.

(160) That is, in one aspect, with each minute determination of the real time glucose level, to determine the associated glucose trend information, the stored past 15 minute data associated with the determined glucose level is retrieved, including the current glucose level. In this manner, the buffered prior glucose levels may be updated with new calibration to improve accuracy of the glucose trend information.

(161) In one aspect, the glucose trend information is determined based on the past 15 minutes (or some other predetermined time interval) of glucose data including, for example, the current calibration parameter such as current sensitivity. Thereafter, when the next glucose data is received

(at the next minute or based on some other timed interval), a new sensitivity is determined based on the new data point associated with the new glucose data. Also, the trend information may be determined based on the new glucose data and the past 14 minutes of glucose data (to total 15 minutes of glucose data). It is to be noted that while the trend information is determined based on 15 minutes of data as described above, within the scope of the present disclosure, other time intervals may be used to determine the trend information, including, for example, 30 minutes of glucose data, 10 minutes of glucose data, 20 minutes of glucose data, or any other appropriate time intervals to attain an accurate estimation of the glucose trend information.

(162) In this manner, in one aspect of the present disclosure, the trend information for the historical glucose information may be updated based on each new glucose data received, retrospectively, based on the new or current glucose level information, and the prior 14 glucose data points (or other suitable number of past glucose level information). In another aspect, the trend information may be updated based on a select number of recent glucose level information such that, it is updated periodically based on a predetermined number of determined glucose level information for display or output to the user.

(163) In still another aspect, in wireless communication systems such as the data monitoring and management system **100** (FIG. **10**), the devices or components intended for wireless communication may periodically be out of communication range. For example, the receiver/monitor unit **104/106** may be placed out of the RF communication range of the transmitter unit **102** (FIG. **1**). In such cases, the transmitted data packet from the transmitter unit **102** may not be received by the receiver/monitor unit **104/106**, or due to the weak signaling between the devices, the received data may be invalid or corrupt. In such cases, while there may be missing data points associated with the periodically monitored glucose levels, the trend information may be nevertheless determined, as the trend information is determined based on a predetermined number of past or prior glucose data points (for example, the past 15 minutes of glucose data).

(164) That is, in one aspect, even if there are a certain number of glucose data points within the 15 minute time frame that may be either not received by the receiver/monitor unit **104/106**, or alternatively be corrupt or otherwise invalid due to, for example, weakness in the communication link, the trend information may be determined. For example, given the 15 minutes of glucose data, if three or less non consecutive data points are not received or otherwise corrupt, the receiver/monitor unit **104/106** may determine the glucose trend information based on the prior 12 glucose data points that are received and considered to be accurate. As such, the features or aspects of the analyte monitoring system which are associated with the determined trend information may continue to function or operate as programmed.

(165) That is, the projected alarms or alerts programmed into the receiver/monitor unit **104/106**, or any other alarm conditions associated with the detection of impending hyperglycemia, impending hypoglycemia, hyperglycemic condition or hypoglycemic condition (or any other alarm or notification conditions) may continue to operate as programmed even when there are a predetermined number or less of glucose data points. However, if and when the number of missing glucose data points exceed the tolerance threshold so as to accurately estimate or determine, for example, the glucose trend information, or any other associated alarm conditions, the display or output of the associated glucose trend information or the alarm conditions may be disabled.

(166) For example, in one aspect, the glucose trend information and the rate of change of the glucose level (which is used to determine the trend information) may be based on 15 minute data (or data based on any other suitable time period) of the monitored glucose levels, where a predetermined number of missing data points within the 15 minutes may be tolerated. Moreover, using least squares approach, the rate of change of the monitored glucose level may be determined to estimate the trend, where the monitored glucose data is not evenly spaced in time. In this approach, the least squares approach may provide an uncertainty measure of the rate of change of the monitored glucose level. The uncertainty measure, in turn, may be partially dependent upon the

number of data points available.

(167) Indeed, using the approaches described above, the trend information or the rate of change of the glucose level may be estimated or determined without the need to determine which data point or glucose level is tolerable, and which data point is not tolerable. For example, in one embodiment, the glucose data for each minute including the missing data is retrieved for a predetermined time period (for example, 15 minute time period). Thereafter, least squares technique is applied to the 15 minute data points. Based on the least squares (or any other appropriate) technique, the uncertainty or a probability of potential variance or error of the rate of glucose level change is determined. For example, the rate of change may be determined to be approximately $1.5 \text{ mg/dL/minute} \pm 0.1 \text{ mg/dL/minute}$. In such a case, the 0.1 mg/dL/minute may represent the uncertainty information discussed above, and may be higher or lower depending upon the number of data points in the 15 minutes of data that are missing or corrupt.

(168) In this manner, in one aspect, the glucose trend information and/or the rate of change of monitored glucose level may be determined based on a predefined number of past monitored glucose level data points, even when a subset of the predefined number of past monitored glucose level data points are missing or otherwise determined to be corrupt. On the other hand, when the number of past glucose level data points based on which the glucose trend information is determined, exceeds the tolerance or acceptance level, for example, the display or output of the glucose trend information may be disabled. Additionally, in a further aspect, if it is determined that the underlying data points associated with the monitored glucose level based on which the trend information is determined, includes uncertainty or error factor that exceeds the tolerance level (for example, when there are more than a predetermined number of data points which deviate from a predefined level), the receiver/monitor unit **104/106**, for example, may be configured to disable or disallow the display or output of the glucose trend information.

(169) For example, when the 15 minute glucose data including the current glucose level as well as the past 14 minutes of glucose level data is to be displayed or output to the user, and the determined rate variance of the 15 data points exceeds a preset threshold level (for example, 3.0), the glucose trend information display function may be disabled. In one aspect, the variance may be determined based on the square function of the standard deviation of the 15 data points. In one aspect, this approach may be performed substantially on a real time basis for each minute glucose data. Accordingly, as discussed above, the glucose trend information may be output or displayed substantially in real time, and based on each new glucose data point received from the sensor/transmitter unit.

(170) Additionally, when it is determined that the 15 data points (or any other suitable number of data points for determining glucose trend information, for example), deviate beyond a predetermined tolerance range, in one aspect, the 15 minute data may be deemed error prone or inaccurate. In this case, rather than outputting or displaying glucose trend information that may be erroneous, the receiver/monitor unit **104/106** may be configured to display the output or display function related to the output or display of the determined glucose trend information. The same may apply to the output or display of projected alarms whose estimates may be based in part, on the determined trend information. Accordingly, in one aspect, there may be instances when the projected alarm feature may be temporarily disabled where the underlying monitored glucose data points are considered to include more than acceptable levels of uncertainty or error.

(171) In a further aspect, it is desired to determine an estimate of sensor sensitivity, and/or a range of acceptable or reasonable sensitivity. For example, during determination or verification of the glucose rate of change prior to calibration, the estimated sensor sensitivity information is necessary, for example, to determine whether the rate of change is within or below an acceptable threshold level, and/or further, within a desired range. Moreover, when determining whether the sensor sensitivity is within an acceptable or reasonable level, it may be necessary to ascertain a range of reasonable or acceptable sensitivity—for example, a verification range for the sensitivity value for

a given sensor or batch of sensors.

(172) Accordingly, in one aspect, during sensor manufacturing process, a predetermined number of sensor samples (for example, 16 samples) may be evaluated from each manufacturing lot of sensors (which may include, for example, approximately 500 sensors) and the nominal sensitivity for each lot (based, for example, on a mean calculation) may be determined. For example, during the manufacturing process, the predetermined number of sensors (for example, the 16 sensors) are sampled, and the sensitivity of each sampled sensor is measured in vitro. Thereafter, a mean sensitivity may be determined as an average value of the 16 sampled sensor's measured sensitivity, and thereafter, the corresponding sensor code is determined where the determined mean sensitivity falls within the preassigned sensitivity range. Based on the determined sensor code, the sensor packaging is labeled with the sensor code.

(173) For example, each sensor code value (e.g., **105**, **106**, **107** or any suitable predetermined number or code) may be preassigned a sensitivity range (For example, code **105**: S1-S2, code **106**: S2-S3, and code **107**: S3-S4), where each sensitivity range (e.g., S1-S2, or S2-S3, or S3-S4) is approximately over a 10 percent increment (for example, S1 is approximately 90% of S2). Also, each sensor code (e.g., **105**, **106**, **107**, etc.) is assigned a nominal sensitivity value (Sn) that is within the respective preassigned sensitivity range.

(174) Referring back, when the user inserts the sensor or positions the sensor transcutaneously in place, the receiver/monitor unit **104/106** in one embodiment prompts the user to enter the associated sensor code. When the user enters the sensor code (as derived from the sensor packing label discussed above), the receiver/monitor unit **104/106** is configured to retrieve or look up the nominal sensitivity associated with the user input sensor code (and the nominal sensitivity which falls within the preassigned sensitivity range associated with that sensor code, as described above). Thereafter, the receiver/monitor unit **104/106** may be configured to use the sensor code in performing associated routines such as glucose rate of change verification, data quality checks discussed above, and/or sensor sensitivity range acceptability or confirmation.

(175) In a further aspect, the sensor codes may be associated with a coefficient of variation of the predetermined number of sampled sensors discussed above in addition to using the mean value determined as discussed above. In one embodiment, the coefficient of variation may be determined from the predetermined number of sampled sensors during the manufacturing process. In addition, the mean response time of the sampled sensors may be used by separately measuring the predetermined number of sampled sensors which may be used for lag correction adjustments and the like.

(176) In this manner, in one aspect, the manufacturing process control described above ensures that the coefficient of variation of the sampled sensors is within a threshold value. That is, the value of the nominal sensitivity is used to determine a sensor code, selected or looked up from a predetermined table, and that is assigned to the sensors from the respective sensor lot in manufacturing. The user then enters the sensor code into the receiver/monitor unit that uses the sensor code to determine the glucose rate of change for purposes of data quality checking, for example, and also to determine validity or reasonableness of the sensitivity that is determined.

(177) In one embodiment a method may comprise receiving a plurality of signals associated with a monitored analyte level detected by an vivo sensor for a predetermined time period, comparing each of the plurality of the received signals to a predefined signal range, and modifying a parameter associated with a trend information determined based on comparing the plurality of the received signals to the predefined signal range.

(178) The plurality of signals may be substantially evenly temporally spaced within the predetermined time period.

(179) The predefined signal range may define a valid signal range.

(180) The trend information may be based on the plurality of signals and provide a prospective direction of the monitored analyte level.

- (181) Modifying the parameter associated with the trend information may include disabling output of the trend information.
- (182) The trend information output may be disabled when a predetermined number of the plurality of the received signals are outside the predefined signal range.
- (183) In one embodiment, an apparatus may comprise a communication unit configured to receive a plurality of signals associated with a monitored analyte level using an in vivo analyte sensor for a predetermined time period, and a data processing unit coupled to the communication unit, and configured to compare each of the plurality of the received signals to a predefined signal range, and modify a parameter associated with a trend information determined based on comparing the plurality of the received signals to the predefined signal range.
- (184) The plurality of signals may be substantially evenly temporally spaced within the predetermined time period.
- (185) The predefined signal range may define a valid signal range.
- (186) The trend information may be based on the plurality of signals and provide a prospective direction of the monitored analyte level.
- (187) The data processing unit may be configured to disable output of the trend information.
- (188) The data processing unit may be configured to disable the trend information output when a predetermined number of the plurality of the received signals are outside the predefined signal range.
- (189) The trend information may include a projected alarm.
- (190) One aspect may include an output unit coupled to the data processing unit.
- (191) The output unit may be configured to present one or more of a visual, an audible or a vibratory output associated with the trend information.
- (192) The trend information may include a projected alarm.
- (193) The analyte sensor may be a glucose sensor.
- (194) In one embodiment, a method may comprise receiving a signal associated with a monitored analyte level of an individual from an in vivo analyte sensor, retrieving at least one previously stored signal associated with the monitored analyte level of the individual, determining a tolerance parameter associated with a rate of change of the monitored analyte level based on the received signal and the retrieved at least one previously stored signal, comparing the tolerance parameter to a predetermined threshold value, and generating an output data based on the result of the comparison.
- (195) One aspect may include retrieving the previously stored signal, which includes retrieving a predetermined number of previously stored signals associated with the monitored analyte level.
- (196) The tolerance parameter may include an uncertainty value associated with the rate of change of the monitored analyte level based on a least squares determination.
- (197) The generated output data may include a command to prevent the output of a projected alarm information when the tolerance parameter exceeds the predetermined threshold value.
- (198) The generated output data may include a command to prevent the output of a monitored analyte level trend information when the tolerance parameter exceeds the predetermined threshold value.
- (199) In one embodiment, an analyte monitoring device may comprise a processing unit configured to receive a signal associated with a monitored analyte level of an individual from an in vivo analyte sensor; the processing unit further configured to retrieve at least one previously stored signal associated with the monitored analyte level of the individual, determine a tolerance parameter associated with a rate of change of the monitored analyte level based on the received signal and the retrieved at least one previously stored signal, compare the tolerance parameter to a predetermined threshold value, and to generate an output data based on the result of the comparison.
- (200) The processing unit may be configured to retrieve a predetermined number of previously

stored signals associated with the monitored analyte level.

(201) The tolerance parameter may include an uncertainty value associated with the rate of change of the monitored analyte level based on a least squares determination.

(202) The generated output data may include a command to prevent the output of a projected alarm information when the tolerance parameter exceeds the predetermined threshold value.

(203) The generated output data may include a command to prevent the output of a monitored analyte level trend information when the tolerance parameter exceeds the predetermined threshold value.

(204) One aspect may include an output unit operatively coupled to the processing unit, the output unit configured to output the generated output data.

(205) The output data may include one or more of a graphical display, a text display, an audible output, or a vibratory output.

(206) Various other modifications and alterations in the structure and method of operation of this invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims

1. A glucose monitoring device, comprising: a data communication unit comprising a RF transmitter, the data communication unit configured to wirelessly receive sensor data generated by an in vivo glucose sensor when the sensor is positioned in contact with biofluid under a skin surface of a user, the sensor data being indicative of a monitored glucose level of the user and one or more uncertainty indicators corresponding to uncertain conditions detected during measurement; one or more memories configured to store the received data; a data processing unit comprising one or more processors, the data processing unit operatively coupled to the data communication unit and the one or more memories, the data processing unit configured to: obtain the monitored glucose level from the sensor data; determine one or more data points over a period of time based on the sensor data and the one or more uncertainty indicators; determine an uncertainty parameter using a number of the uncertainty indicators received over the period of time; and determine glucose trend information corresponding to the monitored glucose level when the uncertainty parameter indicates that the number of the one or more uncertainty indicators received over the period of time are less than a predetermined amount; and one or more output units of the glucose monitoring device configured to output one or more notifications upon detection of one or more alarm conditions associated with the one or more uncertainty indicators exceeding a predetermined threshold level.

2. The device of claim 1, wherein the biofluid is interstitial fluid.

3. The device of claim 1, wherein the data communication unit is configured to wirelessly receive the sensor data corresponding to the monitored glucose level using a communication protocol, the communication protocol comprising at least one of an RF communication protocol, an infrared communication protocol, an 802.11x wireless communication protocol, or an IEEE 802.15.4-based protocol such as ZIGBEE transmission protocol.

4. The device of claim 1, wherein the one or more uncertainty indicators comprise one or more missing or unavailable values in one or more data fields of the sensor data.

5. The device of claim 1, wherein the data processing unit is configured to postpone determining the glucose trend information when the one or more uncertainty indicators are less than the predetermined amount.

6. The device of claim 1, wherein the in vivo glucose sensor comprises a plurality of electrodes

including a working electrode comprising a glucose-responsive enzyme bonded to a polymer disposed on the working electrode.

7. The device of claim 6, wherein the glucose-responsive enzyme is chemically bonded to the polymer disposed on the working electrode.

8. The device of claim 6, wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode.

9. The device of claim 8, wherein the mediator is crosslinked with the polymer disposed on the working electrode.

10. The device of claim 1, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

11. The device of claim 1, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine and output one or more notifications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

12. The device of claim 1, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications indications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

13. The device of claim 1, wherein the one or more notifications, associated with the one or more corresponding alarm conditions, are assigned and viewed with different priorities in a predetermined notification hierarchy structure.

14. The device of claim 1, wherein the determination of the one or more data points over the period of time is further based on at least one calibration factor from a calibration event.

15. The device of claim 1, wherein the one or more uncertainty indicators comprises a rate variance of the one or more data points.

16. The device of claim 1, wherein the one or more uncertainty indicators comprises a number of the one or more data points deviating beyond a predetermined tolerance range.

17. The device of claim 1, wherein the one or more notifications are disabled.

18. A glucose monitoring system, comprising: an in vivo glucose sensor configured to be positioned in contact with biofluid under a skin surface and to generate sensor data, the sensor data being indicative of a monitored glucose level and one or more uncertainty indicators corresponding to uncertain conditions detected during measurement; a transmitter unit operatively coupled to the in vivo glucose sensor to receive the sensor data; and a receiving device communicatively coupled to the transmitter unit, the receiving device comprising: a data communication unit comprising a RF transmitter, the data communication unit configured to wirelessly receive the sensor data; one or more memory memories configured to store the sensor data; and a data processing unit comprising one or more processors, the data processing unit operatively coupled to the data communication unit and the one or more memories, the data processing unit configured to: determine the monitored glucose level from the sensor data; determine one or more data points over a period of time based on the sensor data and the one or more uncertainty indicators; determine an uncertainty parameter using a number of the one or more uncertainty indicators received over the period of time; determine glucose trend information corresponding to the monitored glucose level when the uncertainty parameter indicates that the number of the one or more uncertainty indicators received over the period of time are less than a predetermined amount; and one or more output units of the receiving device configured to output one or more notifications upon detection of one or more alarm conditions associated with the one or more uncertainty indicators exceeding a predetermined threshold level.

19. The system of claim 18, wherein the biofluid is interstitial fluid.
 20. The system of claim 18, wherein the data communication unit is configured to wirelessly receive the sensor data corresponding to the monitored glucose level using a communication protocol, the communication protocol being one of an RF communication protocol, an infrared communication protocol, or an 802.11x wireless communication protocol, or an IEEE 802.15.4-based protocol such as ZIGBEE transmission protocol.
 21. The system of claim 18, wherein the one or more uncertainty indicators comprise one or more missing or unavailable values in one or more data fields of the sensor data.
 22. The system of claim 18, wherein the data processing unit is configured to postpone determining the glucose trend information when the one or more uncertainty indicators are less than the predetermined amount.
 23. The system of claim 18, wherein the in vivo glucose sensor comprises a plurality of electrodes including a working electrode comprising a glucose-responsive enzyme bonded to a polymer disposed on the working electrode.
 24. The system of claim 23, wherein the glucose-responsive enzyme is chemically bonded to the polymer disposed on the working electrode.
 25. The system of claim 23, wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode.
 26. The system of claim 25, wherein the mediator is crosslinked with the polymer disposed on the working electrode.
 27. The system of claim 18, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.
 28. The system of claim 18, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine and output one or more notifications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.
 29. The system of claim 18, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications indications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.
 30. The system of claim 18, wherein the one or more notifications, associated with the one or more corresponding alarm conditions, are assigned and viewed with different priorities in a predetermined notification hierarchy structure.
 31. The system of claim 18, wherein the determination of the one or more data points over the period of time is further based on at least one calibration factor from a calibration event.
 32. The system of claim 18, wherein the one or more uncertainty indicators comprises a rate variance of the one or more data points.
 33. The system of claim 18, wherein the one or more uncertainty indicators comprises a number of the one or more data points deviating beyond a predetermined tolerance range.
 34. The system of claim 18, wherein the one or more notifications are disabled.
-